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Abstract 
 
Tetraploidy has long been proposed as an intermediate cellular stage en route to 
the aneuploidy and chromosomal instability that is observed in many cancer types. 
Although tetraploidy has been shown to be an unstable cellular state, an in depth 
analysis of the effect of a spontaneous tetraploidisation event on the cancer 
genome has not been carried out. 
 
Using an isogenic system of naturally occurring tetraploid cells derived from a 
chromosomally stable colorectal cancer cell line, the effect of tetraploidisation on 
genome stability over time was assessed. Tetraploid cells were shown to have 
increased structural and numerical instability on a per cell but not per chromosome 
basis. Over time the tetraploid genome became increasingly genomically unstable, 
which is likely due to the increased ability of tetraploid clones to propagate 
segregation errors. The genomic landscape of tetraploid clones began to 
recapitulate the genomic architecture of chromosomally unstable colorectal cancer, 
and allowed for the selection of clinically high risk chromosomal losses over time. 
Genome doubling was further shown to be a predictive marker of poor prognosis in 
colorectal cancer. Exhaustive analysis of DNA and mRNA failed to reveal any 
common changes in tetraploid clones that are likely to explain their aneuploidy 
tolerance phenotype. Instead a focussed siRNA screen of genes commonly 
mutated in genome-doubled tumours of multiple cancer types was carried out.  
 
Given the high-risk clinical phenotypes associated with tetraploidy and 
chromosomal instability, it remains a priority to identify the mechanisms allowing 
tumour cells to undergo tetraploidisation and to sustain chromosome segregation 
errors.   
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Chapter 1. Introduction 
Intra-tumour heterogeneity has been observed in many different cancer types, and 
is likely to represent a significant barrier to the effective treatment of advanced 
disease (Gerlinger et al., 2014, McGranahan and Swanton, 2015). This observed 
heterogeneity within different regions or cells of the same tumour is likely caused 
by a multitude of genetic instability processes, coupled with differing selection 
pressures within the tumour microenvironment. A driver of inter-cellular 
heterogeneity is chromosomal instability (CIN), the continual alteration of 
chromosome number and structure across multiple generations (Lengauer et al., 
1997). CIN is associated with worse patient prognosis across many different cancer 
types (McGranahan et al., 2012), as well as with intrinsic drug resistance (Lee et al., 
2011). Typically CIN is characterised in tumour cells by high levels of aneuploidy, 
an unbalanced chromosome number.  
 
Tetraploid cells, with a complete doubling of the diploid chromosome number, have 
been observed in the early stages of carcinogenesis in several different cancer 
types, including oesophageal adenocarcinoma and cervical cancer (Galipeau et al., 
1996, Olaharski, 2006). Recent genomics analyses have used copy number data to 
infer that a tetraploidisation, or genome-doubling event is common in the evolution 
of many different cancer types (Carter et al., 2012, Zack et al., 2013). Tetraploidy 
has long been suggested to be an unstable cellular state, leading to the production 
of aneuploid cells (Shackney et al., 1989, Lv et al., 2012). However the relationship 
between tetraploidy and the dynamic state of CIN has not been fully explored.  
 
Understanding the interplay between different drivers of genetic instability, 
including tetraploidy, aneuploidy and chromosomal instability is of clear importance 
to better define their contribution to intra-tumour heterogeneity. In this thesis, a 
study of the contribution of tetraploidy to the genetic instability observed in 
colorectal cancer, through in vitro studies combined with bioinformatics analyses 
has been carried out.  
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Parts of this thesis have been published as primary research papers and reviews, a 
full list of which can be found in the Appendix, Section 8.1. 
 
1.1 The mammalian cell cycle 
Cell growth and division is tightly controlled in mammalian cells to ensure that cells 
divide in a timely fashion with a correctly and completely duplicated genome. 
Furthermore, external signals are integrated into this decision to grow or divide to 
ensure the correct response to external stimuli such as growth factors. Together 
this complex signalling network is sometimes called the cell cycle clock, and is 
governed by the different activities of master cell cycle regulators called cyclins, 
and their activators and inhibitors (Lim and Kaldis, 2013). 
 
1.1.1 Phases of the cell cycle 
The different stages of cell growth and division are commonly divided into phases. 
There are two ‘gap’ phases, known as gap 1 (G1) and gap 2 (G2). These phases 
are separated by the synthesis phase (S phase), where the entire genome is 
replicated. In G1, cells make critical decisions about whether to continue growing or 
not, and are responsive to external stimuli. However, once the cell cycle has 
proceeded past a certain point in G1, originally called the restriction point, or R 
point, cells are no longer responsive to external stimuli and will proceed through the 
rest of the cell cycle phases in a manner that is independent of external signalling. 
After synthesis of DNA during S phase, cells enter the second gap phase G2. 
During G2 cells prepare for entrance into the next phase, which is mitosis (or M 
phase). During M phase duplicated DNA is condensed into chromosomes during 
prophase, aligned at the metaphase plate in metaphase, and each sister chromatid 
is separated to a daughter cell pole during anaphase. The final stage of M phase is 
telophase, where the nuclear envelope starts to re-form around each of the 
daughter nuclei, followed by cytokinesis, the physical separation of the two new 
daughter cells. A representation of the main cell cycle phases and the stages of 
mitosis are shown in Figure 1.1. 
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Figure 1.1: The cell cycle and phases of mitosis 
A) The phases of the mammalian cell cycle and their functions.  
B) The main stages of mitosis.  
 
1.1.2 Cyclins and cyclin dependent kinases 
The main drivers of the cell cycle are the cyclin-dependent kinases (CDKs), and 
their regulatory binding partners, the cyclins. The binding of CDKs, which are 
serine/threonine kinases, to specific regulatory cyclins activates their catalytic 
activity. Each CDK has many downstream targets that carry out the activities 
necessary for each cell cycle phase. Different cyclins are differentially regulated 
throughout the cell cycle, leading to differential activity of their partner CDKs 
(Morgan, 1997). In G1 two main CDKs, CDK4 and CDK6 are responsible for driving 
cell cycle progression in partnership with a family of D type cyclins (cyclin D1, D2 
and D3) that are regulated in response to external stimuli. After the restriction point, 
when cells can no longer respond to external growth cues, CDK2 becomes active 
when binding to E type cyclins and initiates the entry into S phase. The main 
regulator of the transition from G1 to S phase is the protein Rb (retinoblastoma), 
which is hyper-phosphorylated by cyclin E-CDK2 complexes, and leads to 
dissociation with E2F transcription factors that govern the entry of the cell into S 
phase. During S phase CDK2 binds to A-type cyclins, allowing S phase 
progression. At the culmination of S phase the A-type cyclins dissociate from CDK2 
and bind to CDC2 (also called CDK1). As G2 phase commences A-type cyclins are 
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replaced by B-type cyclins. The complexes of CDC2 and B-type cyclins drive many 
of the processes necessary for entry into M phase.  
 
Control of cell cycle progression is maintained by differential activity of these 
different cyclin-CDK complexes. The main regulation of these complexes is through 
the rapid degradation and gene transcription of different cyclins in different phases 
of the cell cycle (Morgan, 1997). This concerted regulation of cyclin-CDK activity 
ensures that the cell cycle can only proceed in one direction. 
 
1.2 Polyploidy in normal development 
Polyploidy describes cells with multiple complete sets of the normal diploid 
complement of homologous chromosomes. Tetraploidy is a specific type of 
polyploidy in which a cell has twice the normal chromosome number. Whole 
organism polyploidy is common among some genera, in particular plant species 
(Otto and Whitton, 2000). However, among mammals there are no known cases of 
polyploid organisms (Svartman et al., 2005). The fact that whole-organism 
polyploidy is likely to be incompatible with survival in mammals is illustrated by the 
fact that 20% of human miscarriages caused by chromosomal abnormalities are 
due to polyploidy (Stephenson and Kutteh, 2007).  
 
Although polyploidy is not observed in mammals at the whole-organism level, there 
are several examples of specialised cell types that display polyploidy.  
 
1.2.1 Placental giant trophoblast cells 
Trophoblast giant cells (TGCs) are extra-embryonic cells that are important for the 
correct implantation of the fertilised egg into the placenta during embryogenesis 
(Zybina and Zybina, 1996, Hu and Cross, 2010). TGCs arise from the 
trophoectoderm of the blastocyst, and undergo repeated rounds of endocycling, in 
which cells cycle from G1 to S phase of the cell cycle with no cell division (Lee et 
al., 2009). This results in highly polyploid cells containing polytene chromosomes, 
where the replicated sister chromatids remain synapsed together (Lee et al., 2009). 
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The specialised endocyling in TGCs involves reduced association of cyclin B and 
CDK1 during G2 phase, which is likely to be caused by inhibition of CDK1 by p57 
(Ullah et al., 2008). Subsequent oscillations of p57 protein levels are thought to 
define the two phases of the endocycle: a G2 phase in which p57 levels are high, 
and a G1 phase where p57 levels decline before entry into S phase (Hattori et al., 
2000).  
 
In general it is thought that cell volume increases alongside genome size (Gregory, 
2001), and therefore polyploidisation could be an efficient way to grow specialised 
tissues without expending excess energy, for example on new membrane 
synthesis during cell division (Lee et al., 2009). The exact function of the polyploidy 
observed in TGCs is not known, however it has been speculated that the synthesis 
of DNA without cell division conserves energy that can be used for protein 
synthesis (Hu and Cross, 2010). The continual replication without mitosis could 
also be a method to protect against tumour formation in a cell type that is 
specialised to invade the local placenta (Hemberger, 2008).  
 
1.2.2 Megakaryocytes 
Megakaryocytes are blood cells that are responsible for the formation of 
thrombocytes (platelets). These cells go though a normal mitosis forming daughter 
nuclei, but cytokinesis fails, leading to a polyploid cell with two nuclei. The 
cytokinesis failure is thought to occur due to low levels of cyclin B/Cdk1 complexes 
(Ravid et al., 2002). The newly formed nuclear envelopes break down and the DNA 
is encompassed into one nucleus (see Figure 1.2B). The cell can re-enter S phase 
from this G1 like state may times, resulting in cells with up to 128N (diploid =2N) 
DNA content (Ravid et al., 2002).  
 
The polyploidisation of megakaryocytes is associated with an increase in cell size, 
mRNA and protein synthesis (Ravid et al., 2002). Since the function of these cells 
is to produce large amounts of thrombocytes, it may be more energy efficient to 
increase cell size and production capacity by increasing DNA content rather than 
by cell number (Davoli and de Lange, 2011).  
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Figure 1.2: The cell cycles of specialised polyploid somatic cells 
A) The specialised endocycle of a TGC. The cell cycles continuously between G1, 
S and G2, skipping mitosis (M) completely. Chromosomes are not separated after 
G2, and hence form polytene chromosomes. 
B) After cytokinesis failure, binucleated megakaryocytes will become 
mononucleated. 
C) Hepatocytes can either be multinucleated or mononucleated after cytokinesis 
failure. For references see text. 
 
1.2.3 Hepatocytes 
In mammalian liver the incidence of polyploid cells increases as the organ develops 
(Gupta, 2000). In fact, in adult humans 40% of all liver cells are tetraploid (Toyoda 
et al., 2005). The formation of polyploid cells in rodent liver occurs due to failure to 
establish a cleavage plane during cytokinesis, likely due to defects in the 
recruitment of Rho GTPase because of altered cytoskeletal dynamics (Margall-
Ducos et al., 2007). It was shown that signalling from insulin through the 
Phosphoinositide-3 kinase (PI3K)/Akt (Protein kinase B) pathway leads to 
increased cytokinesis failure, and as such, inhibition of Akt prevented formation of 
tetraploid hepatocytes (Celton-Morizur et al., 2009).  
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In normal development it is not clear what function the polyploidisation of 
hepatocytes plays. It has been suggested that as liver tissue is exposed to high 
levels of environmental stress, including the metabolism of toxic compounds, that 
increased polyploidy can protect cells from genotoxic stress (Gentric et al., 2012). 
In support of this hypothesis, the levels of endoreduplication in the liver increase in 
response to DNA damage induced by telomere dysfunction (Lazzerini Denchi et al., 
2006). In this way the liver can regenerate using growth of endoreduplicating cells 
instead of through cell division, which is inhibited when the genome has been 
subjected to extensive DNA damage (Lazzerini Denchi et al., 2006). Polyploidy in 
the normal liver could also be a mechanism for triggering particular patterns of 
gene expression that may be associated with promoting cell survival in stressful 
conditions (Anatskaya and Vinogradov, 2007).  
 
It has been shown that as well as increasing their ploidy, hepatocytes can undergo 
reductive rounds of cell division to create a genetically diverse pool of cells 
(Duncan et al., 2010). These reductive cell divisions often involved multipolar 
mitosis, where chromosomes are randomly segregated into multiple daughter cells, 
resulting in aneuploidy. Specific chromosome aneuploidies in liver cells have been 
shown to lead to resistance to chronic liver injury (Duncan et al., 2012), suggesting 
that formation of diverse aneuploid daughter cells in the liver could be 
advantageous in response to exogenous stresses. 
 
1.2.4 Polyploidy incidence under stress 
As described above, the incidence of polyploidy (via endoreduplication) in liver 
hepatocytes increases in response to genotoxic stress caused by telomere 
dysfunction (Lazzerini Denchi et al., 2006). An increase in the ploidy of liver cells is 
also observed after oxidative stress (Gorla et al., 2001). A similar increase in 
polyploidy under varied exogenous stresses has been observed in other tissue 
types, including cardiac tissue after myocardial infarction (Meckert et al., 2005), 
and in inflamed bronchial lesions (Lothschutz et al., 2002). It has been suggested 
that this increase in polyploidy under stressful conditions could help tissue recovery 
and growth in scenarios where the genome may be compromised (Lee et al., 2009), 
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although the specific function of polyploidisation in most of these scenarios remains 
unknown. It is possible that polyploidisation in these instances reflects general 
cellular dysfunction after stress resulting in failure to complete normal cell cycles, 
rather than a specialised function. However, the activation of specific gene 
expression profiles after polyploidisation in both liver and heart tissue suggest that 
polyploidisation can act as a tool for adaptation to stress (Anatskaya and 
Vinogradov, 2010). For example in the heart, polyploidisation results in up-
regulation of more energy efficient contractile proteins such as beta myosin heavy 
chain, and coincident down-regulation of energy intensive proteins such as alpha 
myosin heavy chain which utilises three times as much ATP (Anatskaya and 
Vinogradov, 2010).  
1.3 Evidence for polyploidisation in cancer   
Many in vitro studies and in vivo observations indicate that tetraploidy could occur 
as an early event during tumour formation and progression. It has been shown that 
tetraploidy occurs alongside spontaneous neoplastic transformation in different 
rodent cell lines when cultured in vitro (Hsu et al., 1961, Barski and Cassingena, 
1963, Jackson et al., 1970), and that transformation of normal fibroblasts with SV40 
can also lead to tetraploidisation (Cooper and Black, 1963, Moorhead and Saksela, 
1965). Polyploid cells are observed in different cancer types with varying frequency. 
Many tumour types exhibit a distinct bimodal pattern of chromosome numbers, with 
a peak near diploid chromosome numbers (46 chromosomes) and a second peak 
with triploid or near-tetraploid chromosome numbers (Mitelman F, 2015, Storchova 
and Kuffer, 2008, Davoli and de Lange, 2011). This suggests that many tumours 
may have undergone polyploidisation at some point in their evolutionary histories, 
as tumours with high numbers of chromosome are more likely to have arisen in a 
single tetraploidisation event generating twice as many chromosomes, compared to 
continued chromosome non-disjunction resulting in chromosome increases 
(Storchova and Kuffer, 2008, Davoli and de Lange, 2011).  
1.3.1 Tetraploidy and aneuploidy in cancer 
A model to describe the origin of tumours with high chromosome numbers was first 
proposed by Shackney and colleagues in 1989 (Shackney et al., 1989). They 
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proposed that a tetraploidisation event followed by chromosome loss is the most 
likely route to aneuploid tumour cells with high numbers of chromosomes, based on 
computer simulations, but also on cytogenetic evidence suggesting that tetraploidy 
and subsequent chromosome losses are common events in multiple different 
cancer types (Shackney et al., 1989). In the pre-malignant condition of Barrett’s 
oesophagus that predisposes patients to the onset of oesophageal 
adenocarcinoma, tetraploid cells are observed before the onset of aneuploidy and 
progression to malignant disease (Galipeau et al., 1996). Of 75 patients whose 
disease did not initially show an increase in the 4N cell fraction, only 11% 
progressed to aneuploidy in subsequent biopsies. However, in the 15 patients who 
initially had elevated levels of 4N cells, 73% progressed to aneuploidy. The 
presence of 4N cells was significantly correlated with loss of the chromosome 
region 17p, which harbours the tumour suppressor gene TP53 (Galipeau et al., 
1996). In cervical cancer tetraploidy has also been implicated as a precursor to 
aneuploidy. In a study of 143 patient samples of cervical malignancy, tetraploidy 
(as assessed by dual chromosome probes for chromosome 3 and 17) was 
frequently observed without aneuploidy (23.8% of cases) (Olaharski, 2006). 
However, it was rare to observe aneuploidy without tetraploidy (only 4.2% of cases). 
Indeed, when aneuploid cells were observed, they were commonly near-tetraploid 
aneuploid (74.3% of cases). This suggests that tetraploidy is an early event in 
cervical carcinogenesis and is likely to precede aneuploidy development (Olaharski, 
2006). 
 
A careful in vitro analysis of the transformation of mouse surface ovarian cells has 
also shown that tetraploidy can lead to aneuploidy (Lv et al., 2012). Mouse ovarian 
surface epithelial cells (MOSECs) can be cultured in vitro as a model to 
characterise ovarian carcinogenesis (Roberts et al., 2005). Lv and colleagues 
utilised this model to observe changes in ploidy and chromosome number during 
carcinogenic progression (Lv et al., 2012). The proportion of diploid cells in a 
MOSEC culture decreased steadily until passage 36, when they were no longer 
present. In contrast, the percentage of tetraploid cells increased through culture. 
Using chromosome counting from metaphase spreads, fluorescence in situ 
hybridisation (FISH) and live cell imaging, the authors showed that the first 
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aneuploid cells to emerge were near-tetraploid aneuploid, and concluded that 
aneuploid MOSECs are derived from tetraploid cells (Lv et al., 2012).  
 
Taken together these studies indicate that tetraploidy is likely to be a frequent 
event in cancer that can predispose to the onset of aneuploidy. How tetraploid cells 
can lead to aneuploidy is discussed in Section 1.10. 
 
1.3.2 Inference of polyploidisation from genomics studies 
In recent years there has been a dramatic rise in the number of tumours being 
subjected to genomics analysis, predominantly through next-generation 
sequencing (Koboldt et al., 2013). Using advanced bioinformatics tools has allowed 
researchers to reconstruct the evolutionary histories of tumours in unprecedented 
detail (Nik-Zainal et al., 2012). Analysing the sub-clonal architecture of one 
particular breast cancer sequenced to a high depth revealed a sub-clone that was 
likely to have undergone tetraploidisation, with subsequent chromosome losses 
affecting 11 chromosomes (Nik-Zainal et al., 2012). This indicates that tetraploidy 
can occur as a late event in tumours.  
 
The frequency of tetraploidisation has also been inferred from tumour copy number 
data (Carter et al., 2012). Carter and colleagues devised a bioinformatics method 
for assigning copy number information across the whole genome of cancer 
samples using either massively parallel sequencing or DNA microarrays. Many 
tumours that were analysed exhibited a bimodal distribution of copy numbers, 
similar to previous observations (Storchova and Kuffer, 2008, Mitelman F, 2015). In 
order to ascertain whether the high ploidy copy numbers were more likely to have 
arisen from a single whole genome duplication followed by copy number loss, or 
through sequential gains of individual chromosomes, the authors developed a 
bioinformatics algorithm to infer the most likely route by which the copy number 
state of individual tumours occurred (Carter et al., 2012). If a tumour undergoes 
whole genome duplication, then both homologous chromosomes will be present at 
two copies across the whole genome. If there is subsequent loss of genetic 
material from one chromosome, then that chromosome will be reduced to an odd 
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copy number (i.e. a copy number of one). However the other allele will still be 
present at an even number of copies (i.e. two copies) throughout the genome (see 
Figure 1.3). When the authors assessed the allele-specific copy number of higher 
ploidy samples, they found that the higher of the two alleles (also called the major 
allele) tended to have an even copy number across the majority of the genome 
(Carter et al., 2012). Using simulations of multiple chromosome gains compared to 
a single whole genome duplication event, they found that higher copy number 
states were significantly more likely to have occurred through genome doubling 
(P<10-3) (Carter et al., 2012).  
 
Figure 1.3: Assessing copy number state after whole genome duplication 
A representation of the possible copy number changes after whole genome 
duplication. Even after complete duplication and subsequent copy number loss, the 
major allele will have a copy number of two across the majority of the genome. 
Carter and colleagues devised an algorithm to assess whether the copy number 
state of tumours was likely to have occurred through genome duplication or 
sequential gains of individual chromosomes (Carter et al., 2012).  
 
The frequency of genome doublings was varied across the different cancer types 
analysed, which included acute lymphoblastic leukemia, myeloproliferative disease, 
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hepatocellular carcinoma, medulloblastoma, liposarcoma, colorectal cancer, breast 
cancer, high-grade serous ovarian carcinoma, lung adenocarcinoma and 
oesophageal adenocarcinoma. Genome doubling was almost completely absent 
from the hematopoietic malignancies, and most common in epithelial cancers. 
Oesophageal adenocarcinoma had the highest incidence of genome doubling, 
which is consistent with the known involvement of tetraploidy at early disease 
stages (Galipeau et al., 1996, Maley, 2007).  
 
An extension of this work by the same group also showed genome doubling to be a 
common event across different cancer types, ranging from 11% of samples in 
glioblastoma multiforme to 64% of squamous cell lung cancer samples (Zack et al., 
2013). Tumours that showed evidence of whole genome doubling had higher rates 
of every type of copy number aberration analysed, including focal aberrations and 
arm-level aberrations, but especially deletions (Zack et al., 2013). The authors 
speculate that genome duplication is an early event in the majority of cancers they 
analysed, as most aberrations appear to occur after genome doubling. 
 
Taken together, these studies show that polyploidisation is likely to be an important 
driver of cancer evolution. It appears as though tetraploidy is frequently a precursor 
to aneuploidy in tumours and in in vitro studies (Galipeau et al., 1996, Olaharski et 
al., 2006 2012). Sophisticated analysis of copy number data from multiple cancer 
types has also shown that genome duplications are common events, which in many 
cases precede further genomic alterations (Carter et al., 2012, Zack et al., 2013).  
 
As discussed above, polyploidy is not well tolerated in mammals at the whole 
organism level. However unscheduled polyploidisation clearly occurs relatively 
frequently in cancer. The cell cycle checkpoints normally maintaining a diploid 
chromosome complement throughout the cell cycle, and the mechanisms that can 
generate tetraploid cells and result in whole genome duplication in tumours will now 
be considered. 
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1.4 Cell cycle checkpoints 
Although the phases of the cell cycle are carefully coordinated, as discussed in 
Section 1.1, the capacity to halt progression must still exist in order to ensure the 
integrity of the genome. This function is mainly carried out by cyclin-dependent 
kinase inhibitors (CKIs), which inhibit the function of cyclin-CDK complexes. CKIs 
can be broadly categorised into two classes: the INK4 proteins (p16INK4a, p15INK4b 
p18INK4c and p19INK4d), which inhibit CDK4 and CDK6 in G1, and the Cip/Kip 
proteins (p21Cip1, p27Kip1 and p57Kip2), which inhibit all of the other cyclin-CDK 
complexes (Sherr and Roberts, 1999). Various signalling checkpoints activate 
these CKIs to halt progression of the cell cycle and ensure the integrity of the DNA. 
These cell cycle checkpoints are discussed below. 
 
1.4.1 DNA damage checkpoints 
The DNA in cells is constantly susceptible to damage, from both exogenous and 
endogenous sources. Endogenous biochemical processes such as deamination, 
where the amine groups of bases are lost, can damage DNA. This can lead to 
transition mutations as deaminated bases get mis-read by replication machinery 
(Lindahl and Barnes, 2000). Spontaneous deamination is particularly common at 5-
methlycytosine bases, and particularly dangerous, as it forms a natural thymine 
product that is not recognised as an incorrect base. DNA damage can also arise 
spontaneously from errors in DNA replication and repair. These spontaneous DNA 
damage processes have been estimated to result in up to 105 lesions per cell per 
day (Hoeijmakers, 2009). DNA can also be affected by multiple exogenous sources. 
Ionising radiation can cause both single and double strand breaks through the 
generation of reactive oxygen species (ROS). Ultra-violet (UV) light also affects 
DNA, resulting in the formation of covalent bonds between adjacent pyrimidine 
bases (called pyrimidine dimers). Furthermore, a variety of chemical compounds 
that enter cells from exogenous sources can cause DNA damage, such as the 
alkylation of DNA bases by alkylating chemotherapeutic agents. 
 
Multiple pathways exist to repair different types of DNA damage, and DNA repair is 
normally coordinated by cell cycle phase. There are three main checkpoints that 
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operate in cells in response to DNA damage. These are the G1/S phase checkpoint, 
the intra-S phase checkpoint and the G2/M checkpoint. The DNA damage 
response is primarily activated by two different kinases ATM (ataxia telangiectasia 
mutated) and ATR (ATM and Rad-3 related) that mediate the DNA damage 
response through activation of their downstream targets the checkpoint kinases 
CHK1 and CHK2 (Stracker et al., 2009). ATM is predominately activated in 
response to double strand breaks (DSBs) and ATR in response to single-stranded 
DNA (ssDNA) which can be formed during DNA repair processes and also at 
stalled or collapsed replication forks (Ciccia and Elledge, 2010). Recruitment of 
ATM to DSBs results in the phosphorylation of the histone variant H2AX by ATM, 
resulting in phospho-H2AX (known as γ-H2AX), which is commonly used as a 
marker for DNA damage (Bonner et al., 2008). 
 
1.4.1.1 The G1/S checkpoint 
It is important for a cell not to enter S phase with damaged DNA to avoid copying 
errors into the newly synthesised DNA strand. Therefore at the boundary between 
G1 and S phase, DNA damage signalling through ATM and CHK2 results in the 
phosphorylation and destruction of CDC25 phosphatase, which controls CDK 
activity at the G1-S boundary, thereby blocking S phase entry by inhibition of cyclin 
E-CDK2 activity (Mailand et al., 2000, Falck et al., 2001). CHK2 further inhibits cell 
cycle progression indirectly through the degradation of MDM2, which normally 
ubiquitinates p53, thereby resulting in up-regulation of p53 and its downstream 
target, the CKI p21Cip1 (Chen et al., 2005, Jin et al., 2006). DNA damage also 
results in the up-regulation of one of the INK4 proteins, p16INK4a, which prevents the 
hyper-phosphorylation of Rb and results in G1 arrest (Gil and Peters, 2006). Cells 
with defective p53 or Rb signalling responses cannot sustain a G1 arrest (Kuerbitz 
et al., 1992, Bunz et al., 1998). 
 
1.4.1.2 The intra-S phase checkpoint 
During replication DNA is subject to damage, usually occurring near the replication 
fork. Stalled or collapsed replication forks results in single stranded DNA tracts 
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which become coated in the ssDNA binding protein RPA (heterotrimeric replication 
protein A) which recruits ATRIP, the targeting subunit of ATR (Zou and Elledge, 
2003). Subsequent stimulation of ATR by TOPBP1 results in the activation of the 
ATR signalling cascade (Mordes et al., 2008). Downstream checkpoint signalling at 
replication forks is additionally controlled by Claspin, which mediates CHK1 
phosphorylation by ATR (Kumagai and Dunphy, 2000). Unlike the G1-S phase 
checkpoint, the intra-S checkpoint is a transient arrest that functions to allow the re-
start of stalled replication forks. Inhibition of CDK2 by the intra-S phase checkpoint 
results in a delay of several hours to S phase completion (Falck et al., 2001). 
 
1.4.1.3 The G2/M checkpoint 
DNA damage that is sensed in G2 results in cell cycle arrest in order to prevent a 
cell entering mitosis and segregating damaged DNA to the new daughter cells. 
Both the ATM and ATR signalling pathways tend to be activated together in G2. 
ATM is activated by DSBs as in G1, but the resection of DSBs for repair by 
homologous recombination also results in ATR activation (Jazayeri et al., 2006). 
The activation of CHK1/2 leads to cell cycle arrest through the inhibition of CDC25, 
which subsequently cannot activate CDC2-cyclin B complexes, and therefore entry 
into M phase is inhibited. Unlike the G1-S checkpoint, the G2-M checkpoint is not 
dependent on p53, so p53 mutant cells can still display a G2 arrest in response to 
DNA damage (Kastan and Bartek, 2004). 
 
1.4.2 The spindle assembly checkpoint and error correction machinery 
As well as responding to DNA damage to ensure genome integrity, the events 
during M phase must be coordinated to ensure that one copy of each sister 
chromatid is segregated to each new daughter cell. The timely segregation of 
chromosomes is controlled by the spindle assembly checkpoint (SAC), whilst the 
error correction machinery monitors incorrect kinetochore-microtubule attachments. 
 
After prophase, when chromosomes have condensed, the spindle apparatus must 
correctly attach to all kinetochores so that when anaphase begins, sister 
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chromatids are pulled to opposite poles (Figure 1.1B). The entry into anaphase is 
initiated by the anaphase promoting complex (APC/C), a E3 ubiquitin ligase that 
degrades cyclin B and securin, allowing mitotic exit and chromosome separation 
(Pines, 2011). Unattached kinetochores assemble complexes that signal to and 
inhibit the APC/C, delaying anaphase until all chromosomes are attached to the 
spindle (Rieder et al., 1995). The signal at kinetochores that inhibits the APC/C is 
called the mitotic checkpoint complex (MCC). It is generated by a network of 
proteins that assemble at unattached kinetochores known as the KMN network 
(Sacristan and Kops, 2015). The KMN network is composed of KNL1-C, MIS12-C 
and NDC80-C protein complexes (DeLuca and Musacchio, 2012, Lara-Gonzalez et 
al., 2012). The formation of the MCC at kinetochores is regulated by the kinase 
MPS1, which is associated with the NDC80-C part of the KMN network (Nijenhuis 
et al., 2013). MPS1 then recruits other SAC proteins to the kinetochores, including 
BUB1, BUB3, MAD1, MAD2 and BUBR1/Mad3 (Sacristan and Kops, 2015). The 
assembly of the MCC complex at kinetochores inhibits the APC/C through inhibition 
of CDC20. The precise role for all the proteins present at the kinetochore in the 
MCC has not yet been established, but it is clear that MAD2 and BUBR1 are critical 
for the correct binding and inhibition of the APC/C (Sudakin et al., 2001, Herzog et 
al., 2009, Sacristan and Kops, 2015). Once a kinetochore is correctly attached to 
the spindle, MAD20 is removed from kinetochores by transport along microtubules 
(Howell et al., 2001). Once all kinetochores are attached, there is no longer 
inhibition of the APC/C, leading to ubiquitination of its substrates cyclin B and 
securin. The degradation of securin leads to separase activation. Separase cleaves 
the cohesion complexes which hold sister chromatids together during metaphase, 
resulting in their separation (Reddy et al., 2007, Pines, 2011). 
 
A second important point of regulation during M phase involves the ‘error correction 
machinery’ that corrects kinetochore-microtubule attachment errors. Incorrect 
attachments include syntelic attachments, where both sister chromatids are 
attached to the same pole, or merotelic attachments, where one kinetochore is 
attached to both poles (see Figure 1.4A and Cimini et al., 2001). These types of 
attachment can satisfy the SAC, as kinetochores are attached to microtubules, but 
may result in lagging chromosomes and chromosome non-disjunction (Cimini et al., 
2001, Cimini et al., 2002). Hence, it is important that error correction machinery 
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exists during M phase to correct these errors. Improper-kinetochore microtubule 
attachments are monitored by the activity of Aurora kinase B (Aurora B) and the 
chromosomal passenger complex (CPC) (see Figure 1.4B and Hauf et al., 2003). 
 
 
Figure 1.4: Kinetochore-microtubule attachment and error correction 
A) Different types of kinetochore-microtubule attachments. Amphitlelic attachments 
occur when each kinetochore is correctly attached to both spindle poles. Merotelic 
attachments mean one kinetochore is attached to both spindle poles, and syntelic 
attachments are where both kinetochores are attached to one pole.  
B) The mechanism of error correction at incorrectly attached kinetochores. The 
Chromosomal Passenger Complex (CPC) is located at the inner kinetochore. 
When there is no tension between sister chromatids the CPC is able to 
phosphorylate targets such as MCAK, which destabilises microtubules. Upon 
correct amphitelic attachment, the CPC is no longer able to phosphorylate its 
targets, and substrates such as MCAK as dephosphorylated by phosphatases such 
as PP1A, which is located at the outer kinetochore.  
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Aurora B is the catalytic component of the CPC, which is also comprised of 
Survivin, Borealin and INCENP (Ruchaud et al., 2007). The CPC is localised to the 
centromere, and in the absence of the correct microtubule tension emanating from 
opposite poles, it can access its substrates in the outer kinetochore and 
phosphorylate them (Liu et al., 2009).  All components of the CPC are essential for 
its localisation to centromeres during mitosis (Honda et al., 2003, Klein et al., 2006). 
One of the most important substrates of the CPC is the microtubule depolymerase 
MCAK (mitotic centromere-associated kinesin, also called Kif2c) (Andrews et al., 
2004). When activated by the CPC, MCAK destabilises microtubules and therefore 
removes the incorrect attachment (Liu et al., 2009).  Aurora B also destabilises 
microtubule attachments through phosphorylation of the N-terminal tail of NDC-80, 
one of the KMN network components, as well as other proteins present at the 
kinetochore such as KNL1 and Mis12 (DeLuca et al., 2006, Welburn et al., 2010). 
When a kinetochore is correctly attached to spindles emanating from both poles, it 
is hypothesised that tension pulls sister kinetochores apart, meaning the CPC can 
no longer access important substrates such as MCAK (Tanaka et al., 2002, 
Lampson et al., 2004). Furthermore, when balanced (amphitelic) attachments are 
created, a counteracting phosphatase to Aurora B called protein phosphatase 1 
(PP1) dephosphorylates Aurora B targets at the outer kinetochore, resulting in the 
stabilisation of attachments (Liu et al., 2010a). However, if merotelic attachments 
create sufficient tension across the kinetochore to prevent Aurora B kinase activity, 
then these mis-attachments can go undetected, and result in lagging chromosomes 
(Cimini et al., 2001, Cimini et al., 2002). 
1.4.3 Regulation of cytokinesis – the abscission checkpoint 
As well as controlling the separation of chromosomes during M phase, cells must 
also coordinate cytokinesis to complete the correct segregation of DNA into two 
daughter cells. At the onset of cytokinesis the mitotic spindle undergoes 
reorganisation to form a dense array of anti-parallel filaments at the equator of the 
cell, which is known as the spindle mid-zone (Fededa and Gerlich, 2012). There is 
subsequent formation of a contractile ring around the spindle mid-zone, which is 
composed of actin and myosin filaments. Myosin II activity at the contractile ring 
provides the main force that results in the constriction of the cell membrane, 
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forming a cleavage furrow (Robinson and Spudich, 2004, Nagasaki et al., 2002). 
As the cleavage furrow ingresses, the cytoplasm becomes separated, eventually 
only being joined by a narrow bridge formed by a dense array of microtubules that 
are joined at the centre by a structure known as the mid-body (or Flemming body) 
that anchors the cleavage furrow (Mullins and Biesele, 1977, Fededa and Gerlich, 
2012). The final stage in cytokinesis is abscission, where the plasma membrane is 
split between the two daughter cells. Abscission is mediated by a group of proteins 
called the ESCRT complex (Endosomal Sorting Complex Required for Transport) 
(Carlton and Martin-Serrano, 2007, Morita et al., 2007, Hurley and Hanson, 2010). 
 
The events of cytokinesis need to be regulated to ensure all chromosomes have 
properly segregated into two daughter cells to avoid aneuploidy. Furthermore, it 
has been shown that chromosomes trapped in the mid-zone during cleavage 
furrow formation can sustain significant DNA damage (Janssen et al., 2011). 
Hence it is crucial that the events of cytokinesis are coupled to the segregation of 
DNA during mitosis to ensure genomic integrity. In yeast, the presence of DNA in 
the cleavage furrow results in regression of the furrow and cessation of cytokinesis. 
The pathway controlling this regression is termed the NoCut pathway (Norden et al., 
2006, Mendoza et al., 2009). It is thought that a similar checkpoint exists in 
mammalian cells that is regulated by Aurora B kinase signalling (Steigemann et al., 
2009). A subunit of the ESCRT complex, CHMP4C, was shown to be involved in 
the regulation of abscission delay in response to trapped chromatin (Carlton et al., 
2012). CHMP4C was shown to bind the CPC through interaction with Borealin, and 
inhibited abscission upon phosphorylation by the active kinase of the CPC, Aurora 
B (Carlton et al., 2012). It was recently shown that a novel protein ANCHR 
(Abscission/NoCut Checkpoint Regulator; ZFYVE19) can regulate this checkpoint 
though spatial regulation of another member of the ESCRT complex, VSP4 
(Thoresen et al., 2014). VSP4 normally catalyses the final step in membrane 
abscission through its ATPase activity (Carlton and Martin-Serrano, 2007, Morita et 
al., 2007, Hurley and Hanson, 2010). The association of ANCHR and CHMP4C are 
proposed to act by tethering VSP4 to the mid-zone and preventing its re-
localisation to the abscission zone (Thoresen et al., 2014). A key future direction 
will be to identify how Aurora B is activated in response to trapped chromatin to 
control this abscission checkpoint. 
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1.5 The generation of tetraploid cells in cancer 
Despite the multitude of cell cycle checkpoints that exist in mammalian cells, 
polyploidy is observed frequently in cancer (as discussed in Section 1.3). The 
different ways in which these tetraploid cells could arise are described below, and 
also depicted in Figure 1.5. 
1.5.1 Cytokinesis failure 
Gross abnormalities in mitosis that result in chromatin lagging within the cleavage 
furrow result in the failure of cytokinesis (Mullins and Biesele, 1973, Mullins and 
Biesele, 1977). If cytokinesis fails to complete a binucleated tetraploid cell will be 
formed. If this cell can continue to subsequent rounds of cell division it will likely 
form a mononucleated tetraploid cell. The signalling pathways responsible for 
cleavage furrow regression in response to trapped DNA are just beginning to be 
elucidated (see Section 1.4.3). Many different defects can lead to chromatin 
lagging at the cleavage furrow, and so this mechanism could potentially account for 
a proportion of the tetraploid cells observed in cancer (Davoli and de Lange, 2011). 
 
Chromosome non-disjunction has also been shown to lead to cytokinesis failure 
and tetraploidy, rather than aneuploidy (Shi and King, 2005). Increasing the rate of 
chromosome missegregation by genetic and chemical means resulted in a higher 
frequency of binucleated daughter cells in HeLa cells and immortalised 
keratinocytes. However the majority of binucleated tetraploid cells appeared to 
arise from a normal bipolar mitosis, but that underwent delayed regression of the 
cleavage furrow (an average of 13.6 hours after mitosis) (Shi and King, 2005). 
Upon analysis of the chromosome copy number status of these cells by FISH, the 
authors estimated that 94% of binucleated cells were likely to have undergone 
chromosome non-disjunction. However, binucleation did not appear to be tightly 
coupled with lagging chromosomes or bridges, but rather the presence of a 
missegregated chromosome in the daughter nuclei. Although there is no 
mechanistic basis proposed for how a missegregated chromosome could lead to 
cleavage furrow regression, this intriguing finding could explain why tetraploid cells 
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are frequently seen in cancer, since many tumour cells exhibit high levels of 
chromosome missegregation (Lengauer et al., 1997, Shi and King, 2005, King, 
2008). However, the generality of this mechanism has yet to be proven, as defects 
in SAC activation can directly lead to aneuploid cells, and so chromosome non-
disjunction cannot always be coupled with cytokinesis failure (King, 2008). 
 
 
Figure 1.5: Proposed mechanisms of tetraploidisation in cancer 
A) Cytokinesis failure generates tetraploid cells. OE = over expression. 
B) Mitotic dysfunction can lead to cells exiting mitosis with duplicated DNA 
C) Endoreduplication is a specialised cell cycle that skips mitosis. 
D) The fusion of two diploid cells will create a tetraploid cell. For references see 
text. 
 
Defects in several different signalling pathways have also been shown to lead to 
cytokinesis failure and the production of tetraploid daughter cells. Inhibition of the 
kinase large tumour suppressor 1 (LATS1) results in cytokinesis failure (Yang et al., 
2004). LATS1 regulates cytokinesis through its regulation of the kinase LIMK1, 
which controls actin polymerisation at the contractile ring (Yang et al., 2004). 
Overexpression of the mitotic kinase Aurora A has also been shown to lead to an 
abortive cytokinesis and subsequent increase in binucleated daughter cells 
(Meraldi et al., 2002). Aurora A is also amplified or overexpressed in many solid 
tumour types (Nikonova et al., 2013). 
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1.5.2 Mitotic dysfunction 
Prolonged arrest in mitosis by the SAC can lead to cells escaping mitosis, and 
returning to a G1 phase, but with a duplicated DNA content (Elhajouji et al., 1998). 
This is known as mitotic slippage. The escape from mitosis is brought about by 
gradual degradation of cyclin B, which eventually falls below a critical threshold to 
maintain mitosis, and the cell escapes into G1 phase (Brito and Rieder, 2006). 
Unlike cytokinesis failure, mitotic slippage will result in a mononucleated tetraploid 
daughter cell (Figure 1.5B). A variety of cell cycle defects can lead to tetraploid 
cells after mitotic slippage. Overexpression of the SAC protein Mad2 leads to the 
accumulation of 4N cells after stalling of the cell cycle in G2/M (Sotillo et al., 2007). 
Overexpression of another regulator of the APC/C, Emi1, also leads to 
tetraploidisation in p53 deficient cells (Lehman et al., 2006). Both Mad2 and Emi1 
can be overexpressed in several different cancer types (Lehman et al., 2007, Kim 
et al., 2014, Teixeira et al., 2015). Overexpression of the mitotic kinesin Eg5 in 
mice, which functions to ensure bipolar division by regulating centrosome 
separation, also leads to an accumulation of 4N mouse embryonic fibroblasts 
(MEFs) due to prolonged G2/M arrest (Castillo et al., 2007). Overexpression of Eg5 
has also been linked to cancer progression and poor patient prognosis (Liu et al., 
2010b, Ding et al., 2011). Problems with the spindle assembly checkpoint can be 
caused by loss of the APC (Adenomatous polyposis coli) gene, which plays a 
crucial role in the development of most colon cancers (Fodde et al., 2001, 
Dikovskaya et al., 2007). APC loss can cause mitotic slippage, a reduction in 
apoptosis and the production of a viable pool of tetraploid cells (Dikovskaya et al., 
2007). Other problems in mitosis can also lead to the production of tetraploid cells. 
Overexpression of the mitotic kinase Aurora B has been shown to lead to the 
generation of tetraploid cells through a mechanism of premature chromatid 
separation in anaphase (Nguyen et al., 2009). It is thought that this may occur due 
to rapid exit from mitosis caused by excessive dissociation of the cohesin complex 
(Nguyen et al., 2009). 
1.5.3 Endoreduplication 
Endoreduplication describes variation in the normal cell cycle progression from G1 
through to M phase, which results in cells with more than 2N DNA content (Lee et 
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al., 2009). As discussed above (see Section 1.2.1) some cells are programmed to 
undergo specialised programmes of repeated DNA synthesis without cell division to 
achieve high levels of ploidy. Endoreduplication is normally characterised by a 
complete skipping of the mitotic phase of the cell cycle, with cells entering G1 
immediately after G2 (Lee et al., 2009).  
 
It has been shown that persistent DNA damage signalling can lead to 
endoreduplication and the formation of tetraploid cells in the absence of p53 
function (Davoli et al., 2010). Davoli and colleagues induced telomere dysfunction 
by the deletion of the mouse shelterin proteins POT1a and POT1b in immortalised 
MEFs (Hockemeyer et al., 2006, Davoli et al., 2010). This results in a persistent 
ATR kinase response, resulting in activation of CHK1 and CHK2, and the formation 
of polyploid cells (Denchi and de Lange, 2007, Hockemeyer et al., 2006). The 
authors show that polyploidisation can also be induced by a persistent DNA 
damage signal induced by zeocin, doxorubicin, bleomycin or repeated UV 
irradiation. Analysis of chromosome structure following persistent DNA damage 
revealed diplo-chromosomes, which are a hallmark of cells that have undergone 
repeated rounds of DNA replication without cohesin destruction and sister 
chromatid separation (Davoli et al., 2010). The continuous signalling though CHK1 
and CHK2 seemed to result in CDC25 degradation and lower cyclin B- CDC2 
(CDK1) activity, delaying M phase entry. The authors observed subsequent 
degradation of Geminin, which normally functions to inhibit DNA replication, and 
the re-expression of Cdt1 which can re-license replication origins (Davoli et al., 
2010). One of the most likely causes of a persistent DNA damage response in 
cancer is telomere damage, which is thought to occur as a relatively early event in 
most cancer types (Davoli and de Lange, 2011). The authors therefore suggest that 
loss of p53 followed by persistent DNA damage induced by telomere dysfunction, 
and subsequent tetraploidisation could be an important driver of genetic instability 
in some cancer types (Davoli et al., 2010). In a follow up study the same group 
showed that telomere crisis and subsequent tetraploidisation also occur in human 
fibroblasts and mammary epithelial cells that underwent a natural telomere crisis 
after continual passaging (Davoli and de Lange, 2012). This study shows that in 
cancer-relevant cell types, telomere crisis leads to tetraploidisation. However, since 
a specific sequence of events needs to occur in order for tetraploid cells to 
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proliferate in this setting, it remains to be elucidated how common this mechanism 
of tetraploidisation is in human tumours.  
 
Other scenarios in which the DNA damage response has been activated have been 
shown to cause endoreduplication. For example, in XRCC3 deficient cells, which 
are defective in homologous recombination, a low level of endoreduplication was 
observed (Yoshihara et al., 2004). Further, deletion of Nbs1 or Rad17, proteins 
involved in the DSB repair response also result in endoreduplication (Reina-San-
Martin et al., 2005, Wang et al., 2003). Oncogene-induced replication stress could 
also result in a persistent DNA damage response, which could lead to 
tetraploidisation through endoreduplication (Bartkova et al., 2005, Davoli and de 
Lange, 2011).  
 
1.5.4 Cell fusion 
The fusion of two diploid cells will create a cell with a tetraploid DNA content. Cell 
fusion has been observed during both normal development and disease (Zhou and 
Platt, 2011). Cell-to-cell fusion can also occur when cells are infected with viruses. 
This was first observed for cells infected with the respiratory rodent virus Sendai 
virus (Wainberg and Howe, 1973). Some human cancers have an etiological link 
with viral infection, for example human papillomavirus (HPV) infection and cervical 
cancer (Reid, 1983). It has been shown that HPV infection can cause cell fusion 
resulting in binucleated cells, which are a hallmark of pre-cancerous cervical 
lesions (Hu et al., 2009, Mittal et al., 1990). A significant proportion of diagnosed 
cancers worldwide are thought to be related to viral infection (Parkin, 2006).  It will 
be interesting to investigate whether these viruses act oncogenically though cell-
fusion and production of 4N cells.  
 
1.6 Limiting the proliferation of tetraploid cells 
As discussed in Section 1.2, there are only a few specialised cell types in mammals 
that are polyploid. Although tetraploidy is commonly found in tumours, many 
cancers have deregulated cell cycles, and dysfunctional checkpoints (Williams and 
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Stoeber, 2012). This leads to the question of which checkpoints are normally 
activated by tetraploidy, and act to prevent tetraploidisation in somatic tissue. 
Studies using spindle poisons which disrupt the mitotic spindle have shown that 
cells undergo mitotic slippage but without segregation of chromosomes, resulting in 
a prolonged arrest in a tetraploid G1 state (Yvon et al., 1999, Rieder and Maiato, 
2004). It was not known whether this arrest was caused by a specific cell cycle 
checkpoint that could sense a tetraploid state, or whether the arrest was due to 
errors in mitosis caused by the use of spindle poisons.  
 
Data demonstrating the existence of a “tetraploidy checkpoint” was first shown by 
Andreassen and colleagues (Andreassen et al., 2001). Using cytochalasin D, an 
inhibitor of actin assembly, to block cytokinesis, the authors showed that primary 
rat embryo fibroblast cells (REF52 cells), but not transformed versions of the same 
cells, arrested in G1 following cytokinesis failure (Andreassen et al., 2001). They 
noted that cells arrested even when they had undergone a normal bipolar mitosis 
without errors, suggesting that subsequent G1 arrest was not dependent on mitotic 
errors brought about by spindle poison treatment. This arrest was dependent on 
p53, as when cells were infected with a dominant negative p53 mutant, they did not 
arrest. The authors proposed that this p53 dependent mechanism exists in non-
transformed cells to protect against genomic instability. However, later work 
showed that the cell cycle arrest initiated by cytochalasin D could be dependent on 
drug concentration, as lower concentrations did not elicit G1 arrest, even in the 
same REF52 cells (Uetake and Sluder, 2004). These authors speculate that actin 
cytoskeleton disorganisation that persists even after drug washout could be 
responsible for the arrest, however they do not speculate as to why this affects 
binucleated (tetraploid) cells to a greater extent than diploid cells, which did not 
arrest at higher concentrations (Uetake and Sluder, 2004). It is possible that DNA 
damage resulting from the cytokinesis inhibitors and cell synchronisation 
treatments could be responsible for causing a G1 arrest (Wong and Stearns, 2005). 
Furthermore it seems as though cells do not arrest in response to a direct sensing 
of chromosome number, as when diploid cells were fused together they could re-
enter a subsequent cell cycle (Wong and Stearns, 2005). It was also shown that 
the presence of extra centrioles could not cause an arrest, as when diploid cells 
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were fused to enucleated cells containing centrioles they also continued to cycle 
(Wong and Stearns, 2005).  
 
Despite the possibility that drug concentrations and DNA damage could be 
responsible for some of the results discussed above, it is interesting that higher 
concentrations of cytochalasin specifically affected binucleated cells (Uetake and 
Sluder, 2004). Furthermore, spontaneously arising binucleated cells caused by 
chromosome non-disjunction also often undergo cell cycle arrest (Shi and King, 
2005). It appears that although there is no defined checkpoint in all cell types that 
can sense chromosome numbers, many cells are not able to continue to proliferate 
with a tetraploid DNA content. This arrest seems closely linked to p53 function. In 
support of this, tetraploid cells were observed to increase in frequency in Barrett’s 
oesophagus with the loss of chromosome 17p, where p53 is located (Galipeau et 
al., 1996).  
 
Additionally, mitotic slippage and a 4N DNA content can result in apoptosis 
(Castedo et al., 2006). In a study by Kroemer and colleagues, HCT-116 cells were 
acutely treated with the spindle poison nocodazole, which results in an 
accumulation of >4N cells. These cells tended to undergo apoptosis, which was 
measured by the loss of mitochondrial transmembrane potential (Castedo et al., 
2006). This apoptotic phenotype was linked to p53 activation, as p53 knockout cells 
had reduced levels of apoptosis. Apoptotic levels could also be rescued by 
knockout of the pro-apoptotic factor Bax (Castedo et al., 2006). These results 
indicate that tetraploidy can result in apoptosis as well as cell cycle arrest. 
 
It has also been shown that tetraploid cells formed through DNA damage induced 
endoreduplication require inactivation of the tumour suppressor Rb, as well as p53 
inactivation, in order to proliferate (Davoli and de Lange, 2012). Rb blocked entry 
into S phase in cells that experienced DNA damage in G1, but was not sufficient to 
block endoreduplication if cells experienced DNA damage in G2 (Davoli and de 
Lange, 2012). The presence of near-tetraploid karyotypes across different tumour 
types correlates well with inactivation of the Rb pathway (Davoli and de Lange, 
2011). 
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1.6.1 What triggers p53 in tetraploid cells? 
It seems clear that p53 has a role to play in limiting the long-term proliferation of 
tetraploid cells. Many studies have been carried out to try and identify the nature of 
the signal in tetraploid cells that can activate p53.  
 
Using tetraploid clones derived from HCT-116, Kroemer and colleagues showed 
that tetraploidy frequently resulted in aberrant mitoses (Vitale et al., 2007). 
Tetraploid cells that underwent aberrant mitoses tended to display phosphorylation 
of p53 at serine-15, suggesting that catastrophic mitoses trigger p53 in tetraploid 
cells (Vitale et al., 2007). In support of this finding Kuffer and colleagues 
demonstrated through live cell imaging that HCT-116 and RPE-1 cells treated with 
dihydrocytochalasin D (DCD) to prevent cytokinesis mainly arrested or died after 
the first mitosis with a tetraploid DNA content (Kuffer et al., 2013). In accordance 
with this response being due to p53 activation, HCT-116 p53-/- cells did not exhibit 
the same arrest. Similar to the results of Kroemer and colleagues, the arrest in 4N 
HCT-116 cells seemed to be coupled to abnormal mitoses, as either multipolar 
divisions or chromosome segregation errors after bipolar divisions most frequently 
resulted in arrest (Vitale et al., 2007, Kuffer et al., 2013). The increased levels of 
p53 that were observed in tetraploid cells did not seem to be caused by DNA 
damage, as the kinetics of γH2AX foci formation did not correlate with the nuclear 
accumulation of p53 (Kuffer et al., 2013). Instead, the authors found a link with 
increased oxidative stress (as measured by 8-hydroxy-2-deoxyguanosine 
detection) in tetraploid cells, which correlated well with the increase in p53. Using 
siRNA to test a range of mitotic kinases for their ability to activate p53, the authors 
found that ATM depletion could increase the percentage of cycling cells, and 
conclude that ATM is likely to be responsible for the p53 activation in tetraploid 
cells (Kuffer et al., 2013). It will be of interest to determine how abnormal mitoses 
cause an increase in levels of oxidative stress in tetraploid cells.  
 
It has been shown that actin damage caused by cytokinesis inhibitors such as 
cytochalasins induces phosphorylation of p53 at serine-15 and serine-37 
immediately after cytokinesis failure (Chae et al., 2012). In contrast to the results of 
Kuffer and colleagues, p53 did not seem to be up-regulated by ATM in these 
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conditions (Kuffer et al., 2013, Chae et al., 2012) The up-regulation of p53 was not 
observed when cells were treated with actin damaging agents in S phase (Chae et 
al., 2012). These results suggest that there is a specific trigger of p53 in polyploid 
arrested cells. This signal could emanate from the extra centrioles present in 
tetraploid cells formed through cytokinesis failure. Centriole damage can up-
regulate p53 through the stress response kinase p38 (Mikule et al., 2007). 
Depletion of different centrosomal proteins led to p38 activation, subsequent p53 
phosphorylation and cell cycle arrest though p21 activation. Inhibition of p38 
abrogated this G1 arrest (Mikule et al., 2007). It is possible that extra centrioles 
present after cytokinesis failure could also activate this stress response, resulting in 
G1 arrest.  
 
Aylon and colleagues demonstrated a mechanism linking both cytoskeletal damage 
and centrosome dysfunction to p53 up-regulation in G1 arrested tetraploid cells 
(Aylon et al., 2006). The authors report that LATS2 (large tumour suppressor 2) is a 
key mediator of p53 up-regulation after spindle disruption. LATS2 is a centrosomal 
protein that is also thought to play in a role in proper spindle formation (Toji et al., 
Abe et al., 2006). LATS2 knockout cells display defects in cytokinesis, centrosome 
amplification, multipolar mitoses and genetic instability (McPherson et al., 2004). 
LATS2 was shown to interact with the negative regulator of p53, the E3 ubiquitin 
ligase MDM2 (Aylon et al., 2006). This interaction was enhanced upon treatment 
with the microtubule depolymeriser nocodazole, which arrests cells at G2/M, and 
also disrupts centrosome homeostasis (Uzbekov et al., 2002, Burakov et al., 2003). 
Binding of LATS2 to MDM2 decreased p53 ubiquitination, resulting in p53 
stabilisation (Aylon et al., 2006). After nocodazole treatment, LATS2 translocated 
from its centrosomal location to the nucleus, where it could bind MDM2 and 
stabilise p53 levels. This effect was not observed upon DNA damage, suggesting 
that LATS2 relocates to the nucleus specifically in response to spindle disruption. 
The authors describe a positive feedback loop between LATS2 and p53, since 
LATS2 transcription was enhanced by p53 activation (Aylon et al., 2006). Increased 
LATS2 transcription in response to spindle damage was specific to cells in G2/M 
phase. Increased expression of LATS2 in U2OS cells that do not normally arrest in 
response to nocodazole resulted in the restoration of cell cycle arrest. This arrest 
was dependent on the kinase function of LATS2, as a kinase dead version could 
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not initiate an arrest (Aylon et al., 2006). Furthermore, knockdown of LATS2 
phenocopied p53 knockdown with respect to abrogating cell cycle arrest after 
cytokinesis failure. This important finding demonstrates that LATS2 is a key 
regulator of cell cycle arrest that is activated in response to microtubule or 
centrosome disruption. 
 
Pellman and colleagues, who identified LATS2 in a screen for regulators of cell 
cycle arrest after cytokinesis failure, further described the mechanism that activates 
LATS2 in tetraploid cells (Ganem et al., 2014). They noted that as well as the p53 
induction due to MDM2 binding described by Aylon and colleagues, LATS2 also 
caused cell cycle arrest through its canonical downstream pathway members YAP 
and TAZ (Aylon et al., 2006, Ganem et al., 2014). Depletion of LATS2 by siRNA 
resulted in an increase in YAP expression and accumulation of YAP in the nucleus. 
YAP and TAZ activation normally initiate oncogenic proliferation; therefore 
activation of LATS2 after cytokinesis failure normally inhibits YAP and stops cell 
cycle progression (Ganem et al., 2014). To understand how LATS2 was activated 
in tetraploid cells Ganem and colleagues looked for upstream regulators of LATS2 
signalling. Reduced RhoA activity and cytoskeletal reorganisation have previously 
been shown to activate LATS2 (Zhao et al., 2012, Yu et al., 2012) Ganem and 
colleagues found that RhoA activity was reduced in tetraploids, and could partially 
attribute this to the increase in Rac1 activity in tetraploid cells that is due to the 
presence of extra centrioles (Godinho and Pellman, 2014, Ganem et al., 2014). 
Although they do not show a functional link between Rac1 and RhoA, they 
demonstrate that the Hippo pathway is activated in response to the presence of 
extra centrosomes induced by PLK4 overexpression, and in mouse hepatocytes 
that become tetraploid as the adult liver develops. Although the authors establish 
that RhoA and reduced cytoskeletal contractility are important for LATS2 activation 
in tetraploid cells, it is still unknown how RhoA inhibits the Hippo pathway. 
Intriguingly however, the authors show that in high ploidy tumours, there is a 
significant correlation with YAP amplification and deletion of LATS2 suggesting that 
inactivation of the Hippo pathway may be a key event necessary for the sustained 
proliferation of polyploid tumours (Ganem et al., 2014).   
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The above work has contributed greatly to an understanding of the fundamental 
pathways that limit the proliferation of tetraploid cells, which are summarised in 
Figure 1.6. 
 
 
 
Figure 1.6: Mechanisms to limit tetraploid cell proliferation 
Schematic representing the main pathways in tetraploid cells (formed through 
cytokinesis failure or mitotic slippage) that either result in cell cycle arrest or 
apoptosis. For references see text. 
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generally lead to cell cycle arrest or apoptosis. However, there are still unanswered 
questions, such as elucidating exactly how oxidative damage is caused by 
abnormal mitosis and chromosome missegregation (Kuffer et al., 2013). There may 
well also be additional stresses occurring in tetraploid cells that have not yet been 
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uncovered. The role of LATS2 in regulating not only the p53 response to mitotic 
slippage and cytokinesis failure, but also the inhibition of YAP and TAZ mediated 
transcription is becoming clear (Aylon et al., 2006, Ganem et al., 2014). However, 
the exact mechanism linking Rac1 activation, decreased RhoA contractility and 
increased LATS2 still requires refinement. In addition the applicability of this 
pathway to different cell types could be investigated.  
 
1.6.2 An indirect mechanism to eliminate tetraploid cells 
A novel mechanism to eliminate tetraploid cells within the tumour environment has 
also been demonstrated. Senovilla and colleagues showed that tetraploid cancer 
cells formed through cytokinesis failure exhibit an endoplasmic-reticulum (ER) 
stress response, characterised by the translocation of calreticulin to the cell surface 
(Senovilla et al., 2012). The expression of calreticulin on the cell surface is thought 
to be one of the factors determining whether immunogenic cell death occurs after 
cytotoxic treatments (Obeid et al., 2007). Hence, the authors tested whether 
polyploid cancer cells were more easily recognised and culled by the immune 
system of mice (Senovilla et al., 2012). Indeed, they found that polyploid cancer 
cells grew more slowly in immune-competent mice than diploid cancer cells. 
Furthermore tumours that had arisen from polyploid cancer cells appeared to have 
undergone ‘immuno-selection’ for cells with a lower DNA content (Senovilla et al., 
2012). This intriguing mechanism of ploidy ‘immuno surveillance’ could be an 
interesting anti-cancer immune mechanism to limit the proliferation of genetically 
unstable polyploid cells (Senovilla et al., 2012). The exact cause of the ER-stress 
and calreticulin membrane localisation in tetraploid cancer cells has yet to be 
elucidated.  
 
1.7 The consequences of tetraploidisation 
Since tetraploidy appears to be a common occurrence in cancer, many studies 
have been undertaken using tetraploid cells generated in different ways to assess 
how tetraploidy could be linked to tumour formation. The consequences of 
experimentally induced tetraploidisation are discussed below. 
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1.7.1 Increased tumorigenicity of tetraploid cells 
A landmark study by the Pellman laboratory was the first to show that tetraploid 
cells generated from cytokinesis failure were more tumorigenic than diploid cells 
(Fujiwara et al., 2005). Using the cytokinesis inhibitor dihydrocytochalasin B (DCB), 
the authors generated a proliferating population of p53-/- mouse mammary 
epithelial cells (MMECs). Consistent with the notion that p53 plays an important 
role in limiting the proliferation of tetraploid cells, p53 proficient tetraploid MMECs 
could not be propagated in culture. Using an initiation/promotion transformation 
assay, the authors showed that only tetraploid p53-/- MMECs exhibited anchorage 
independent growth in soft agar. Even more strikingly, only tetraploid p53-/- 
MMECs developed tumours when injected subcutaneously into nude mice, whilst 
diploid p53-/- MMECs did not form any tumours (Fujiwara et al., 2005).  
 
Tetraploid cells formed through defects in mitosis have also been indirectly shown 
to be tumorigenic. The overexpression of Aurora A causes premature chromatid 
separation and the formation of tetraploid cells (Meraldi et al., 2002). In a study of 
transgenic mice overexpressing Aurora A, tetraploid cells were seen in 
premalignant stages of mammary gland tumourigenesis, suggesting they may be a 
cause of tumour formation (Nguyen et al., 2009).  
 
Direct evidence that tetraploidy can cause tumourigenesis was also shown for 
tetraploid cells formed through cell fusion. Normal human diploid fibroblasts were 
altered by the expression of adenoviral E1A, which inactivates Rb, and the 
oncogene HRAS, which prevents apoptosis (Duelli et al., 2007). A population of 
fibroblasts was then fused by infection with an otherwise harmless retrovirus 
MPMVE. One out of three cell populations that had deregulated oncogenes and had 
been fused with the virus formed tumours when injected into nude mice, but none 
of the other cell populations formed tumours (Duelli et al., 2007). 
 
Endoreduplication caused by telomere crisis has also been shown to result in 
increased tumourigenesis (Davoli and de Lange, 2012). MEFs lacking the shelterin 
proteins POT1a and POT1b have been shown previously to form tetraploid cells 
through endoreduplication (Davoli et al., 2010). These tetraploid MEFs showed 
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enhanced growth in soft agar compared to diploid MEFs, and also formed a greater 
frequency of tumours when injected into nude mice (Davoli and de Lange, 2012).  
 
Taken together these studies show that tetraploidisation, which can be 
experimentally achieved through multiple routes, frequently leads to an enhanced 
ability to form tumours. This work sheds light on the observation of tetraploid cells 
at early stages of premalignant conditions such as Barrett’s oesophagus (Galipeau 
et al., 1996).  
 
1.7.2 Genetic instability in tetraploid cells 
In the above studies experimentally induced tetraploidisation frequently led to 
numerical and structural chromosomal instability as well as increased 
tumourigenesis. In the study by Fujiwara and colleagues, tetraploid cells induced 
via cytokinesis failure exhibited increased levels of gross chromosomal 
rearrangements and whole chromosome aneuploidy compared to diploid cells 
(Fujiwara et al., 2005). However diploid MMECs do exhibit both whole chromosome 
aneuploidy and gross chromosomal rearrangements, suggesting that the 
mechanisms generating these types of genetic instability are already present in 
diploid cells. As the tetraploid cells formed tumours whereas the diploid MMECs did 
not, the karyotype of tetraploid-derived tumours was assessed by array CGH. 
Tetraploid derived MMEC tumours displayed both numerical and structural 
chromosome aberrations. Furthermore all tumours analysed showed a recurrent 
gain of a segment of chromosome 9, containing a cluster of matrix 
metalloproteinase (MMP) genes that are also overexpressed in human breast 
cancers (Fujiwara et al., 2005).  
 
Tetraploid cells generated through cell fusion also showed gross chromosomal 
abnormalities (Duelli et al., 2007). These included both numerical and structural 
chromosome aberrations that were diverse between different cells of the same 
population: in a spectral karyotyping (SKY) analysis, all of the ninety cells that were 
analysed had a different karyotype (Duelli et al., 2007). The degree of 
chromosomal instability observed in these virally fused cells was much greater than 
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that from the Fujiwara study of tetraploid cells derived from cytokinesis failure, 
suggesting that the mechanism of tetraploidisation, as well as the genetic 
background of the cell type used, can affect the degree of chromosomal instability 
(Fujiwara et al., 2005, Duelli et al., 2007).  
 
Telomere-driven tetraploidisation also results in tumours that are genetically 
diverse (Davoli and de Lange, 2012).  Cell lines were established from tumours 
derived from MEFs that had undergone telomere crisis and become tetraploid. 
Upon passaging of these tetraploid-tumour derived cell lines there was an increase 
in numerical chromosome instability, as assessed by metaphase chromosome 
counting (Davoli and de Lange, 2012). The tetraploid cell lines showed high rates 
of chromosome loss compared to diploid-derived tumours (Davoli and de Lange, 
2012).  
 
Table 1.1: Summary of studies investigating genome stability after 
tetraploidisation (TP) 
Study Cell line Mechanism of TP 
Method of 
TP 
p53 
status Rb status 
Structural 
instability 
Numerical 
instability 
Fujiwara 
et al., 
2005 
MMECs -
mouse 
epithelial 
cells  
Cytokinesis 
failure DCB 2µM p53-/-   
SKY     
number of 
translocations 
Chromosome 
counts - 
metaphase 
spreads 
Duelli et 
al., 2007 
D551 -
human 
diploid 
fibroblasts 
Virally 
induced cell 
fusion 
Adenoviral 
E1A + 
HRAS + 
MPMVE 
infection 
  Rb inactivated SKY SKY 
Davoli et 
al., 2012 MEFs 
Telomere 
dysfunction 
POT1a-
tetOFF 
p53 
inactivated 
Rb 
inactivated  NA 
Chromosome 
counts - 
metaphase 
spreads (from 
TP derived 
tumours) 
 
These studies all indicate that tetraploidy results in karyotypic diversification. That 
tetraploid cells formed though different mechanisms all show genetic instability 
suggests that this phenotype is related to tetraploidy itself, rather than the 
experimental procedures used to generate it, although different mechanisms of 
tetraploidisation can affect the levels of genetic instability (Duelli et al., 2007, 
Fujiwara et al., 2005). Interestingly all the above studies have used cell lines in 
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which p53 and/or Rb function was disrupted (Table 1.1). This could have affected 
the prevalence of genetic instability observed in these studies.  
 
1.7.3 Altered response to drug treatment in tetraploid cells 
Several studies have shown an altered response to drug treatment in tetraploid 
cells. An acute tetraploid cell cycle arrest has been shown to lead to resistance to 
the DNA damaging drug cisplatin (Shen et al., 2013). Naturally occurring cisplatin 
sensitive and cisplatin resistant clones were isolated from HCT-116. The resistant 
clones had both a prolonged G2 arrest, and a G1 tetraploid arrest in response to 
cisplatin treatment. Abrogation of either of these arrests with inhibition of cell cycle 
regulators led to cisplatin sensitisation (Shen et al., 2013). This result indicates that 
in the initial response to cisplatin treatment, a 4N arrest is necessary for cell 
survival, otherwise cells continue to catastrophic mitosis and die. Tetraploidy has 
also been shown to be important in the long-term treatment of cells with DNA 
damaging agents. In a study by Kroemer and colleagues investigating the 
regulation of apoptosis in tetraploid cells, it was found that tetraploids from both 
HCT-116 and RKO colorectal cancer cell lines were more resistant to cisplatin, 
oxaliplatin and camptothecin, as well as physical DNA damage induced by UV or γ-
irradiation (Castedo et al., 2006). The authors found that this resistance was due to 
a small number of p53 target genes found to be transcriptionally altered between 
diploid and tetraploids. In particular the knockdown of p53R2 (p53-inducible 
ribonucleotide reductase-2, RRM2B) could re-sensitize tetraploid RKO clones to 
cisplatin (Castedo et al., 2006). This interesting study demonstrates that small 
differences in transcriptional regulation between diploid and tetraploid clones can 
result in marked differences in response to drugs. Another study has shown that 
tetraploid cells that have arisen through endoreduplication are also more resistant 
to both cisplatin and ionising radiation (Shen et al., 2008). The continued treatment 
of HCT-116 and U2OS cells with the MDM2 antagonist Nutlin-3a, which results in 
p53 stabilisation, caused prolonged arrest in G2 from which cells eventually re-
replicated their DNA to become tetraploid (Shen et al., 2013). These 
endoreduplicated cells were shown to be more resistant to cisplatin and ionising 
radiation, evidenced by reduced apoptosis. However, prolonged treatment with 
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ionising radiation revealed that long-term clonogenic survival of tetraploid HCT-116 
cells in response to ionising radiation was not increased (Shen et al., 2013). 
 
In contrast to the above studies, tetraploid hepatocellular carcinoma cancer cells 
derived from mitotic failure caused by nocodazole treatment exhibited increased 
sensitivity to DNA damage (Hau et al., 2006). Tetraploid Hep3B cells were more 
sensitive than parental diploid Hep3B cells to ionizing radiation, and also to the 
topoisomerase II inhibitor Adriamycin. The authors concluded that the increased 
sensitivity of tetraploid cells to these DNA damaging treatments was likely due to 
the increased DNA content, since tetraploid Hep3B cells contained more γ-H2AX 
foci than diploid cells in response to the same dose of irradiation (Hau et al., 2006). 
In a further study using the same hepatocellular carcinoma cells, the authors found 
that tetraploid Hep3B were also more sensitive to Aurora B inhibition (Marxer et al., 
2012). In addition, tetraploid cells formed through fusion of Swiss 3T3 fibroblasts 
were also more sensitive to Aurora B inhibitors. The apoptosis induced by Aurora B 
inhibition appeared to be dependent on cells undergoing repeated rounds of failed 
cytokinesis and genome reduplication. In support of this, the same sensitivity was 
observed in tetraploid cells in response to cytochalasin B, which inhibits cytokinesis.  
In diploid cells this apoptosis seemed to occur in very high ploidy cells (of up to 
16N) (Marxer et al., 2012). The authors therefore hypothesise that the increased 
sensitivity of tetraploid cells is due to them reaching this critical ‘ploidy limit’ quicker 
than diploid cells, as they start with a higher DNA content (Marxer et al., 2012). 
 
Studies have also been undertaken to try and find specific vulnerabilities in 
tetraploid cancer cells that could be exploited therapeutically. Using the same 
tetraploid cells derived from HCT-116 and RKO in which they had demonstrated 
increased resistance to cisplatin and other DNA damaging agents, Kroemer and 
colleagues searched for specific kinases that may be able to target tetraploid cells 
(Vitale et al., 2007). They found that tetraploidy was linked to abnormal mitosis, 
even in the presence of a functional SAC, and speculated that tetraploid cells may 
therefore be more vulnerable to inhibition of the checkpoint kinase CHK1 (Vitale et 
al., 2007). Indeed tetraploid cells were more sensitive to CHK1 knockdown and 
chemical inhibition, which resulted in increased apoptosis compared to diploid cells. 
The authors found that CHK1 inhibition resulted in the up-regulation of many 
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apoptotic p53 target genes specifically in tetraploid cells. The mechanism by which 
CHK1 kills tetraploid cells was not elucidated, but the authors speculate it could be 
due to CHK1 depletion resulting in premature mitotic exit due to CDK1-cyclin B 
activation (Vitale et al., 2007). The same group later showed that CHK1 inhibition 
up-regulated p53 through p38 MAPK (Vitale et al., 2010a).  
 
Other vulnerabilities that also target mitosis have been found in tetraploid cells. 
Since many tetraploid cells contain extra centrosomes, Kwon and colleagues 
inhibited centrosome clustering by knocking down the kinesin HSET (Kwon et al., 
2008). HSET knockdown increased the frequency of multipolar anaphases in 
tetraploid BJ fibroblasts and NIH3T3 cells, which they showed can lead to 
increased cell death in other cell lines with extra centrosomes (Kwon et al., 2008). 
Inhibition of another mitotic kinesin, Eg5 (or KIF11), which normally separates 
centrosomes for proper bipolar spindle formation, was also more effective at killing 
tetraploid cells (Rello-Varona et al., 2009). In an unbiased screen for agents that 
could selectively kill tetraploid cells, resveratrol and other AMPK (AMP-activated 
protein kinases) inhibitors were found to specifically target tetraploid cancer cells 
(Lissa et al., 2014). Although the cause of the vulnerability to these agents in 
tetraploid cells was not uncovered, it was shown that treatment of a mouse model 
of colon cancer with resveratrol reduced the frequency of tetraploid cells (Lissa et 
al., 2014). Whether this reduction in tetraploid cell formation is directly responsible 
for the previously reported chemo-preventive effect of this compound is not yet 
known (Schneider et al., 2001, Sale et al., 2005). 
 
Taken together these studies demonstrate that there is likely to be cell-type specific 
effects of tetraploidy on the response to drugs. Although some studies have shown 
increased resistance to DNA damaging agents, others have shown increased 
sensitivity in tetraploid cells. In several of these studies the HCT-116 colorectal 
cancer has been used to test the response of diploid and tetraploid clones to 
cisplatin. However, since HCT-116 has been shown to contain cells that have a 
varied response to cisplatin (Shen et al., 2013), the differences noted between 
diploids and tetraploids could be due to inherent clonal variation within the HCT-
116 population. Larger studies still need to be conducted on tetraploid cells formed 
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through different mechanisms to conclude whether tetraploidy inherently leads to 
drug resistance or drug sensitivity.  
 
1.7.4 An altered response to DNA damage in polyploid cells 
An increased level of replication stress normally activates cell cycle checkpoints 
that act as a barrier to tumourigenesis. This replication stress can be modelled by 
introducing mutations in key DNA replication genes such as FEN1 (flap-
endonuclease-1) (Zheng et al., 2011). Interestingly, when cells are subjected to this 
replication stress they frequently become tetraploid and aneuploid (Zheng et al., 
2011). Using a mouse model with mutations in the FEN1 gene, the same authors 
showed that near-polyploid aneuploid cells have a unique response to DNA 
replication stress (Zheng et al., 2012). Upon serial expansion of MEFs from these 
FEN1 mutant mice, populations of cells with unlimited proliferative potential were 
isolated. These cells were near-polyploid aneuploid and appeared to have altered 
their response to DNA damage in order to overcome replication stress induced 
senescence (Zheng et al., 2012). The polyploid cells exhibited reduced CXCL2 
expression, which normally activates ATR/ATM mediated DNA damage response 
signalling, as well as a reduction in the expression of p53 and p21 target genes. 
Further, the polyploid cells heterogeneously overexpressed BRCA1 and the 
p19INK4D ARF protein, which appeared to enhance their capacity for single stranded 
DNA repair. Polyploid cells also showed an increased capacity for NHEJ (non-
homologous end joining) repair. These results suggest there is flexibility within a 
polyploid genome that can allow cells to overcome barriers to tumour progression 
(Zheng et al., 2012). Interestingly these cells did not have a p53 mutation, but 
appeared to have methylated several downstream targets of p53, such as p21, 
resulting in loss of expression, and allowing the polyploid cells to continue 
proliferating (Zheng et al., 2012). It will be of interest to discover whether 
polyploidisation and subsequent adaptation to escape replication stress induced 
senescence occur in different tumour types. Furthermore it would be interesting to 
investigate whether similar changes in the response to DNA damage had occurred 
in other tetraploid cell models, especially those which have been shown to be either 
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sensitive or resistant to DNA damaging agents (Castedo et al., 2006, Hau et al., 
2006).  
 
1.8 Mechanisms of chromosomal instability 
Chromosomal instability (CIN) is a dynamic process that describes a continual 
change in karyotype between cell generations. It is characterised by changes both 
in chromosome number and structure (Lengauer et al., 1997). CIN is a common 
feature of most solid tumour types (Thompson and Compton, 2011b, Beroukhim et 
al., 2010). Although CIN is normally described separately in terms of W-CIN (whole 
chromosome CIN, or numerical CIN) and S-CIN (structural CIN), both forms of CIN 
are usually observed together in tumours (Venkitaraman, 2007, Gaasenbeek et al., 
2006). This observation suggests that there may be mechanisms simultaneously 
responsible for causing both W-CIN and S-CIN (Venkitaraman, 2007). Studies of 
CIN in cell lines have shown that this phenotype is normally characterised by an 
elevated rate of chromosome missegregation (Lengauer et al., 1997, Roschke et 
al., 2003, Thompson and Compton, 2008). Therefore investigations into 
mechanisms of chromosomal instability (and in particular W-CIN) have largely 
focussed on the cause of the increase in anaphase chromosome segregation 
errors.  
 
1.8.1 Mitotic checkpoint defects in CIN cells  
As the SAC and error correction machinery are normally responsible for ensuring 
faithful chromosome partitioning into two daughter cells at anaphase (see Section 
1.4.2), defects in these pathways have been suggested to lead to CIN (Kops et al., 
2004). Some rare somatic mutations have been found in mitotic checkpoint genes 
such as BUB1B (BUBR1) (Cahill et al., 1998) and members of the KMN network 
such as ROD and ZWILCH (Wang et al., 2004b). However, in vivo studies have 
shown that complete loss of the mitotic checkpoint is embryonic lethal in mice 
(Kalitsis et al., 2000), and ablation of the checkpoint is also lethal to cancer cells in 
vitro (Kops et al., 2004). These data have led to speculation that the mitotic 
checkpoint is more likely to be weakened in CIN tumours than completely 
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abolished (Michel et al., 2004, Iwanaga et al., 2007, Janssen and Medema, 2012). 
Indeed, altered expression of many mitotic checkpoint genes have been shown in 
human cancers to affect the functioning of the mitotic checkpoint (Janssen and 
Medema, 2012). A common alteration in a mitotic checkpoint gene is the 
overexpression of MAD2, which can be caused by dysfunction of the Rb pathway, 
a common occurrence in cancer (Hernando et al., 2004). MAD2 overexpression 
leads to aneuploidy and spontaneous tumour formation in mice (Sotillo et al., 2007). 
Taken together, mutations in checkpoint genes and decreased expression of 
checkpoint proteins do occur in some cancers, albeit rarely. A more common 
mechanism of checkpoint weakening appears to be altered expression of a variety 
of checkpoint genes, but in particular MAD2 (Janssen and Medema, 2012). 
 
1.8.2 Chromosome attachment errors and CIN 
CIN cell lines are characterised by an increase in chromosome segregation errors. 
Although checkpoint defects are relatively rare in CIN cancers, some types of 
chromosome mis-attachments to the mitotic spindle are not recognised by the error 
correction machinery (see Section 1.4.2). Merotelic attachments, where one 
kinetochore is attached to microtubules from both poles (see Figure 1.4), lead to 
lagging chromosomes and missegregation (Cimini et al., 2001, Thompson and 
Compton, 2011a). The different causes of merotelic attachments, and their 
relevance to cancer are discussed below. 
 
1.8.2.1 Spindle morphology and merotelic attachments  
The formation of a bipolar spindle is essential for the correct progression through 
mitosis. Correct spindle formation largely relies on the separation and positioning of 
centrosomes at opposite poles of the cell (Bettencourt-Dias and Glover, 2007). The 
centrosome is the microtubule organising centre of mammalian cells, and in mitosis 
controls microtubule mediated separation of genomic material (Nigg, 2006, 
Bettencourt-Dias and Glover, 2007). Centrosomes either separate before nuclear 
envelope breakdown (NEBD) in prophase, or after NEBD, in pro-metaphase (Toso 
et al., 2009).  
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It has been shown that cells in which centrosome separation occurs after NEBD 
are more likely to contain increased frequencies of chromosomes that are mis-
attached to the mitotic spindle (Silkworth et al., 2012). This is thought to be due to 
cells proceeding through an intermediate monopolar spindle stage, where both 
centrosomes are in close proximity to each other (Silkworth et al., 2012). In support 
of this, treating cells with monastrol, a drug that induces monopolar spindle 
formation through inhibition of the kinesin Eg5 (KIF11) can increase segregation 
error frequency (Choi and McCollum, 2012). The deubiquitinase USP44 has been 
shown to play a role in correct centrosome separation by direct binding to the 
centriolar protein centrin (Zhang et al., 2012). Loss of USP44 delays centrosome 
separation and increases the frequency of segregation errors. Furthermore, USP44 
knockout mice developed an increased frequency of spontaneous tumours (Zhang 
et al., 2012).  
 
As well as delayed centrosome separation, accelerated centrosome separation has 
also been shown to increase the frequency of chromosome segregation errors 
(Nam and van Deursen, 2014). The overexpression of cyclin-B2, which is a 
common occurrence in cancer, was shown to accelerate centrosome separation 
and result in lagging chromosomes (Nam and van Deursen, 2014). The mechanism 
by which accelerated centrosome separation increases the frequency of mis-
attached chromosomes has yet to be revealed, but it has been suggested that 
mature kinetochore structures that usually correct these errors may not have 
formed properly in early pro-metaphase (Nam et al., 2015). 
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Figure 1.7: Centrosome dynamics influence chromosome segregation fidelity 
Figure adapted from (Nam et al., 2015). Aberrant centrosome dynamics and 
centrosome numbers can influence chromosome attachment to the mitotic spindle. 
Merotelically attached chromosomes will result in lagging chromosome at 
anaphase. For references see text in Section 1.8.2.1. MT= microtubule. 
  
 
As well as correct centrosome separation, centrosome number also impacts upon 
spindle morphology and kinetochore-microtubule attachments. Centrosome 
amplification is common in tumours (Pihan et al., 1998, Nigg, 2006). An early 
theory, proposed by Theodor Boveri, suggested that extra centrosomes would 
result in aneuploidy by causing multipolar cell divisions (Boveri, 2008). However, 
work from the Pellman laboratory showed that cancer cells with extra centrosomes 
rarely undergo multipolar divisions (Ganem et al., 2009). Instead, the authors 
showed that these cells undergo a transient multipolar stage, but eventually cluster 
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their centrosomes and divide in a bipolar fashion. This multipolar spindle 
intermediate causes an increase in the frequency of merotelic chromosome 
attachments (Ganem et al., 2009, Silkworth et al., 2009). The kinesin, HSET, is 
specifically required for cells with supernumerary centrosomes, including tetraploid 
cells, to form a bipolar spindle (Kwon et al., 2008).  
 
Increased microtubule assembly rates have also been shown to contribute to CIN 
through abnormal spindle geometry (Ertych et al., 2014). Using a fluorescently 
tagged microtubule plus end binding protein, EB3, the authors tracked microtubule 
assembly rates in a panel of CIN- and CIN+ colorectal cancer cell lines, and 
showed CIN+ cell lines had consistently higher microtubule plus end assembly 
rates (Stepanova et al., 2003, Ertych et al., 2014). Crucially, restoration of normal 
microtubule assembly rates could stabilise the karyotypes of CIN cells. Increased 
microtubule assembly rates altered normal spindle morphology, promoting transient 
abnormalities in spindle axis positioning that resulted in lagging chromosomes. The 
increase in microtubule assembly rates was shown to be linked to two genetic 
alterations that are common in colorectal cancer, Aurora kinase A overexpression, 
and loss of CHK2 (Ertych et al., 2014). 
 
1.8.2.2 Microtubule dynamics and merotelic attachments 
The correction of merotelic attachments depends upon the ability of the error 
correction machinery to depolymerise microtubules. It has been shown that an 
increased stability of kinetochore-microtubule attachments in CIN cells underlies 
the increase in merotelic attachments and chromosome segregation errors 
(Bakhoum et al., 2009a). Inhibiting the ability of the error correction machinery to 
destabilise attachments in normal diploid RPE-1 cells, for example by inhibiting 
MCAK activity, resulted in an increase in segregation errors comparable to the 
levels observed in CIN cells (Bakhoum et al., 2009b). Intriguingly, the 
overexpression of the checkpoint protein MAD2 can increase the stability of 
kinetochore-microtubule attachments through a reduction in Aurora B activity at 
centromeres (Kabeche and Compton, 2012). This reduction in Aurora B activity is 
independent of the normal checkpoint function of MAD2, but the exact mechanism 
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by which it impedes Aurora B has yet to be established (Kabeche and Compton, 
2012, Janssen and Medema, 2012).  
 
1.8.3 Defective sister chromatid cohesion 
During cell division sister chromatids are held together by the cohesin complex 
before separation during anaphase. Maintaining proper cohesion between sister 
chromatids until anaphase onset is critical for ensuring accurate chromosome 
segregation (Jallepalli et al., 2001, Iwaizumi et al., 2009). Many different cancer 
types show evidence of mutations in various subunits of the cohesin complex 
(Barber et al., 2008, Wang et al., 2004a, Thota et al., 2014). Mutations in the 
cohesin complex have been suggested to underlie chromosomal instability in 
colorectal cancer, as their down-regulation caused cohesion defects and 
segregation errors in cultured cells (Barber et al., 2008). The cohesin complex 
subunit STAG2 is mutated in multiple cancer types, and deletion of STAG2 in 
diploid cell lines resulted in segregation errors (Solomon et al., 2011).  Furthermore, 
reconstitution of STAG2 in aneuploid cell lines lacking the endogenous locus 
restored chromosomal stability (Solomon et al., 2011). STAG2 has recently been 
shown to have a role in error correction during mitosis (Kleyman et al., 2014). 
STAG2 depleted cells showed an increase in the stability of kinetochore-
microtubule attachments, and improper localisation of the CPC components Aurora 
B and Bub1 (Kleyman et al., 2014). How STAG2 normally corrects improper-
kinetochore attachments and affects localisation of the CPC during mitosis has not 
been determined. However, recent genomics studies have shown that STAG2 
mutations are not associated with aneuploidy in tumours (Balbas-Martinez et al., 
2013, Djos et al., 2013, Taylor et al., 2014). Given that cohesin has multiple roles in 
the cell besides cohesion of sister chromatids, including transcriptional regulation, 
DNA repair and telomere protection, the precise contribution of STAG2 mutations 
to cancer development requires further investigation.  
 
Depletion of the retinoblastoma protein (Rb) has been shown to cause cohesion 
defects and increased chromosome segregation in diploid cells (Manning et al., 
2010, van Harn et al., 2010). Rb depletion was shown to lead to an altered 
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distribution of cohesin on chromatin, likely because of altered histone 4 methylation 
(H4K20 marks) (Manning et al., 2014). The cohesion defects in these cells 
produced altered replication dynamics, DNA damage and impaired mitotic fidelity, 
which could all be rescued by establishment of proper cohesion (Manning et al., 
2014). Increasing cohesion by inactivation of WapI, a cohesin antagonist, could 
also rescue CIN in Rb deficient cancer cells (Manning et al., 2014). The 
mechanism by which cohesion loss leads to replication defects will be an 
interesting area of future research. 
 
1.8.4 DNA damage in CIN cancers 
Many different sources of DNA damage, both endogenous and exogenous, pose a 
risk to genomic integrity (see Section 1.4.1), and most structural chromosome 
aberrations are caused by either mis- or un-repaired double-strand breaks (DSBs) 
(Thompson and Compton, 2011b, Gisselsson, 2008, Janssen and Medema, 2012). 
Many cancers are caused by germline mutations in DNA repair factors, 
emphasising the importance of correct DNA repair in genetic stability (Duker, 2002, 
Hartlerode and Scully, 2009). Structurally abnormal chromosomes can lead to an 
increase in chromosome segregation errors in mitosis such as anaphase bridges, 
and acentric chromosome fragments (Gisselsson, 2008). Anaphase bridges (a 
continual bridge of DNA between the two daughter chromosome masses) occur as 
the normal mitotic machinery tries to segregate chromosomes that have two 
centromeres (dicentric chromosomes). Dicentric chromosomes are either formed 
from sister chromatid fusion, or fusion between different chromosomes following 
DNA damage and erroneous repair. Dicentric chromosomes and anaphase bridges 
can also be caused by DNA damage specifically at the telomeres (Artandi et al., 
2000, Gisselsson et al., 2001). Acentric lagging chromosomes occur because the 
acentric fragment is unable to attach to the mitotic spindle, and is therefore 
segregated randomly between the daughter cells.  
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1.8.5 DNA replication stress 
Replication stress is a broad term that encompasses the many processes that can 
result in hindrance of the replication fork during S phase (Gaillard et al., 2015). 
These processes include DNA damage, oncogene activation, tumour suppressor 
loss, replication machinery defects, nucleotide deficiency, DNA secondary 
structures and hard to replicate sequences (Gaillard et al., 2015, Bartkova et al., 
2006, Bester et al., 2011, Schwartz et al., 2006, Branzei and Foiani, 2010). 
Replication defects can result in DNA damage, chromosome rearrangement and 
chromosome missegregation (Gaillard et al., 2015). It has been shown in this 
laboratory that CIN+ colorectal cancer cell lines exhibit signs of replication stress, 
including delayed replication fork speed (Burrell et al., 2013). Furthermore, a 
frequent region of chromosome loss in CIN+ colorectal cancers, chromosome 18q, 
was found to encode three novel CIN suppressor genes that when silenced could 
increase replication stress and chromosome missegregation in diploid cell lines 
(Burrell et al., 2013). It has also recently been shown that Rb deficiency leads to 
replication stress and aneuploidy (Coschi et al., 2014). As discussed above 
(Section 1.8.3), Rb deficiency has been shown to result in defective chromatid 
cohesion and mitotic defects (Manning et al., 2010, Manning et al., 2014). In a new 
study Rb haploinsufficiency is shown to disrupt the formation of Rb-E2F1-
Condensin II at pericentromeric loci, which results in replication stress (Coschi et 
al., 2014). It is suggested that reduced localisation of this complex to 
pericentromeric regions could lead to unresolved replication intermediates and 
centromere and kinetochore disruption (Coschi et al., 2014). Clearly, since many 
defects can lead to replication stress, shown to link chromosome structure and 
proper chromosome segregation, this phenomenon is likely to be a significant 
driver of chromosomal instability in human cancers.  
 
1.8.6 Mechanisms that link numerical and structural CIN 
Since W-CIN and S-CIN are frequently observed together in cancer, efforts have 
been made to establish whether singular mechanisms can explain both phenotypes 
(Venkitaraman, 2007). Since some genes have roles both in regulating DNA 
replication and/or repair processes and in mitotic progression, defects in these 
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genes could simultaneously lead to changes in chromosome number and structure. 
Examples of these categories of genes would include BRCA1 and CHK2, which are 
reported to function in mitotic fidelity as well as in the DNA damage response (Stolz 
et al., 2010). Structural chromosome aberrations, such as telomere dysfunction that 
can generate dicentric chromosomes, also increase the frequency of numerical 
chromosomal aberrations (Pampalona et al., 2010). Replication stress mediated 
by loss of three novel CIN suppressor genes was also shown to lead to numerical 
chromosomal instability (Burrell et al., 2013). Recent work has also shown that 
lagging chromosomes can become trapped in the cleavage furrow during 
cytokinesis and sustain DNA damage, resulting infrequently in chromosome 
translocations (Janssen et al., 2011). Furthermore lagging chromosomes can 
become entrapped in micronuclei, which may then fail to completely replicate 
before a subsequent mitosis, resulting in catastrophic chromosome breakages, or 
chromothripsis (Crasta et al., 2012, Zhang et al., 2015). Activation of the DNA 
damage response after chromosome missegregation has also been shown to 
induce further numerical instability (Bakhoum et al., 2014). The authors showed 
that after chromosomes were damaged during mitosis, there was an increase in the 
stability of kinetochore-microtubule attachments, resulting in an increase in lagging 
chromosomes at the next mitosis (Bakhoum et al., 2014). 
 
Since CIN is so frequently observed in cancer, occurring in many different tissues 
of origin and genetic contexts, it has been hard to ascribe a single mechanism to 
explain the origin of CIN in all cancer types. It is likely that a combination of all the 
above mechanisms can be responsible for CIN, but these mechanisms may occur 
together or separately, and at different times in tumour development. More work is 
needed to understand how CIN shapes the genomic evolution of different cancer 
types. 
1.9 Consequences of chromosomal instability  
As CIN manifests itself as an increase in chromosome missegregation rates, many 
studies have investigated the cellular consequences of missegregated 
chromosomes.  
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It has been shown that chromosome missegregation induces p53 and p21 in 
diploid cells, and that this acts to supress the generation of aneuploid and CIN cells 
(Thompson and Compton, 2010). It has further been demonstrated that this 
activation of p53 can be linked to ATM (Li et al., 2010). The activation of ATM could 
be due to increasing levels of ROS that have been noted in aneuploid cells (Kumari 
et al., 2014, Li et al., 2010). This data correlates well with the fact that many CIN 
and aneuploid tumours exhibit defects in the p53 pathway (Tomasini et al., 2008). 
However, there are still many open questions in the field about the exact 
mechanism by which p53 is activated after chromosome missegregation. 
 
A single missegregated chromosome will result in aneuploidy in both daughter cells. 
The cellular consequences of single chromosome aneuploidies have been 
extensively investigated in yeast (Torres et al., 2007, Pavelka et al., 2010, Zhu et 
al., 2012, Sheltzer et al., 2011, Sheltzer et al., 2012). Simple chromosome 
aneuploidies have also been studied in human cells, showing that aneuploidy can 
lead to defects in cell proliferation (Williams et al., 2008) and conserved 
transcriptional and proteomic changes, including activation of autophagy (Stingele 
et al., 2012, Durrbaum et al., 2014). Aneuploid cells have also been reported to be 
deficient in HSP90-mediated protein folding response (Donnelly et al., 2014). This 
defect in protein folding was shown to be due to decreased expression of the heat 
shock factor HSF-1 in aneuploid cells, and re-expression of HSF-1 could rescue 
the defect in protein folding (Donnelly et al., 2014). These studies are supported by 
the fact that trisomic MEFS have been found to be more sensitive to autophagy 
inhibitors and inhibition of the chaperone protein HSP90 (Tang et al., 2011). How 
these studies of stable simple chromosome aneuploidies in human cells relate to 
the more complex chromosomal instability found in cancer cells remains an open 
question.  
 
1.9.1 CIN and patient prognosis  
CIN has been shown to correlate with poor patient prognosis across a range of 
different cancer types (McGranahan et al., 2012). These include lung cancer, 
breast cancer, colon cancer, ovarian cancer, endometrial cancer and diffuse large 
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B-cell lymphoma (Choi et al., 2009, Carter et al., 2006, Kronenwett et al., 2004, 
Walther et al., 2008, Mettu et al., 2010, Murayama-Hosokawa et al., 2010, 
Bakhoum et al., 2011). The connection between CIN and poor patient prognosis 
could stem from the fact that CIN is likely to create a highly genetically diverse pool 
of cells within a tumour due to its dynamic nature. This genetic diversity could 
mean that tumours are harder to treat with drugs, as there is a greater chance of 
developing resistance (Lee et al., 2011 2009, Duesberg, 2000). Indeed, CIN+ cell 
lines have been shown to acquire multidrug resistance faster than diploid cells 
(Duesberg et al., 2000). This laboratory has also shown that a panel of CIN+ 
colorectal cancer cell lines are more resistant to a large panel of kinase inhibitors 
than diploid CIN- colorectal cancer cell lines (Lee et al., 2011).  
 
Conversely it has also been shown that extremely high levels of CIN can be 
beneficial for patient survival (Roylance et al., 2011, Jamal-Hanjani et al., 2015). 
This data suggest that there may be an optimal level of CIN that can be tolerated 
by cancer cells, and above this threshold there may be too much instability for a 
cell to survive, especially when tumours are challenged with chemotherapeutics.  
 
1.10    Linking tetraploidy and chromosomal instability 
Although there is a correlation between tetraploidy and aneuploidy in cancer (see 
Section 1.3.1), and experimental studies have shown that tetraploidisation can 
result in increased numerical and structural chromosome changes (see Section 
1.7.3), the mechanisms specific to tetraploid cells that could lead to chromosomal 
instability are not fully understood. 
 
A comprehensive genetic analysis of polyploidy in yeast revealed several potential 
pathways that are specifically required for survival in polyploids that could shed 
light on this question (Storchova et al., 2006). Storchova and colleagues analysed 
gene deletions for a total of 3540 genes in polyploid yeast strains, and identified 
three key categories of genes that were specifically required for polyploid yeast cell 
survival. These gene groups were DNA repair through homologous recombination, 
sister chromatid cohesion and mitotic spindle function (Storchova et al., 2006). 
Chapter 1 Introduction 
 54 
These results suggest that there is a genetic instability defect inherent to polyploid 
yeast. The authors observed a 200-fold increase in the rates of chromosome loss 
and an increase in spontaneous DNA damage that correlated with DNA content. 
Most striking was the mitotic defect present in tetraploid yeast, which manifested in 
a 3.6 fold increase in the frequency of syntelic kinetochore-microtubule 
attachments (Storchova et al., 2006). The authors suggest that this increase could 
be due to unequal scaling effects observed in tetraploid cells. The spindle length 
was the same in tetraploid yeast as both haploid and diploid yeast, although the 
cell volume was increased. Further, the spindle pole body (SPB) had a greater 
surface area in tetraploids. The authors suggest that these mismatches in scaling 
of core mitotic components could result in the increase in syntelic attachments 
(Storchova et al., 2006).  
 
Studies have shown that tetraploid cells are subject to a higher rate of 
chromosomes loss (Mayer and Aguilera, 1990, Andalis et al., 2004, Fujiwara et al., 
2005, Storchova et al., 2006, Davoli and de Lange, 2012). Since tetraploids formed 
through mitotic dysfunction or cytokinesis failure will contain extra centrosomes, 
this could provide a link between tetraploidy and numerical chromosomal instability. 
Extra centrosomes can lead to multipolar division, which would randomly segregate 
chromosomes into daughter cells, and could lead to high levels of aneuploidy 
(Gisselsson et al., 2008). However, most multipolar mitoses do not result in viable 
daughter cells, and so whether this mechanism contributes to tetraploidy-mediated 
chromosomal instability remains unclear (Ganem et al., 2009, Kuffer et al., 2013). 
As discussed in section 1.8.2.1, extra centrosomes can also lead to chromosome 
missegregation though transient multipolar spindles and an increased frequency of 
merotelic attachments (Ganem et al., 2009). This mechanism could be responsible 
for numerical chromosomal instability in tetraploid cells. However, as the yeast 
analysed by Storchova and colleagues did not have additional SPBs and still 
showed evidence of chromosomal instability, tetraploid mammalian cells may be 
subject to other mechanisms driving numerical instability aside from an increase in 
centrosome number (Storchova et al., 2006, Storchova and Kuffer, 2008, Ganem et 
al., 2007).  
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Tetraploid cells have also been shown to have an increase in structural 
chromosome aberrations (Fujiwara et al., 2005). How tetraploidy per se leads to 
this increase in structural chromosome aberrations remains unclear. One possibility 
is an increase in the level of spontaneous DNA damage in tetraploids, since 
tetraploid cells have more DNA. This is seen in tetraploid yeast strains (Storchova 
et al., 2006). However, no increase in DNA damage foci was reported for cells that 
had undergone cytokinesis failure, suggesting that tetraploidy may not always lead 
to an increase in DNA damage (Fujiwara et al., 2005).  However, some studies 
have demonstrated increased sensitivity to DNA damaging agents in tetraploid 
cells, suggesting that tetraploid cells may have deficient DNA repair, or exceed a 
threshold of tolerable DNA damage faster than diploid cells (Hau et al., 2006). DNA 
damage and structural instability could also occur in tetraploid cells due to 
catastrophic missegregation of chromosomes in a multipolar division (Gisselsson et 
al., 2008). The frequency of these multipolar divisions in the long-term propagation 
of tetraploid cells has yet to be established, but it may be relatively infrequent 
(Ganem et al., 2009). Alternatively DNA could be damaged during missegregation 
of chromosomes in normal bipolar divisions (Janssen and Medema, 2012, Crasta 
et al., 2012).  
 
1.11     Genomic instability in colorectal cancer 
Colorectal cancer (CRC) is the second most prevalent cancer worldwide (Bray et 
al., 2013). The genetics of colorectal cancer are fairly well understood, with 15-20% 
of CRCs displaying microsatellite instability (MSI/MIN), and the majority displaying 
chromosomal instability (CIN). MIN and CIN do not generally co-occur in CRC, 
possibly suggesting that excessive genetic instability is detrimental to a cancer 
(Sieber et al., 2002, Abdel-Rahman et al., 2001, Lengauer et al., 1997). In general, 
MSI is a marker for better patient prognosis, and CIN has been shown to lead to 
poor patient prognosis (Guastadisegni et al., 2010, Lengauer et al., 1998, 
Mouradov et al., 2013). 
 
Microsatellite instability is caused by mutations or defects in the mismatch repair 
(MMR) machinery (MSH2, MSH6, MLH1 and PMS2). The MMR pathway usually 
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corrects DNA replication errors that frequently occur when copying microsatellite 
repeats; repeated sequences of DNA found throughout the genome. MSI tumours 
therefore have a high frequency of mutations, particularly in genes that contain 
microsatellite sequences, for example TGFBR2 (TGF-β type II receptor). Germ-line 
mutations in MMR genes cause a hereditary form of colon cancer, called Lynch 
syndrome (also formerly known as hereditary non-polyposis colon cancer, HNPCC). 
The most commonly mutated Lynch syndrome genes are MLH1 and MSH2 (90% of 
cases), whilst mutations in MSH6 and PMS2 are relatively uncommon (Grady and 
Carethers, 2008). Germline mutations in Lynch syndrome patients are followed by 
inactivation of the remaining wild type allele. Lynch syndrome patients account for 
2-5% of all CRC cases (Umar et al., 2004). In sporadic CRC, MSI is most 
frequently caused by hyper-methylation of the MLH1 gene promoter, resulting in 
loss of MLH1 expression (Herman et al., 1998, Veigl et al., 1998). MSI tumours 
tend to be diploid, with a high mutation rate. They also tend to occur on the right-
side colon, and display mucinous histology and high lymphocytic infiltrate (Kim et 
al., 1994). 
 
In a large cohort of tumours subject to exome-sequence analysis, the eight most 
frequently mutated genes in non-hypermutated CIN+ tumours were APC, TP53, 
KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2 and NRAS (Cancer Genome Atlas, 
2012). Hypermutated tumours in this cohort tended to have mutations in different 
genes than the non-mutated cohort, supporting a separate genetic basis for these 
two kinds of instability in CRC (Cancer Genome Atlas, 2012). As expected, the 
number of somatic copy number aberrations (SCNAs) was greater in non-
hypermutated tumours (Cancer Genome Atlas, 2012). Over 94% of these tumours 
had mutations in one or more genes in the WNT signalling pathway, and other 
deregulated signalling pathways included the MAPK, Pi3K, TGF-β and p53 
pathways (Cancer Genome Atlas, 2012). The contribution of these different 
mutations to the CIN phenotype currently remains unclear.  
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1.12     Conclusion 
Tetraploidy is a common occurrence in many different cancer types, where it 
seems to be associated with the onset of aneuploidy. In vitro studies of 
experimentally induced tetraploidisation have shown that tetraploidy is associated 
with increased tumorigenicity and genomic instability in short-term assays. The 
cellular consequences of tetraploidisation, and how these might impact upon its 
association with carcinogenesis have been less well explored. Furthermore, the 
long-term impact of tetraploidisation on a stable diploid genome have not been 
investigated, and nor have the mechanisms by which tetraploidy might contribute to 
the dynamic phenotype of CIN in vivo. Understanding the contribution of tetraploidy 
to CIN will help define the processes that drive cancer evolution and the 
emergence of intra-tumour heterogeneity.  
 
In this thesis, the impact of tetraploidisation on the long-term genomic stability of a 
diploid genome was explored. Using a diploid cell line with a naturally occurring 
tetraploid fraction, isogenic diploid and tetraploid clones could be compared over 
longer than 18 months of continuous culture. This revealed that tetraploid cells 
were able to specifically propagate both numerical and structural chromosome 
aberrations, resulting in a markedly altered genomic profile. A mutational 
mechanism for this CIN tolerance phenotype was not uncovered, leading to the 
conclusion that tetraploidy could be a permissive state for chromosomal instability. 
The genetic changes that initially allow tetraploid cells to overcome cell-cycle 
checkpoint barriers were then considered. A targeted screen was carried out to 
identify regulators of cell cycle re-entry after cytokinesis failure, which is thought to 
be one of the most common routes to tetraploidisation in cancer.  
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Chapter 2. Materials & Methods 
2.1 Cell culture 
HCT-116 and RKO cells were obtained from the European Collection of Animal 
Cell Cultures (ECACC) by Cancer Research UK, HCT-116_MLH1.3 was kindly 
gifted by Françoise Praz (Saint-Antoine Research Centre Paris) and RPE-FUCCI 
cells were a kind gift from Dr Laurent Sansregret (Cancer Research UK). All cell 
lines were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 4.5/L D-
glucose, L-glutamine and pyruvate (Gibco, Life Technologies), containing 10% FBS 
(LabTech) and 1X Penicillin Streptomycin (Sigma) at 37°C in a 5% CO2 
atmosphere.  
 
2.2 Isolating diploid and tetraploid clones from cell lines 
To isolate diploid and tetraploid clones from cell lines, cells were trypsinised and 
stained in 10µg/mL Hoescht 33342 (Sigma) for 1 hour at 37°C with occasional 
shaking. Cells were then washed twice in PBS, before straining using a 70µm cell 
strainer. Fluorescent-activated-cell sorting (FACS) was carried out using a MoFLo 
Cell Sorter (Beckman Coulter) equipped with a UV laser. Single cells were sorted 
into 96-well plates containing 20% FBS media. Diploid clones were selected from 
the 2N peak, and tetraploid cells were selected from the >4N peak. Andrew Rowan 
carried out the original isolation of diploid and tetraploid clones. The ploidy of all 
clones was checked using flow cytometry for DNA content (see below). Diploid and 
tetraploid clones were passaged once a week by seeding 150,000 cells into a 
10cm dish containing fresh media. All passage numbers represented in figures are 
correct to within <4 passages. 
 
The cloning efficiency of HCT-116 diploid cells was assessed using CellTiter-Blue 
(Promega) according to the manufacturer’s instructions, colonies were counted as 
wells that had CellTiter-Blue values >1.5 the mean value of blank wells. Data was 
corrected using the Poisson distribution; efficiency = (-100) x ln(# of wells with no 
colony/total #of wells) % (Leight and Sugden, 2001). The cloning efficiency of HCT-
Chapter 2 Materials and Methods 
 
 60 
116 tetraploid cells was calculated after verification of the ploidy of all surviving 
clones. The cloning efficiency was calculated from the number of tetraploid clones 
arising from a given number of wells.  Cloning efficiency was estimated across 
three independent experiments.  
 
2.3 Transfections 
2.3.1 Plasmid preparation 
The H2B-mRFP plasmid was a gift from Anne Straube (University of Warwick, 
Coventry, UK). 
 
Plasmids were prepared using heat-shock of XL-10TM Gold Ultracompetent Cells 
(Agilent) following the manufacturer’s instructions. Bacteria were then spread on 
agar plates containing appropriate antibiotics (Ampicillin, Sigma) and grown 
overnight at 37°C, before colony selection and expansion in L-broth also containing 
the relevant antibiotic. DNA was extracted using Quiagen Cartridge Midi/Maxi kits 
according to the manufacturer’s instructions, and the concentration and quality of 
the DNA was quantified on a spectrophotometer (NanoDrop, Thermo Scientific).  
 
2.3.2 Plasmid transfection 
The H2BmRFP plasmid was transfected using Fugene 6.0 (Promega). Per 10 cm2 
dish, 9µL of Fugene was incubated with 300µL of Opti-MEM® reduced serum 
media (Gibco, Life Technologies) for 5 minutes, before adding 3µg of plasmid. This 
was further incubated for 15 minutes before adding to cells with 6mL of media. 
Cells were selected after 48 hours using 1µg/mL G418 (Life Technologies), and 
cell-sorted using fluorescence for RFP expression. After sorting, cells were 
maintained in 0.5µg/mL of G418 containing media.  
2.3.3 siRNA preparation 
siRNAs were ordered from Dharmacon, and were On-Target-Plus siRNAs unless 
otherwise stated. siRNAs were re-suspended using 5X siRNA buffer (Thermo 
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Scientific) diluted with nuclease free water (Ambion) to the desired concentration 
and mixed at RT (room temperature) for 30 minutes before storage at -20°C.  
A list of common siRNA sequences used is shown in Table 2.4, and the full list of 
sequences ordered for the screen described in Chapter 6 is shown in the Appendix 
(Section 8.2). 
2.3.4 siRNA transfection 
The final concentration of siRNA used in all experiments was 40nM. The different 
transfection agents used were Lipofectamine™ RNAiMax (Invitrogen), Lullaby (OZ 
Biosciences) and INTERFERin® (Polyplus Transfections™). 
For 96-well plate transfections, siRNAs were diluted in Hank’s buffered salt solution 
(HBSS, without CaCl2 or MgCl2, Gibco, Life Technologies) to 400nM (10X final 
concentration), and 10µL was added to each well. Opti-MEM® reduced serum 
media (Gibco, Life Technologies) was mixed with transfection reagents and left at 
RT for 5 minutes, before 10µL was added to each well. The concentrations of 
transfection reagent per well are indicated in the figures and text of this thesis. The 
mixture of siRNA in HBSS and transfection reagent in Opti-MEM was left at RT in 
96-well plates for 30 minutes, before 80µL of cells in suspension in normal media 
were added, bringing the total volume in each well to 100µL. 
For 6-well plate transfections, 3µL of 20µM siRNA was mixed with 250uL of Opti-
MEM in eppendorf tubes. Simultaneously, 3.5µL of transfection reagent was added 
to 250µL of Opti-MEM and left at RT for 5 minutes. This was then mixed with the 
siRNA containing Opti-MEM and left at RT for 30 minutes. 1mL of cells in 
suspension in normal media were then added to wells, and 500µL total volume of 
transfection mix was added. 
 
2.3.5 Virus preparation 
The pBabe Hygromycin-Luciferase plasmid was a kind gift from Dr Miguel Murillo 
(manuscript in preparation). Viruses were prepared by Dr Carolina Navas. 293-
Phoenix Packaging Cells were obtained from Cancer Research UK Cell Services 
facility and grown in DMEM with 4.5g/L D-glucose, L-glutamine and pyruvate 
(Gibco, Life Technologies), containing 10% FBS (LabTech) and 1X Penicillin 
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Streptomycin (Sigma) at 37°C in a 5% CO2 atmosphere. These cells were 
transfected by mixing 35µL Lipofectamine™ transfection reagent (Life 
Technologies) and 500µL of Opti-MEM for 5 minutes at RT, before mixing with 
10µg of pBabe Hygromycin-Luciferase and 500µL of Opti-MEM and adding to cells 
after 20 minutes. After 16 hours media was replaced. Media was then collected and 
replaced every 24 hours for 2 days. Collected media was filtered using 0.22µm 
PVDF filters.  
 
2.3.6 Virus infection 
DC-14 and TC-13 cells at passage 8 were infected with filtered virus containing 
media with 8µg/mL Polybrene (Sigma, H9268). Cells were maintained in virus 
containing media for 3 days, before splitting into selection media containing 
20µg/mL Blasticidin antibiotic (Life Technologies).  
 
2.4 Immunofluorescence 
Cells were grown on 22 x 22 mm glass cover slips coated with poly-L-lysine 
(Sigma). Cells were washed with PBS and then fixed and permeabilised using 
PTMEF fixative (4% formaldehyde, 20mM PIPES, 10mM EGTA, 1mM MgCl2) for 
10 minutes at RT. Coverslips were rinsed in PBS, and then blocked for 1 hour at 
RT, or until required at 4°C, in 3% BSA-PBS. Coverslips were incubated with 
150µL of primary antibody in 3% BSA-PBS for 1.5 hours at RT, washed three times 
with PBS, and then incubated for 1.5 hours with secondary antibodies and DAPI 
(1µg/mL, Roche) in 3% BSA-PBS at RT protected from light. Coverslips were 
washed again three times with PBS, and then mounted on glass slides with 
Vectashield mounting medium (Vecta H-1000), before sealing with clear nail 
varnish. Secondary antibodies were from Molecular probes, and used at 1:500 
dilution (Goat anti-mouse conjugated to AlexaFluor [AF] 488, goat anti-rabbit 
AF594, goat anti-human AF647). 
 
Primary antibodies used in this thesis are listed in Table 2.1. 
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Table 2.1: Primary antibodies used for immunofluorescence  
Primary Antibody Species Company  Dilution 
γ-H2AX Mouse Millipore 05-636 1:500 
53BP1 Rabbit Santa-Cruz sc-22760 1:500 
β-tubulin Rabbit Abcam ab6046 1:1000 
Centrin-3 Mouse Abcam ab54531 1:1000 
CREST Human Fitzgerald 90C-CS1058 1:2000 
LaminA/C Mouse Santa Cruz sc-7292 1:1000 
p21 Rabbit CRUK antibody, MH9  1:2000 
p53 Mouse CalbioChem OP43 1:500 
 
2.4.1 Image acquisition for immunofluorescence 
Unless otherwise stated, all image acquisition for immunofluorescence slides was 
carried out using an Olympus Deltavision RT microscope (Applied Precision LLC) 
equipped with a CoolSnap HQ camera. Images were deconvolved using 
conservative settings for 8 cycles. Images were analysed using softWoRX Explorer 
(Applied Precision LLC). 
 
2.4.2 Segregation error scoring 
To score segregation errors, slides were stained with CREST to visualise 
centromeres, and β-tubulin and DAPI to identify bipolar anaphase cells. Telophase 
cells, where tubulin had formed a narrow bridge between the two daughter cells, 
were excluded from this analysis. Multipolar anaphases were also excluded. 
Approximately 100 z-stacks of 0.2µm were obtained for each cell to visualise the 
entire anaphase using an Olympus 100X 1.4 numerical aperture UPlanSApo 
objective. 
2.4.2.1 Segregation error classification 
Segregation errors were classified as follows: 
Anaphase bridges – A clear DAPI signal extending from one daughter cell 
chromosome mass to the other. 
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Acentric lagging chromosome fragments – A clear DAPI signal that is between 
and separated from the two daughter chromosome masses that is completely 
devoid of centromeric CREST staining.  
Lagging chromosomes – A DAPI signal that is between and separated from the 
two daughter chromosome masses that has a clear centromeric CREST signal. 
Other – Any clear anaphase error that could not be classified into the above 
categories. These included lagging dicentric chromosomes joined by bridges. 
 
Examples of segregation error types are shown in Figure 2.1. 
 
Figure 2.1: Examples of segregation error classification 
Types of segregation error commonly observed in HCT-116 and derivative cell 
lines. DNA is stained with DAPI, and centromeres are detected using 
immunofluorescence with antibodies against human CREST. Inset shows a close 
up of error. 
 
2.4.3 Interphase DNA damage scoring 
To score interphase DNA damage foci, slides were stained with 53BP1 and γ-
H2AX. Approximately 65 z-stacks of 0.2µm were obtained for each field of view, 
using an Olympus 40X 1.3 numerical aperture UPlanSApo objective. Interphase 
Lagging centric chromosome
Lagging acentric chromosome 
fragment
Anaphase bridge
Other - (joined lagging dicentric 
chromosome)
DAPI Crest
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cells were assessed from DAPI staining, and foci were scored when 53BP1 and γ-
H2AX foci co-localised. 
 
2.4.4 Spindle morphology 
To assess spindle morphology slides were stained with β-tubulin, centrin-3 and 
DAPI. DAPI was used to identify pre-anaphase cells. Approximately 65 z-stacks of 
0.2µm were obtained for each cell using a using an Olympus 60X 1.42 numerical 
aperture UPlanSApo objective. 
 
2.4.5 Centriole number 
To assess centriole number slides were stained with β-tubulin, centrin-3 and DAPI. 
DAPI was used to identify prophase cells. Approximately 100 z-stacks of 0.1µm 
were obtained for each cell using a using an Olympus 100X 1.4 numerical aperture 
UPlanSApo objective. 
 
2.5 Metaphase spreads 
2.5.1 Slide preparation 
Cycling cells were treated for 1-2 hours with 100ng/mL Colcemid (Gibco) before 
trypsinisation and washing in PBS. Cells were re-suspended in a small amount of 
PBS, before a 7-minute incubation in a hypotonic solution (4% KCl, 4% sodium 
citrate) at 37°C. Cell pellets were collected by centrifugation (1000 rpm for 5 
minutes) before gentle re-suspension in fixative (3:1 Methanol: Acetic Acid). Cell 
suspensions were left in fixative for 30 minutes at RT, centrifuged and re-
suspended in fresh fixative for a further 20 minutes. After another round of 
centrifugation and re-suspension in fresh fixative, the solution was dropped onto 
glass slides using a Pasteur pipette. Slides were aged at RT for at least 48 hours 
before analysis.  
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2.5.2 Hybridisation 
Slides were hybridised to an all-human centromere alpha-satellite DNA probe 
(FITC labelled, Posiedon) to visualise structural chromosome aberrations. Slides 
were incubated for 15 minutes at 37°C in 2X SSC with 0.5% Tween 20, and 
dehydrated through an Ethanol series (70-85-100%) before air-drying. Probe was 
sealed under a 22 x 22 mm coverslip sealed with rubber cement before 
denaturation for 10 minutes on a hot block at 75°C. Probes were hybridised 
overnight at 37°C in a humidified chamber. Rubber cement was removed and 
slides were rinsed in 2X SSC 0.5% Tween20, before a two minute wash at 72°C in 
0.5X SSC with 0.4% Tween20. Slides were rinsed again at RT in in 2X SSC 0.5% 
Tween20 before incubation for 15 minutes in PBS containing 1µg/mL DAPI (Roche), 
dehydration through an Ethanol series and mounting with Vectashield (Vecta H-
1000) and sealing with clear nail varnish. 
 
2.5.3 Analysis 
Slides were visualised on an Olympus Deltavision RT microscope (Applied 
Precision LLC) equipped with a CoolSnap HQ camera using an Olympus 60X 1.42 
numerical aperture UPlanSApo objective. Approximately 15 z-sections were taken 
at 0.1µm intervals, and deconvolved using conservative settings for 8 cycles. 
Images were analysed using softWoRX Explorer (Applied Precision LLC). 
 
2.5.4 Structural chromosome abnormalities 
Structural chromosome abnormalities were classified as follows (examples are 
shown in Figure 2.2): 
 
Acentric chromosome fragments – any chromosome or part of a chromosome 
lacking any discernible signal from the centromeric probe. 
Dicentric chromosomes – chromosomes clearly harbouring two centromeric 
signals that were separated from each other. 
Double strand breaks – Chromosome arms showing a clear break in DAPI signal, 
where the intact chromosome has one shorter chromosome arm as a result. 
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Other – Some cells showed evidence of different aberrations that could not be 
classified into the above three categories. These included shattered chromosomes, 
and abnormal chromosome shapes (see Figure 2.2 for examples).  
 
Figure 2.2: Classification of structural chromosome abnormalities 
Examples of structural chromosome abnormalities scored. DNA is stained with 
DAPI, and centromeres are hybridised to an all-human centromeric probe. White 
arrows indicate chromosome of interest. 
 
2.6 Clonal fluorescence in-situ hybridisation (FISH) 
2.6.1 Slide preparation 
Glass sides were coated in poly-L-lysine and placed inside a 10 cm2 tissue-culture 
dish. Cells were seeded at a density of 500 cells per slide in 1mL of media. Cells 
were left overnight to attach to the glass slide, and the dish was filled with normal 
media the next day. After 10-14 days the slides were washed in PBS, cells were 
swelled for 7 minutes with 0.4% KCl-0.4% sodium citrate solution and fixed in 3:1 
Methanol: Acetic Acid for 30 minutes before air drying and ageing at RT for at least 
1 week.  
2.6.2 Hybridisation 
Slides were treated with SPOT-light tissue pre-treatment solution (Invitrogen) at 
100°C for 10 minutes, before two 3 minute washes in PBS. Slides were then 
dehydrated through an Ethanol series (70-85-100%). Slides were probed with FISH 
DAPI Centromeric probe
Normal metaphase 
chromosome
Acentric chromosome 
fragment Dicentric chromosome DNA double strand break 
Other abnormalities
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probes specific to chromosome 2 (CEP2, D271, SO) and chromosome 8 (CEP8, 
D872, SGn, both Abbott Molecular probes). Probes were added to slides on a 22 x 
22 mm coverslip diluted with Hybridisation buffer (Abbott Molecular probes), and 
sealed with rubber cement. Slides were co-denatured on a hot block at 95°C for 5 
minutes, before incubation in a humidified chamber overnight at 37°C. Rubber 
cement was removed with tweezers and slides were rinsed with 0.5 X SSC at RT to 
remove coverslips. Slides were washed in 0.5 X SSC for 5 minutes at 75°C, before 
another wash in 0.5 X SSC at RT before rinsing in ddH20. Slides were incubated in 
PBS containing 1µg/mL DAPI (Roche) for 15 minutes at RT before dehydration 
through an Ethanol series (70-85-100%). Slides were mounted in Vectashield 
(Vecta H-1000) and sealed with clear nail varnish. 
 
2.6.3 Analysis 
Clonal FISH slides were scanned using an Ariol semi-automated microscope (Leica 
Microsystems). Slides were scanned initially at 10X magnification, and discrete 
colonies were selected. Colonies were then scanned at 40X magnification with z-
stacks of 9 x 0.7µm. Analysis was carried out using custom-made software from 
Leica Microsystems that identified isolated nuclei from the DAPI signal and 
categorised chromosome numbers from the green and orange channels for the 
chromosome probes. Individual cells were categorised according to their copy 
number state for the two chromosomes. Data was manually curated, and cells that 
had been mis-categorised were re-categorised by hand. Three slides were scored 
using an Olympus Deltavision RT microscope (Applied Precision, LLC) equipped 
with a CoolSnap HQ camera with an Olympus 40X 1.3 numerical aperture oil 
immersion objective, and analysed with softWoRX Explorer (Applied Precision, 
LLC). Data was comparable between the two different scoring methods.  
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2.7 Flow cytometry 
2.7.1 DNA profiles 
Cells were trypsinised and washed in PBS before fixation and storage in 70% 
Ethanol until required at 4°C. Cells were washed twice in PBS, before staining with 
Propidium Iodide (Sigma) and treating with RNase (Life Technologies). 
Alternatively cells were stained with Hoechst 33342 (Sigma). DNA profiles were 
collected after setting laser voltages for the parental diploid cell line. 
 
2.7.2 S phase duration 
To assess the duration of S-phase, a BrdU pulse experiment was performed. Cells 
were treated with 10µM BrdU (Sigma, B5002) for 15 minutes, before three washes 
in PBS. A sample was fixed at this time point (0 hours) and then subsequent 
samples were fixed at 2, 4, 6, 8 and 24 hours after the BrdU pulse in 70% Ethanol 
until required. Samples were centrifuged (1400 rpm for 5 minutes) out of the 70% 
Ethanol, and rinsed in PBS containing 1% FBS, before incubation in 2M HCl for 20 
minutes at RT to denature DNA. Samples were centrifuged out of HCl and rinsed in 
1% FBS/PBS again, before a 5 minute wash in 0.5% TritonX-100 in 1% FBS/PBS 
to permeabilise cells. After two more 1% FBS/PBS washes, samples were 
incubated overnight at 4°C with a Mouse anti-BrdU antibody (BD Biosciences) at 
1:500 dilution in 3% BSA/PBS. After primary antibody incubation, samples were 
washed twice with 1% FBS/PBS, before incubation protected from light at RT with 
a secondary antibody (Goat anti-mouse conjugated to AlexaFluor488, Molecular 
probes) at 1:300 dilution in 3% BSA/PBS for 30 minutes. Samples were washed 
twice with 1% FCS/PBS before re-suspension in PBS and staining with Propidium 
Iodide (Sigma) to visualise DNA. Samples were analysed on a Fortessa flow 
cytometer (BD Biosciences). Positive BrdU cells were identified using an untreated 
control sample. The cell cycle phases of BrdU positive cells at 0, 6, 8 and 24 hours 
were analysed using the Watson-Pragmatic cell cycle function of the FlowJo 
programme using standard settings (Watson et al., 1987).  
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2.8 Proliferation curves 
To assess proliferation rates between different cell lines, all cell lines were seeded 
at an initial density of 2000 cells per well of a 96-well plate (6 well replicates per cell 
line) in 6 plate replicates. The first plate was fixed as soon as cells were attached, 
and then a plate was fixed every 24 hours in 70% Ethanol and stored at -20°C. 
Plates were washed in PBS, and stained with DAPI (Roche) at 1µg/mL for 5 
minutes, before rinsing in PBS. Nuclei were counted using an Acumen cell counter 
(TTP LabTech). Cell number was normalised to the cell count from the first fixed 
plate and expressed as a fold change.  
 
2.9 Drug sensitivity assays 
To test sensitivity of different cell lines to specific drugs, cells were seeded at a 
density of 2000 cells per well of a 96-well plate, and treated with varying 
concentrations of cisplatin (Sigma, P4394), paclitaxel (LC Labs, P9600) or 
camptothecin (Sigma, C9911) 24 hours later. Plates were left for 72 hours in the 
presence of drug before treatment with CellTiter-Blue (Promega), according to the 
manufacturer’s instructions, to assess cell viability. Viability was normalised to wells 
treated with a vehicle control.  
 
2.10   Calbiochem Kinase Inhibitor Screen 
Calbiochem Kinase Inhibitor libraries I and II were obtained from Merck Millipore, 
totalling 160 inhibitors. All cell lines were seeded in triplicate at a density of 4000 
cells per well using an automated WellMate liquid handling system (Thermo Fisher 
Scientific). Cells were treated with all inhibitors at a concentration of 10µM 24 hours 
later and incubated for 72 hours in a rotating tissue culture inhibitor. To assess cell 
viability plates were treated with CellTiter-Blue (Promega) according to the 
manufacturer’s instructions. 16 wells per plate were treated with DMSO as a 
vehicle control. All treated wells were normalised to the average value for DMSO 
treated wells. The average normalised value for the triplicate repeats was taken for 
each cell line. Dr Pierre Martinez prepared cumulative distribution frequency graphs 
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using the statistical programme R. A Kolmogorov-Smirnov test was performed to 
assess differences between cumulative distributions of diploid and tetraploid cell 
lines. The effect of different drugs on diploid and tetraploid clones was assessed by 
comparing the log fold change difference in relative cell numbers. 
 
2.11   Exome sequencing 
2.11.1 Sample preparation 
DNA extraction was carried out using the Quiagen DNeasy Blood and Tissue 
extraction kit following the manufacturer’s instructions. DNA quality was assessed 
using a QuBit instrument (Life Technologies). DNA preparation and sequencing 
was carried out by the Advanced Sequencing Facility at Cancer Research UK 
London Research Institute. Paired end sequencing was carried out as described 
(Gerlinger et al., 2012). Briefly, DNA was fragmented into 250-300 base pair (bp) 
fragments, before adaptors were ligated to each end. Adaptor-ligated templates 
were purified with Agencourt AMPure SPRI beads, and amplified by ligation 
mediated PCR (polymerase chain reaction). DNA was then hybridised to 
SureSelect Biotinylated RNA library (BAITS) and bound to streptavidin beads. Each 
sample was loaded onto an Illumina Genome Analyser II, and paired end 
sequencing was performed to at least 30X coverage. Raw image files were 
processed with HCS1.4.8 using default parameters to call bases. 
 
2.11.2 Alignment and variant calling analysis 
Alignment and variant calling was carried out by Harshil Patel (Bioinformatics and 
Biostatistics, London Research Institute). Raw reads were aligned to the human 
hg19 genome assembly using BWA 0.5.9 (Li and Durbin, 2009), with a maximum 
mismatch threshold of 4 within 101bp, all other parameters were left as default. 
Alignments were post-processed to remove reads that mapped to multiple genomic 
loci, and those that could have arisen from PCR duplication (using picard tools 1.81, 
Picard, 2012). The Genome Analysis ToolKit (version 2.3-9-ge5ebf34, DePristo et 
al., 2011) was used to perform indel realignment and indel left alignment. After 
filtering, a median exome coverage of 76X was observed per sample. 
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Base-level nucleotide counts were obtained using the deepSNV package 
(Gerstung et al., 2012), with a minimum base quality threshold of 20, and 
subsequent variant calling was performed across all samples simultaneously using 
scripts written in Python. Variants with a minimum nucleotide count of 5 and an 
allele frequency less than 0.1 were excluded from further analysis. Variant 
annotation was performed with ANNOVAR release 2012Oct23 (Wang et al., 2010). 
 
2.11.3 Downstream filtering 
All variant calls in all samples were filtered as follows. The number of times a 
variant appeared in diploid and tetraploid samples was added as a filter. Mutations 
occurring in any diploid sample were removed. Unique tetraploid mutations were 
then filtered for how many samples they occurred in. Different amino acid 
substitutions in the same gene occurring in the same tetraploid sample were not 
counted as two different samples. Only genes that were mutated in more than one 
tetraploid sample are shown in Table 5.4. The predicted consequence of each 
mutation was assessed using the tools SIFT-predictor, PolyPhen-predictor and 
Mutation-taster contained in the ANNOVAR variant calling package (Wang et al., 
2010). 
2.12   Microarray profiling 
RNA was extracted using the Quiagen RNeasy extraction kit following the 
manufacturer’s instructions. RNA quality was tested using a Qubit (Life 
Technologies). RNA was sent to the Cancer Research UK Manchester Institute for 
analysis using Affymetrix Human Gene 1.0 ST arrays.  
 
Microarray data analysis was carried out by Probir Chakravarty, Dr Tejal Joshi, Dr 
Nicolai Birkbak and Nicholas McGranahan. 
 
Data was normalised using the frozen Robust Microarray Analysis (fRMA) method 
(McCall et al., 2010), summarising probes sets at gene level. Genes showing 
significant differential expression between diploid and tetraploid cell lines were 
identified using a Students T-test with a significance threshold of P<0.05. 
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Significant genes were further filtered by only including genes that showed at least 
a two-fold difference in means. To compare against the list of genes differentially 
expressed between diploid and tetraploids in Castedo et al., a Spearman’s rank 
correlation was used (Castedo et al., 2006). Statistical analysis was carried out 
using the R statistical environment.  
 
 
2.13   Western blotting 
For p53 and p21 western blots, cells were treated for 1 hour with 1µM Doxorubicin 
(Sigma), before recovery for 7 hours in normal media. Cells were rinsed in PBS 
and frozen at -80°C until required. Samples were lysed on ice using lysis buffer 
containing 50mM HEPES [pH 7.2], 150mM NaCl, 1mM EDTA, 20mM MaF and 
complete protease inhibitors (Roche). Samples were separated on NuPAGE 4-12% 
Bis-Tris gel (Invitrogen), with MES running buffer (Invitrogen), before semi-dry 
transfer to a poly-vinylidene fluoride (PVDF) membrane. Membranes were blocked 
with 0.1% TBS Tween20 with 5% Milk, before incubation with primary antibodies 
over night at 4°C (p21 Rabbit, 1:1000, Cancer Research UK Tim Hunt Laboratory; 
p53 Mouse, 1:500 Santa Cruz sc126; β-catenin, 1:500, 610154 BD Biosciences). 
After washing in 0.1% TBS Tween, secondary antibodies (actin directly conjugated 
HRP, 1:50000, Sigma, swine anti-goat RRP and swine anti-rabbit HRP, 1:25000, 
both Dako) were added for 1 hour at RT. Detection was carried out with Immobilon 
Chemiluminescent HRP substrate (Merck Millipore). 
 
For LATS 2 western blotting, siRNA transfections were carried out in a 6-well plate 
format as described in Section 2.3.4. After 72 hours cells were rinsed in PBS and 
frozen at -80°C until required. Cells were lysed using RIPA buffer containing 
complete protease inhibitors (Roche). Samples were resolved on a NuPAGE 4-
12% Bis-Tris gel (Invitrogen) with MOPS running buffer, and transferred to a PVDF 
membrane for 2 hours using wet-transfer with buffer containing 192mM Tris, 25mM 
Glycine, 10% Methanol and 0.01% SDS. Membranes were blocked for 2 hours with 
0.5% TBS Tween20 with 5% Milk. Primary antibody (LATS2 Rabbit, 1:1000, Cell 
Signalling Technology 13646) was added overnight at 4°C. After washing, 
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secondary antibody (swine anti-rabbit HRP, 1:25000, Dako) was incubated at RT 
for 1 hour. Detection was carried out with Immobilon Chemiluminescent HRP 
substrate (Merck Millipore). 
 
2.14   Live Cell Imaging 
2.14.1 Mitotic timing 
H2B mRFP expressing cells were seeded in 8-well glass bottomed imaging 
chambers (LabTek) at a density of 50,000 cells per well. Chambers were visualised 
on an Olympus Deltavision RT microscope (Applied Precision, LLC) equipped with 
a CoolSnap HQ camera in 5% CO2 at 37°C. A total of 7 z-stacks of 2µm were 
taken every 3 minutes for 6 hours. The movies were analysed on softWoRX 
Explorer (Applied Precision LLC). The time from nuclear envelope breakdown to 
anaphase onset was recorded. Only cells that underwent a normal bipolar division 
with no errors were included for analysis.  
2.14.2 Segregation error cell-fate  
H2B-mRFP cells lines were seeded as for mitotic timing movies, and imaged using 
the same microscope equipment. A total of 7 z-stacks of 2µm were taken every 3 
minutes for the first 6 hours, and then every 15 minutes for a subsequent 60 hours 
to record cell fate. Cells that divided during the imaging period were examined for 
segregation errors, and the subsequent fate of these cells was recorded. Cells 
were scored as arrested if they failed to divide within 48 hours of the first division. 
Multipolar divisions were excluded from analysis.  
 
2.15  DNA fibre assays 
Cells were sequentially labelled with 20-minute treatments of 25µM CldU (5-Chloro-
2’-deoxyuridine, Sigma C6891) and then 250µM IdU (5-Iodo-2’-deoxyuridine, 
Sigma I7125) in fresh media, both of which were equilibrated for at least an hour in 
a 5% CO2 atmosphere. Cells were washed twice with ice-cold PBS, and removed 
from dishes using a cell scraper, counted and diluted to 1 x 106 cells/mL in cold 
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PBS. Cells were spread on glass slides using spreading buffer (200mM Tris-HCl 
pH 7.4, 50mM EDTA, 0.5% SDS) and air dried before fixation in 3:1 Methanol: 
Acetic Acid. To stain, slides were washed twice in H2O for 5 minutes, rinsed in 
2.5M HCl, before denaturation in 2.5M HCl for 1 hour 15 minutes. Slides were 
rinsed twice in PBS, washed twice for 10 minutes in blocking solution (1% 
BSA/PBS, 0.1% Tween20), before a 1-hour incubation in blocking solution. Primary 
antibodies (Rat anti BrdU, Clone BU1/75 [ICR1] Santa Cruz 1:1000, Mouse anti-
BrdU, BD Biosciences, 1:1000) were added and incubated for 1 hour at 37°C. 
Slides were rinsed 3 times in PBS before fixation for 10 minutes in 4% 
paraformaldehyde, followed by a further 3 PBS washes and 3 x 10-minute washes 
with blocking solution. Secondary antibodies (Goat anti-Rat AlexaFluor555 and 
Goat anti-Mouse AlexaFluor488, both 1:500, Molecular probes) were incubated for 
2 hours at 37°C, before 3 rinses in PBS. Slides were mounted in Vectashield H-
1000 and sealed with clear nail varnish. Slides were visualised using an Olympus 
Deltavision RT microscope (Applied Precision, LLC) equipped with a CoolSnap HQ 
camera with a 40X UPlanSApo 1.3 numerical aperture objective and the length of 
fibre tracks was measured using softWoRX Explorer (Applied precision LLC) and 
ImageJ software. Fibre track length was converted to kilobases (kb) using the 
conversion factor 1 µm = 2 kb.  
 
2.16   Spheroid assays 
To form spheroids, 5000 cells were seeded per well of 96-well Costar® Ultra-low 
attachment plates (Corning) with 2.5% growth factor reduced basement membrane 
Matrigel® (Corning). Plates were centrifuged for 10 minutes at -4°C at 820rpm to 
collect cells. Plates were imaged using an inverted Zeiss 510 light microscope with 
a 5X 0.13 numerical aperture objective and automatic stage. Imaging was carried 
out 1, 5 and 7 days after cell seeding. Dr Dominic Alibhai carried out imaging and 
calculation of spheroid volume. Transmitted light images were used to calculate 
spheroid volume, with automatic image segmentation and size determination by in-
house software (Wolfram Mathematica 9.0). Briefly, background signal was 
removed, and small objects (i.e. unformed cell clumps) were removed. The volume 
of each spheroid was calculated assuming spherical symmetry and using the 
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appropriate scaling factor. Eight spheroids per cell line were analysed in each 
experiment. The growth rate of spheroids was calculated using the slope function in 
Excel (Microsoft).  
 
2.17   Primary CRC and matched liver metastasis cohort 
A cohort of matched primary CRC and liver metastasis blocks were obtained from 
Dr Marcell Szasz (Semmelweiss University, Hungary). All clinical data was 
provided by Dr Szasz.  
 
2.17.1 Determination of MSI status 
The MSI status of the tumours had been previously determined by Dr Szasz using 
standard immunohistochemistry (IHC) analysis with antibodies against MLH1, 
MSH2, MSH6 and PMS2. However, some samples had uncertain results from IHC 
analysis, or a mismatch in MSI status between the primary and metastatic lesion. 
Microsatellite PCR analysis was carried out on these samples.  
 
DNA was extracted from paraffin embedded 20µm scrolls using a Quiagen 
DNAeasy Blood and Tissue Kit as follows. Xylene was added to eppendorf tubes 
containing the tissue scrolls to de-wax, tubes were spun at high speed to collect 
tissue, and Xylene was replaced with Ethanol in two wash steps. Sample was dried 
on a hot block at 37°C. 180µL of ATL buffer with 20µL of proteinase K solution was 
added overnight at 56°C, and after 16 hours, additional proteinase K solution was 
added for a further 4 hours. DNA extraction was then completed using the Quiagen 
DNAeasy Blood and Tissue Kit following the manufacturer’s instructions. For 
microsatellite PCR analysis the standard CRC markers D2S 123, D17 250, D5S 
346, D11 S904, BAT25 and BAT26 were used. The sequences of these primers 
are shown in Table 2.2. 
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Table 2.2: Microsatellite PCR primers 
Name Forward primer Reverse primer 
BAT25 TCGCCTCCAAGAATGTAAGT   TCTGCATTTTAACTATGGCTC 
BAT26 TGACTACTTTTGACTTCAGCC AACCATTCAACATTTTTAACCC  
D11 S904 ATGACAAGCAATCCTTGAGC CTGTGTTATATCCCTAAAGTGGTGA 
D2S 123 AAACAGGATGCCTGCCTTTA GGACTTTCCACCTATGGGAC 
D17 250 GGAAGAATCAAATAGACAAT GCTGGCCATATATATATTTAAACC 
D5S346 ACTCACTCTAGTGATAAATCGGG AGCAGATAAGACAGTATTACTAGTT 
 
DNA was subject to PCR with these primers using Quiagen Taq polymerase and 
nucleotides. The PCR programme used was as follows: Step 1: 94°C for 5 minutes. 
Step 2: 94°C for 45 seconds. Step 3: 55°C for 45 seconds. Step 5: 72°C for 1 
minute (repeat steps two to five 45 times). Step 6: 72°C for 10 minutes. PCR 
products were run on 2% agarose gels to assess concentration of PCR product, 
and diluted in water accordingly (standard dilution of 1:100). 3µL of diluted PCR 
product was subjected to microsatellite fragment analysis using an ABI 3130xl 
Genetic Analyser. Samples were analysed using GeneMapper software (Applied 
Biosystems). DNA from normal tissue and MSI+ cell lines used as controls was 
provided by Andrew Rowan. Samples needed to have positive results from >2 of 
the above PCR markers for classification as MSI+.  
 
2.17.2 Image Cytometry 
Image cytometry analysis was carried out by Damhane Oukrif (UCL Pathology). 
 
40µm scrolls were provided for this analysis. Sections were de-waxed in Xylene, 
and rehydrated through an Ethanol series, before digestion with proteinase XXIV 
(Sigma) for 2 hours at 37°C. Samples were washed in PBS and filtered through 
40µm filters. 100µL of nuclear suspension was added to a Shandon single use ez-
cytofunnel (Thermo Scientific) and spun with a Shandon Cytospin 2 at 225 g for 5 
minutes onto Superfrost Plus electrostatically positively charged blue slides (VWR). 
Slides were air-dried for 1 hour and fixed in 5M HCl for 1 hour. Slides were stained 
with Feulgen-Schiff reagent using standard methodology.  
Slides were analysed using a Fairfield DNA Ploidy System (Fairfield Imaging), 
equipped with a Zeiss Axioplan microscope, a 546nm green filter and a high-
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resolution camera (C4742-95, Hamamatsu photonics). The integrated optical 
density was calculated from the optical density and nuclear area of each nucleus. 
At least 1000 nuclei were sorted into the following categories: nuclei of interest, 
lymphocytes, plasma cells and fibroblasts. Lymphocytes were used as a reference 
for the 2C peak. Images were manually curated to remove cut or overlapping nuclei. 
Histograms of DNA and DNA index of nuclei of interest were provided for analysis.  
 
2.18   Bioluminescent imaging in mice 
The two cell lines expressing luciferase (as described in Section 2.3.6) were 
checked for luciferase activity by plating into 96-well black glass-bottomed plates 
(BD Falcon) at decreasing cell numbers, and treating with 150µg/mL Luciferin (D-
Luciferin K salt, Caliper/Xenogen, 122796). Images were obtained using a IVIS 
Spectrum instrument (Xenogen) using Auto acquisition settings, and the specific 
luciferase activity per cell was calculated across a range of cell numbers (average 
flux per well/numbers of cells per well = photons/second/cell). 
 
All mice work was carried out at Cancer Research UK London Research Institute 
under Home Office Project Licence Number PPL 80/2603. Nude mice (Nu/Nu) 
were obtained from Cancer Research UK Biological Resource Unit and kept in ultra 
clean conditions and individually ventilated cages. Mice were injected intravenously 
into the tail-vein with cells suspended in PBS. A maximum of 200µL of solution was 
injected per mouse. After injection mice were imaged once a week where possible 
to monitor tumour growth. Mice were culled when the tumour burden resulted in 
adverse health effects, for example significant weight loss or moribund behaviour, 
according to the thresholds set under the project license.  
 
For imaging, mice were anaesthetised using 2% Isoflurane (IsoFlo, Abbott) in an 
induction chamber, before injection with 100µL of 30mg/mL Luciferin solution (D-
Luciferin K salt Caliper/Xenogen, 122796). Mice were placed in a supine position in 
order to achieve maximum exposure of the lungs (the expected location of 
metastatic deposits) in an Animal Isolation Imaging Chamber (Caliper Life 
Sciences), which was imaged using an a IVIS Spectrum instrument (Xenogen) with 
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an XGI-8 Gas Anaesthesia System (Xenogen). Images were acquired using 
automated sequence acquisition settings (Binning large, FStop 1, Height 1.5, FOV 
D, 1.0 minute delay, 40 segments) until a plateau of luminescent signal was 
reached. Maximum bioluminescent signals from the whole body of the mouse were 
obtained using Living Image 4.3.1 software (Caliper Life Sciences) for analysis. 
Maximum bioluminescent signals were converted into log format for graphical 
representation.  
 
The statistical analysis described below was carried out by Stuart Horswell. To 
compare the growth rate between the different cell lines the statistical package R 
was used to apply a multiple regression analysis including terms for cell line, cell 
dose, mouse, time, and dose: time interaction. ANOVA was used to compare the 
significance of these different terms. The standard R packages lm() and anova() 
were used in this analysis.  
 
2.19  Histopathology 
Tumour tissue was fixed in 10% Neutral Buffered Formalin for 24 hours before 
delivering to the London Research Institute Experimental Histopathology 
department for processing. Tissue was set into blocks using an automated Tissue-
Tek VIP Tissue Processor. Briefly, blocks were sequentially incubated with 
increasing concentrations of methylated spirit (IMS) up to 100% (1 hour each), then 
four replacements with Xylene (1 hour each), followed by four replacements with 
paraffin wax for 45 minutes each (Fibrowax Pastillated, R.A.Lamp/VWR) at 45°C. 
Blocks were sectioned to 3µm thickness using a microtome. H&E staining was 
carried out using a Tissue-Tek Prisma Automated Stainer. Briefly, slides were 
washed in Xylene (2 x 120 seconds) then 100% IMS (2 x 30 seconds), 95% IMS 
(30 seconds), 70% IMS (30 seconds) and H2O (30 seconds). Slides were then 
stained with Harris Haematoxylin (Thermo Scientific/Shandon 6765004) for 420 
seconds, washed in H2O for 30 seconds, then in 1% acid alcohol for 20 seconds, 
before washing in Lithium Carbonate Saturated Solution for 30 seconds, and H2O 
again for 30 seconds. Slides were then stained with Eosin Y (VWR, 341973R) for 
420 seconds, before washing with H2O (30 seconds), and then increasing 
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concentrations of IMS (70, 95, 100%, 30 seconds each), a final 100% IMS wash 
(30 seconds), and two washes in Xylene (30 seconds). 
 
Pathology reports from slides were produced by Professor Gordon Stamp (London 
Research Institute/Royal Marsden Hospital).  
 
Images of H&E slides were acquired using a Nikon Eclipse microscope with a 4X 
0.2 numerical aperture and a 20X 0.75 numerical aperture objective (Nikon Japan 
Plan Apo) and a Nikon Digital Sight Camera (DS-U2). The imaging software NIS 
Elements AR 4.00.00 64 bit (Nikon) was used to capture images.  
 
2.20   RT-qPCR 
RNA was extracted using RNeasy Quiagen Kits, with On-Column DNase I 
digestion (Sigma). RNA concentration was quantified on a NanoDrop instrument 
(Thermo Scientific). cDNA was synthesised from 1µg of RNA using an AffinityScript 
cDNA synthesis kit according to the manufacturer’s instructions (Agilent). Real-time 
quantitative polymerase chain reaction (qPCR) primers were designed using 
Primer-BLAST (Ye et al., 2012). Multiple qPCR primers were ordered for each 
target gene, and after testing, the primer pairs that gave a single melt curve were 
retained for further use. qPCR was performed using EXPRESS SYBER® GreenER 
with Premixed ROX (Invitrogen) according to the comparative ΔΔCT method with 
normalisation to the expression of β-actin. Three replicates from each biological 
sample were run in each experiment in a 96-well plate on a 7500FAST machine 
(Applied Biosystems). qPCR primer sequences are shown in Table 2.3. 
 
Table 2.3: RT-qPCR primers used in this thesis 
Gene Forward Primer Reverse primer 
KCNA5 ATGCAGACAGTGCCCGAAG CCAGGCAGAGGGCATAAAGG 
CNGB3 CGCTGACAAAAGTCAACAAGGT GTTTTCTTCCTGTGCTGTGGT 
LATS2 CAAACTACATCGCACCCGAG GATCACCTTCAGCTGGGTTTC 
p21 CCATGTGGACCTGTCACTGT GGCGTTTGGAGTGGTAGAAA 
β-actin TGGATCAGCAAGCAGGAGTATG GCATTTGCGGTGGACGAT 
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2.21   Screen for regulators of cell-cycle arrest after cytokinesis 
failure 
The premise of this screen was based on the protocol described in Ganem et al., 
2014.  
 
A full list of all the siRNA sequences used in this screen is included in the Appendix 
(Section 8.2). A list of separately ordered siRNAs and their sequences are shown 
in Table 2.4. 
 
RPE-FUCCI cells were a kind gift of Dr Laurent Sansregret (London Research 
Institute). On Day 0, cells were seeded at a density of 4 x 106 cells per 15cm tissue 
culture dish. After 24 hours cells were treated with dihydrocytochalasin-B (DCB, 
Sigma) for 16 hours. Cells were washed five times for five minutes in PBS, before 
trypsinisation and staining for 1 hour at 37°C with 10µM Hoechst 33342 (Sigma). 
Samples were prepared for sorting by filtration using 70µM filters and suspension in 
PBS. Samples were sorted using an Influx BD cell sorter (BD Biosciences). The 
FUCCI markers were excited with 561nm (emission 610/20, mCherry) and 488nm 
(emission 530/40, Venus) lasers, and the Hoechst with a 405nm (emission 460/50) 
laser. Cells in the 4N peak were selected, and mCherry(+)/Venus(-) G1 cells were 
sorted. Sorted cells were counted using a Countess cell counter (Life 
Technologies). 4000 cells per well were seeded into 96-well plates, which had been 
previously prepared for transfection as described above in Section 2.3.4. After 
incubation at 37°C for the indicated time periods, cells were treated with S-Trityl-L-
cysteine (STLC) for 12 hours. STLC is an Eg5 inhibitor, which results in cells 
arresting in anaphase. Treatment with STLC traps cells entering M phase, and 
hence results in a greater difference between positive and negative cells. Plates 
were fixed by direct addition of 2X fixative (8% paraformaldehyde, PFA), and kept 
at 4°C until required. Plates were rinsed in PBS, and then simultaneously stained 
with DAPI (1µg/mL) and permeabilised with 0.5% Triton X-100 for 5 minutes at RT. 
Plates were rinsed once in PBS, and kept in PBS during imaging. Plates were 
imaged using a Cellomics Arrayscan Vti machine with a 10X 0.3 numerical aperture 
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objective. The analysis was carried out using the Target Activation Cellomics 
Bioapplication with standard settings.  
 
Transfection efficiency was tested by knockdown, followed by indirect 
immunofluorescence for LaminA/C, p53 and p21. After the sorting procedure cells 
were fixed overnight at 4°C in 4% PFA, permeabilised in 0.2% Triton X-100 for 5 
minutes at RT, blocked with 3% BSA/PBS for one hour at RT before treatment with 
primary antibodies (Lamin A/C 1:1000, Santa Cruz 636, p21 Rb 1:2000, Cancer 
Research UK MH9, p53 1:500 Calbiochem OP43 clone) in 3%BSA/PBS for 1.5 
hours at RT. Plates were washed three times with PBS, before incubation with 
secondary antibody (Goat anti-mouse or Goat anti-rabbit conjugated to AlexaFluor 
647 1:500) for 1.5 hours. Plates were scanned and analysed as above.  
 
An Incucyte live cell imaging system (Essen Bioscience) was used to image plates 
after sorting and transfection. Plates were imaged every 30 minutes using phase-
contrast and fast-fluorescence settings. Exported movies were analysed using 
Image J software. Fibronectin (Sigma, F0895 from human plasma, 1:250 in PBS) 
was used where indicated to coat plates for 30 minutes at RT before cell seeding.  
 
Table 2.4: Additional siRNA sequences 
All siRNAs were ordered from Dharmacon, and are OTP siRNAs unless otherwise 
stated. 
TARGET CATALOG NUMBER SEQUENCE 
Control-1  D-001810-01-05 UGGUUUACAUGUCGACUAA 
Control-2  D-001810-02-05 UGGUUUACAUGUUGUGUGA 
Control-3  D-001810-03-05 UGGUUUACAUGUUUUCUGA 
Control-4  D-001810-04-05 UGGUUUACAUGUUUUCCUA 
Control-5 (siGenome) D-001210-05-05 UGGUUUACAUGUCGACUAA 
RISC free  D-001220-01-05 NA 
p53-1  J-003329-14 GAAAUUUGCGUGUGGAGUA 
p53-2  J-003329-15 GUGCAGCUGUGGGUUGAUU 
p53-3  J-003329-16 GCAGUCAGAUCCUAGCGUC 
p53-4  J-003329-17 GGAGAAUAUUUCACCCUUC 
p21  J-003471-12 AGACCAGCAUGACAGAUUU 
LATS2_1 J-003865-09 GCACGCAUUUUACGAAUUC 
LATS2_2 J-003865-10 ACACUCACCUCGCCCAAUA 
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LATS2_3 J-003865-11 AAUCAGAUAUUCCUUGUUG 
LATS2_4 J-003865-12 GAAGUGAACCGGCAAAUGC 
KCNA5_1 J-006215-06 CUAGAGAAGUGUAACGUCA 
KCNA5_2 J-006215-07 ACAGAGGAGUCCAGCGGAA 
KCNA5_3 J-006215-08 GAAAGGAGAUUCAGGCAGA 
KCNA5_4 J-006215-09 GAACCCAUUUCUCUAGCAU 
CNGB3_1 J-006161-06 GCAAAUAGGAUGUUAAAGU 
CNGB3_2 J-006161-07 GUACUAAAGUUCUGGUUAC 
CNGB3_3 J-006161-08 CUAUUUGCCUGGUGACUUU 
CNGB3_4 J-006161-09 UCGAACAACUGGAUACUUG 
 
 
2.22   Bioinformatics 
All bioinformatics analysis was carried out by Nicholas McGranahan, except where 
indicated.  
 
2.22.1 SNP array processing 
Affymetrix SNP6.0 data was downloaded from The Cancer Genome Atlas (TCGA) 
database of Genotypes and Phenotypes (dbGaP) using accession number 
phs000178.v5.p5. Data from colon adenocarcinoma presented in Chapter 3 and 
Chapter 4 was from 422 tumours from TCGA. For data in Figure 3.1 additional 
SNP6.0 data from 898 breast cancers, 391 lung adenocarcinomas, 407 lung 
squamous cell carcinomas, 506 ovarian cancers and 503 renal cancers was 
obtained. For all copy number analysis any sample that failed Affymetrix 
Genotyping Console quality control (QC) was excluded. The aroma R package 
(Bengtsson et al., 2009), was used to compute LogR and B-allele frequencies 
(BAF). The integer copy number status was determined using OncoSNP (Yau et al., 
2010). 
 
Cell lines described in this thesis were subject to Affymetrix SNP6.0 arrays by Aros 
(Applied Biotechnology). Normalization and integer copy number estimation were 
carried out using PICNIC (Greenman et al., 2010). 
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Copy number for the validation cohort (used in Figure 4.8, Figure 4.9, and Table 
4.1) was performed on Illumina 610 Quad arrays. GenomeStudio V2011.1 and 
Genotyping Module V1.9.4 were used to compute LogR and BAFs. Samples with 
moving standard deviations >0.28 were discarded. Copy numbers were also 
computed with OncoSNP (Yau et al., 2010). 
 
Ploidy estimation for each sample was achieved by summation of the weighted 
median integer copy number for each chromosome, and dividing by the number of 
chromosomes analysed (n=22). The total number of chromosomes in each sample 
was calculated by summing the modal copy number from the segmented copy 
number profile of each chromosome analysed. Segments were weighted according 
to how many bases they covered. Losses and gains of segments were determined 
relative to the median ploidy of each sample.  
 
The Weighted Genome Instability Index (wGII) was calculated as in Burrell et al., 
2013. The GII is the proportion of base-pairs across the whole genome that are 
present at copy numbers that differ from 2 (Chin et al., 2007). GII was adapted to 
take into account the size of each chromosome, such that large chromosomes that 
are more likely to have more aberrations do not bias the score. The percentage of 
aberrant SNPs on each chromosome was calculated, and the mean percentage of 
aberrations across all 22 chromosomes analysed was calculated. 
2.22.2 Genome doubling algorithm 
A modification of the algorithm used by Carter and colleagues to assess the 
likelihood of genome doubling as a route to the copy number profiles observed in 
cancer was used (Carter et al., 2012). All samples, s, were represented as an 
aberration profile of major and minor allele copy numbers at chromosome arm 
resolution. The total number of aberrations, Ns, was then calculated, as well as the 
probability, Ps, of an aberration for each allele at each chromosome arm. 
Simulations were run which applied the Ns sequential aberrations based on the Ps 
to a diploid profile. 10,000 simulations of copy number state were run for each 
sample, s. A P-value for genome doubling in each sample was calculated by 
counting the percentage of simulations in which the proportion of chromosome 
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arms with a major allele copy number of >2 was higher than that which was 
observed in that sample. A P-value threshold of 0.001 was used for samples with 
ploidy ≤3, but for samples with a ploidy of 4, P ≤ 0.05 was used, and all samples 
where ploidy exceeded 5 were classified as genome doubled.  
 
2.22.3 Estimating the timing of genome doubling 
To estimate whether genome doubling occurred before or after the majority of 
losses in CRC samples, the copy numbers of each sample were assessed and 
represented as genotype proportions reflecting copy numbers from zero to eight 
copies. The parental alleles were represented as either A or B. The copy number 
state of parental alleles where there were two copies (either AA, BB or AB) were 
used to assess whether loss occurred before or after genome doubling. If a loss 
occurred before genome doubling the alleles will be represented by either AA or BB. 
If the loss occurred after genome duplication the alleles will be represented by AB. 
The proportion of either AA/BB or AB allele copy numbers was assessed for each 
sample. Samples where the majority of genotype copy numbers were AB, rather 
than AA or BB were deemed to have undergone genome doubling before the 
majority of losses. Conversely, samples where the majority of losses were 
represented by AA or BB rather than AB where said to have incurred most of the 
losses before genome duplication. A representation of this logic is shown in Figure 
3.2. 
2.22.4 Significance of correlation between wGII and copy number loss 
To determine whether the correlation of loss of chromosome 4 was significantly 
associated with high wGII tumours (Figure 4.5), simulations were carried out. The 
percentage of genomic loss in each sample was used to calculate the probability of 
loss in each sample, and this observed probability for loss was used to generate an 
aberration state for each sample. All samples were subjected to a point-biserial 
correlation between this aberration state and the wGII score. Different aberration 
states and correlations were artificially simulated 10,000 times for each sample, 
and a P-value was calculated based on how many simulations showed a greater 
correlation coefficient than that observed for each sample.  
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2.22.5 Validation cohort 
Validation cohort data was kindly provided by Dr Oliver Sieber, Dr Peter Gibbs, Dr 
Robyn Ward, Dr Dmitri Mouradov, Dr Nicholas Hawkins and the Victorian Cancer 
Biobank (Australia). Patients from the validation cohort used to assess the 
relationship between genome doubling and survival were recruited from the Royal 
Melbourne Hospital (Parkville, VIC, Australia), Western Hospital Footscray 
(Footscray, VIC, Australia) and St Vincent’s Hospital Sydney (Darlinghurst, NSW, 
Australia). The study was ethics approved and all patients gave informed consent. 
BioGrid Australia provided de-identified clinical data. 
 
2.22.6 Survival curve analysis 
Survival curves for TCGA patients and validation cohort patients were plotted using 
the Kaplan-Meier method in the statistical package R. Log-rank tests were used to 
assess the significance of univariate analyses of survival, and cox proportional 
hazards regression models were applied to multivariate survival analysis (R 
package, survival).  
  
2.22.7 Relationship between mutational status and genome doubling 
SNP6.0 and variant calls were downloaded from TCGA for bladder cancer, 
squamous cell lung cancer, lung adenocarcinoma, melanoma, head and neck 
cancer, glioblastoma, breast cancer, glioblastoma and colon adenocarcinoma. 
Copy number data was used to assess the likelihood of genome doubling as 
described above. All non-silent mutation calls were used to assess whether a 
difference in the prevalence of somatic aberrations was observed in specific genes 
in genome doubled (GD) compared to non genome-doubled (nGD) tumours. For 
assessment of whether a gene was significantly enriched or depleted in GD 
samples, a Fisher’s exact test was implemented for each gene, yielding an odds 
ratio. The odds ratio reflects the association between mutations in a specific gene 
and the likelihood of genome doubling. To control for different mutation rates in 
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different tumour types, a permutation-based analysis was carried out that assesses 
the mutation rate of each sample, and produces a simulated P-value. MutSigCV, a 
statistical approach that takes into account gene size, replication timing and 
expression was applied separately to GD and nGD tumours to identify significantly 
mutated genes within each cohort (Lawrence et al., 2013). 
 
Downstream processing of the lists of significant genes was carried out as 
described in Section 6.2.1, and the full list of genes included in the screen is shown 
in Table 6.1. 
 
Analysis of the wGII of colon adenocarcinoma tumours was carried out as 
described above, and combined with the mutational data for p53. Three genes 
were identified that were mutated frequently in wGII high but p53 wild-type tumours. 
These genes were also included in the screen described in Chapter 6. 
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Chapter 3. Results 1: Increased numerical and 
structural CIN in tetraploid clones 
3.1  Introduction 
It has long been speculated that tetraploid cells may be a precursor to the onset of 
aneuploidy in tumours (see Section 1.3.1). However it is not clear whether 
tetraploid cells are related to the onset of the dynamic phenotype of chromosomal 
instability (CIN). Many studies have used artificially generated tetraploid cells to 
explore the effects of polyploidy on tumorigenicity, but a systematic analysis of the 
effects of a naturally occurring tetraploidisation event on a stable cell line have not 
been addressed. With a focus on colorectal cancer (CRC), it was set out to 
determine the relationship between tetraploidy and chromosomal instability. A 
novel isogenic system of diploid and tetraploid clones derived from a colorectal 
cancer cell line precursor was used to explore the relationship between these two 
phenotypes. 
3.2 Results 
3.2.1  An association between wGII and ploidy in multiple cancer types 
The bioinformatics data presented below was performed by Nicholas McGranahan. 
 
In order to assess the relationship between ploidy and chromosomal instability in 
CRC, SNP6.0 data was obtained for 404 Stage 1-4 tumours from The Cancer 
Genome Atlas (TCGA).  To assess the level of chromosomal instability in these 
samples, the wGII (weighted genome instability index) was estimated. This takes 
into account the proportion of the genome that is either lost or gained relative to 
median ploidy, and is weighted on a per chromosome basis (see Methods). wGII is 
plotted against mean chromosome copy number for these 404 CRC samples in 
Figure 3.1. Polyploid tumours (ploidy ≥ 3) had significantly higher wGIIs than diploid 
tumours (P<0.0001, Student’s T-test). Further, a modified version of a published 
algorithm (Carter et al., 2012) was applied to assess the likelihood of that tumour 
having undergone a genome-doubling event (see Methods and Section 1.3.2). This 
algorithm takes into account the copy number of the major allele (the allele of the 
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highest copy number) across the whole genome.  If a tumour has undergone 
whole-genome duplication, then the major allele is likely to be an even number 
across the whole genome due to all chromosomes doubling in number at the same 
time. This is in comparison to tumours that may have increased their ploidy by 
subsequent gains of chromosomes. In this scenario the major allele will not 
necessarily be even across the majority of the genome. Those tumours classified 
as genome-doubled (GD) had significantly higher wGIIs than those classified as 
non genome-doubled (nGD) (P<0.0001, Student’s T-test, Figure 1A). This indicates 
a possible causal role for genome doubling in the evolution of chromosomally 
unstable CRCs. However, there are also GD tumours with low wGII scores, and 
nGD tumours with high wGII scores, suggesting there are multiple routes to CIN in 
CRC.  
 
 
 
Figure 3.1: Relationship between ploidy and chromosomal instability in CRC 
A) Weighted genome instability index (wGII) plotted against mean chromosome 
copy number for CRC tumours from TCGA. Each dot represents one tumour. Red 
depicts tumours likely to have undergone genome doubling (GD) (see text and 
Materials and Methods), and blue depicts tumours unlikely to have undergone 
genome doubling (non-GD, nGD). A histogram of the weighted mean chromosome 
copy numbers is shown above the plot.  
B) Chromosome counts and wGIIs are shown for other tumours where data was 
available in TCGA. Lung (Ad) = lung adenocarcinoma, Lung (SC) = lung squamous 
cell carcinoma, Renal (cc) = renal clear cell carcinoma. Chromosome counts for 
each sample are a sum of the modal copy number for each chromosome. N= 
number of tumours analysed. 
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The relationship between chromosomal instability and ploidy was also investigated 
for other cancer types where data was available in TCGA (Figure 3.1B). For each 
of the cancer types analysed (breast carcinoma, lung adenoma, lung squamous 
cell carcinoma, ovarian carcinoma and renal cell carcinoma) increasing ploidy was 
significantly associated with increasing wGII score (P<0.0001, Student’s T-test), 
suggesting there may also be a causal relationship between these two genomic 
aberrations in many cancer types.  
 
In order to ascertain the relative timing of genome doubling compared to the onset 
of chromosomal instability, an analysis of all the genomic losses in genome-
doubled CRC samples was carried out. Genomic losses occurring before a 
genome-doubling event on a diploid background will result in loss-of-heterozygosity 
(LOH) (Figure 3.2Ai), whereas losses occurring after genome doubling will not 
result in LOH (Figure 3.2Aii). Using this approach, it was calculated whether the 
majority of losses in each CRC sample in the TCGA occurred before or after the 
genome-doubling event (Figure 3.2B). Of 196 genome-doubled CRC samples, 130 
samples showed that the majority of genomic loss events had occurred after 
genome doubling, whereas there were only 66 samples where the majority of 
losses occurred before genome doubling. This suggests that genome doubling 
most often occurs as an early event in the evolution of chromosomally unstable 
CRCs. 
 
Across their pan-cancer analysis, Carter and colleagues found that the majority of 
specific large scale chromosomal arm gains and losses were more likely to have 
occurred before genome doubling, since the levels of chromosomal copy number 
alterations were similar between GD and non-GD samples in some cancers (Carter 
et al., 2012). In contrast to arm-level alterations, the authors found that focal 
somatic copy number alterations (SCNAs) were increased in samples that were 
inferred to have undergone GD, suggesting that genome doubling could influence 
genome stability. More recent work by the same group also found that GD was a 
common event, occurring in 37% of all cancer types analysed (range 11-64%), and 
also correlating with a higher overall rate of SCNAs, the majority of which were also 
inferred to occur after GD (Zack et al., 2013). 
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Figure 3.2: GD is an early event in the majority of CRCs 
A) A representation of the expected loss-of heterozygosity (LOH) profiles of 
tumours that either experience loss of genetic material before (i) or after (ii) 
genome doubling. A and B represent the two parental alleles. Balanced losses to 
two copies (AB) are depicted with an orange box with orange dotted lines around 
them. Unbalanced losses to two copies (AA or BB) are depicted with a purple box 
with purple dotted lines. If the majority of losses occur after GD, then the majority of 
LOH events will be balanced (AB), conversely if losses occurred before GD the 
majority of losses will be unbalanced (AA or BB). 
B) The likely timing of GD in CRC samples. The proportion of unbalanced to 
balanced losses for each TCGA tumour is shown. Tumours where the majority of 
losses are likely to have occurred after GD are shown in red (majority are balanced 
losses) n=130. Tumours where the majority of losses were unbalanced and likely to 
have occurred before GD are shown in blue (n=66). 
 
 
3.2.2  An isogenic system of diploid and tetraploid cell lines 
The original FACS isolation of diploid and tetraploid clones from HCT-116 
discussed in this section was carried out by Andrew Rowan, all other experiments 
were conducted by myself. 
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Given the link between genome doubling and chromosomal instability 
demonstrated by bioinformatics analyses, the acute effects of genome doubling in 
an in-vitro system were explored. The microsatellite unstable (MIN) cell line HCT-
116 was chosen as a model system as this cell line has a small fraction (<2%) of 
cells with a >4N DNA content (Figure 3.3A). Fluorescence-activated cell sorting for 
DNA content, using the DNA binding dye Hoechst, was employed to isolate single 
diploid and tetraploid cells from the parental HCT-116 population. Diploid cells were 
selected from the 2N peak, and tetraploid cells from the >4N fraction to avoid 
erroneously selecting G2 phase diploid cells in the 4N peak. The cloning efficiency 
of tetraploid cells was significantly lower than diploid cells (2N =63%, >4N =6%, 
P=0.032, Student’s T-test), suggesting that tetraploidy is poorly tolerated in HCT-
116 cells under normal culture conditions. One diploid clone (DC 8), and two of the 
rare surviving tetraploid clones (TC 3 and TC 4) were expanded for continued 
culture (Figure 3.3C). After several passages in culture, a new tetraploid sub-
population was observed in the diploid clone DC 8 (Figure 3.3D). There are a 
variety of mechanisms that could generate tetraploid cells within a diploid 
population (see Section 1.5). It was not possible to categorically distinguish the 
mechanism that generated the tetraploid cells in the HCT116 and DC 8 cell lines at 
this stage.   
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Figure 3.3: Isolation of isogenic diploid and tetraploid cell lines from HCT116 
A) Flow cytometry of HCT-116 shows a small fraction of cells with >4N DNA 
content. 2N, 4N and >4N populations are indicated on the plot. 
B) The cloning efficiency of 2N and 4N cells is shown with mean and standard error 
of the mean (3 experiments) with Poisson correction for 2N cells (see Methods). 
C) Flow cytometry using Hoechst dye to show DNA content of one diploid clone 
(DC 8) and two tetraploid clones (TC 3 and TC 4) derived from HCT-116 after 
single cell sorting. 
D) Flow cytometry for DNA content in the diploid clone DC 8 at passage 33 reveals 
the emergence of a population with >4N DNA content. Further single cell sorting for 
2N and >4N cells was carried out on DC 8. 
E) Two further diploid clones (DC-14 and DC-25) and four tetraploid clones (TC-13, 
TC-16, TC-17 and TC-35) were isolated from DC 8, and their DNA content as 
assessed by flow cytometry with Hoechst staining is shown (passage 3). 
F) Family tree depicting all diploid clones (blue) and tetraploid clones (red) used in 
this study. 
 
In order to generate tetraploid clones that had arisen within a specific time frame, a 
second generation of diploid and tetraploid clones was isolated from DC 8 (diploid 
clones DC-14 and DC-25 and tetraploid clones TC-13, TC-16, TC-17 and TC-35, 
Figure 3.3E). The tetraploid clones derived from DC 8 must have arisen from a 
single diploid cell within the time frame of the experiment, and could not have been 
cycling in the parental population for an unknown period of time, as is theoretically 
possible for TC 3 and TC4, the two tetraploid clones derived from the HCT-116 cell 
line. The two generations of diploid and tetraploid clones (three diploids and six 
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tetraploids, Figure 3.3F) were then continually passaged once a week for over 18 
months, so that the effects of a genome-doubling event on genome evolution could 
be assessed.  
 
In order to ascertain whether the formation of tetraploid cells in HCT-116 may be 
due to their microsatellite instability, a clone of HCT-116 was obtained (provided by 
Dr Francois Praz), which has a full length wildtype cDNA of the gene hMLH1 
reinserted in a plasmid under the control of the cytomegalovirus (CMV) promoter 
(referred to throughout as HCT-116_MLH1, Jacob et al., 2001). Since these cells 
are no longer mismatch repair defective, they were used to assess whether 
tetraploid cells can also arise in a microsatellite stable background and distinguish 
whether experimental observations were mismatch-repair deficient phenomena. 
Using the same cloning procedures as were used to isolate diploid and tetraploid 
clones from HCT-116, clones could also be isolated from HCT-116_MLH1 cells 
(Figure 3.4A and B). 
 
Further, diploid and tetraploid clones could also be isolated from another MSI CRC 
cell line RKO (Figure 3.4C and D), showing that being able to isolate diploid and 
tetraploid clones from a cell line considered to be chromosomally stable and diploid 
is not confined to only HCT-116.  
 
Chapter 3 Results 
 
 96 
 
Figure 3.4: Diploid and tetraploid clones derived from HCT-116_MLH1 and 
RKO 
A) Flow cytometry of a microsatellite competent clone of HCT-116_MLH1, with 2N, 
4N and >4N populations depicted. Single cell sorting for DNA content was used to 
isolate diploid and tetraploid clones from this cell line. 
B) Flow cytometry analysis with Propidium Iodide (PI) shows the ploidy of the 
parental cell line HCT-116_MLH1, as well as one diploid clone (MLH Diploid C8), 
and four tetraploid clones (MLH Tetraploids C9, C10, C11 and C16) derived from 
HCT-116_MLH1. 
C) Flow cytometry of the MIN CRC cell line RKO also shows a >4N population. 
Single 2N and >4N clones were isolated using FACS. 
D) DNA histograms of RKO and two diploid clones (RKO Diploid C1 and C2), and 
four tetraploid clones (RKO Tetraploid C2, C4, C5 and C7) derived from RKO.  
 
3.2.3 Numerical instability in tetraploid clones 
To assess the level of numerical chromosomal instability in diploid and tetraploid 
clones derived from HCT-116, clonal fluorescence in-situ hybridisation (FISH) was 
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numbers deviating from the modal chromosome number of each colony gives an 
indication of the cell-to-cell variation within each colony that has likely occurred 
during colony expansion (Figure 3.5B). Fluorescent probes for chromosomes 2 and 
8 were chosen, as these chromosomes are not commonly subjected to copy 
number changes in colorectal cancer and therefore are more likely to represent on-
going chromosomal instability. An automated microscope system was used to 
analyse this data (see Methods). Colonies were selected from an initial low 
magnification scan (5X), and then scanned at 40X. The data was analysed using 
an automated assay with manual curation (see Methods). The percentage of cell-
to-cell variation within individual colonies was significantly greater in tetraploid 
clones compared to diploid clones at both passage 5 (approximately 1 month of 
culture, Figure 3.5C, diploid mean=7% [0-23%]; tetraploid mean=28% [5-57%], 
P<0.0001, Student’s T-test) and at passage 50 (approximately 1 year of culture, 
Figure 3.5D, diploid mean=13% [3-34%]; tetraploid mean=33%, [7-68%] P<0.0001, 
Student’s T-test). The level of cell-to-cell variation observed in the parental cell line 
HCT-116 is similar to results from other laboratories carrying out this assay in the 
same cell line (Thompson and Compton, 2008). 
Chapter 3 Results 
 
 98 
 
Figure 3.5: Tetraploid clones show increased cell-to-cell variation in 
chromosome number 
A) Example images of clonal FISH. Two diploid clones DC-25 and DC 8, and two 
tetraploid clones TC-13 and TC-17 are shown. Chromosome 2 (CEP-2) is shown in 
red, and Chromosome 8 (CEP-8) is shown in green. One cell in each image is 
highlighted, and the copy number state for these two chromosomes is shown in the 
inset. Scale bar (in white) = 10µm. 
B) A diagram of a clonal FISH slide is shown, depicting the two measures of 
chromosomal instability that can be measured in this assay. Cell-to-cell variation is 
the number of cells within one colony that vary from the overall modal chromosome 
copy number for each chromosome in that colony (also referred to as deviation 
from the mode). Colony-to-colony variation is the difference in modal chromosome 
number between colonies, also referred to as deviation of the mode. 
C) Cell-to-cell variation in chromosome number between diploid and tetraploid 
clones at passage 5. The average deviation for both of the chromosomes analysed 
(2 and 8) is shown. Each point represents one colony. All passage 5 clones were 
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scored using the Ariol microscope system (see Methods). Colonies with <10 cells 
were excluded from analysis. Median number of cells scored = 2479. 
D) Cell-to-cell variation of chromosomes 2 and 8 at passage 50. All clones were 
scored on the Ariol microscope system, apart from DC 8, TC3 and TC4, which 
were scored on a Deltavision microscope. Median number of cells scored = 2105. 
NB: passage numbers depicted throughout this thesis are correct to within 4 
passages. 
 
 
Clonal FISH was also carried out on HCT-116_MLH1 diploid and tetraploid clones.  
Tetraploid clones from HCT-116_MLH1 also showed a significant increase in cell-
to-cell variation compared to the diploid clone, with a similar magnitude of 
difference between diploid and tetraploids as was observed in MMR deficient 
clones (diploid average 11% [3-29%], tetraploid average 26% [2-61%] P<0.0001, 
Student’s T-test Figure 3.6). This indicates that the increased numerical instability 
in tetraploid clones derived from HCT-116 is not likely to be due to their 
microsatellite instability phenotype. 
 
 
Figure 3.6: HCT-116_MLH1 tetraploid clones also show increased cell-to-cell 
variation in chromosome number 
Clonal FISH in one diploid (DC8), and four tetraploid clones (TC11, TC16, TC9 and 
TC10) derived from HCT-116_MLH1 at passage 5. Each point represents one 
colony. Average cell-to-cell variation for chromosome 2 and 8 is shown. Median 
number of cells scored = 4227. 
 
The increase in cell-to-cell variation in chromosome number observed in tetraploid 
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anaphase segregation errors in all clones was analysed using immunofluorescence 
(Figure 3.7A).  Tetraploid clones had significantly higher frequencies of anaphase 
segregation errors than diploid clones at all 3 passages analysed (passage 5 
P=0.0001, passage 5 P=0.0025, passage P=0.0047, Student’s T-test, diploid 
mean=19% [11-26%]; tetraploid mean=42% [32-55%]).  The frequency of 
segregation errors on a per chromosome basis was then calculated using the 
number of chromosomes calculated from SNP6.0 data (see Section 4.2.3 and 
Methods). The number of segregation errors per chromosome was not significantly 
increased in tetraploid clones (Figure 3.7A). This suggests that the increased 
frequency of anaphase segregation errors in tetraploid clones may simply be a 
consequence of the increased number of chromosomes. 
 
 
Figure 3.7: Frequency of segregation errors in diploid and tetraploid clones 
A) Chromosome segregation errors between diploid and tetraploid clones at 
passage 5, 25 and 50. Segregation errors per cell are shown. Fifty anaphases were 
scored for each clone, only bipolar anaphases are shown. P-values above each 
graph refer to comparisons between all diploid and all tetraploid clones at each 
passage (Student’s T-test). 
B) The frequency of segregation errors on a per chromosome basis for each 
passage, using modal chromosome numbers for each clone calculated from 
SNP6.0 analysis (see Methods). P-values are shown above the graph.  
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3.2.4 Centriole number and spindle polarity in tetraploid clones 
Given the relatively high level of segregation errors in the diploid clones and in the 
parental cell line, it is possible that the tetraploid cells were formed initially through 
a cytokinesis failure, which has been shown to occur after segregation errors cause 
regression of the cleavage furrow (Shi and King, 2005). A failure to undergo 
cytokinesis would result in tetraploid cells with supernumerary centrioles (see 
Section 1.5.1). Given previously published work, which has demonstrated a likely 
causative role between extra centrioles and increased chromosome segregation 
errors the number of centrioles in tetraploid clones was examined (Ganem et al., 
2009 and see Section 1.8.2.1). 
 
The number of centrioles in prophase cells was scored using immunofluorescence 
for centrin-3, a mammalian centrin that is associated with the centrosome. 
Representative images of prophase cells with centrin-3 antibody staining are 
shown in Figure 3.8A. Histograms showing the percentage frequency of centriole 
numbers at both passage 5 and passage 50 are presented in Figure 3.8B and C. 
The percentage of supernumerary centrioles (% of cells with >4 centrioles) is 
shown in Figure 3.8D and E. Tetraploid clones showed significantly more 
supernumerary centrioles at passage 5 (diploids mean = 31% [12-44%], tetraploid 
mean = 72% [43-85%] P=0.0046, Student’s T-test) and passage 50 (diploids mean 
= 30% [25-38%] tetraploid mean = 75% [67-93%] P=0.0002, Student’s T-test). 
Furthermore there was no significant difference in the percentage of 
supernumerary centrioles between passage 5 and passage 50 for diploid or 
tetraploid clones (P=0.6087, Paired T-test). Interestingly this indicates that there is 
no selective pressure over time for these cells to lose extra centrioles, which would 
be expected if the extra centrioles were causing the increase in the frequency of 
segregation errors observed in tetraploid clones (Figure 3.7). 
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Figure 3.8: Maintenance of supernumerary centrioles over time in tetraploid 
clones 
A) Representative images of two cells stained with DAPI (blue) and 
immunofluorescence against centrin-3 (green). 
B) Frequency histogram of the percentage of cells scored displaying the indicated 
centriole number for diploid and tetraploid clones at passage 5. Median number of 
cell scored n=49.  
C) Frequency histogram of centriole number for passage 50 diploid and tetraploid 
clones. Median number of cells scored n=50. 
D) Percentage of cells with supernumerary (>4) centrioles at passage 5. 
E) As above, for passage 50 cells.   
 
As extra centrioles are thought to cause increased segregation errors via the 
formation of transient multipolar spindle intermediates (Ganem et al., 2009), the 
polarity of spindles was scored in pre-anaphase cells using immunofluorescence 
for β-tubulin and centrin-3 (Figure 3.9A).  
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Figure 3.9: Pre-anaphase spindle polarity in diploid and tetraploid clones 
A) Representative images of monopolar, bipolar and multipolar spindles that were 
scored using immunofluorescence for β-tubulin and centrin-3 in this analysis. 
B) Quantification of percentage frequency of each spindle configuration in passage 
5 cells.  
C) As above for passage 50 cells. 
D) Comparison of each spindle configuration between diploid and tetraploids at 
passage 5 (ns = not significant, * = P<0.05, Student’s T-test). 
E) As above, for clones at passage 50. 
 
DAPI staining was used to identify pre-anaphase cells. The percentage frequency 
of each spindle configuration is shown in Figure 3.9B for passage 5 and Figure 
3.9C for passage 50. There was no significant difference at either passage 
between the percentages of monopolar or bipolar spindles (Figure 3.9D and E, 
Student’s T-test). Tetraploid clones showed a slight but significant increase in 
multipolar spindles at passage 5 (P=0.0399, Students T-test), but at passage 50 
there was no significant difference. Interestingly these data suggest that the 
supernumerary centrioles in tetraploid cells only result in a slight increase in 
multipolar spindles in pre-anaphase compared to diploid cells (multipolar spindles: 
passage 5 diploid mean = 3% [0-4%] tetraploid mean = 11% [7-23%], passage 50 
diploid mean =2% [0-5%], tetraploid mean = 4% [2-9%]). Previous studies have 
shown that multipolar divisions often result in non-viable progeny (Ganem et al., 
2009, Kuffer et al., 2013), suggesting a selective pressure for cells to be able to 
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divide in a bipolar fashion. This is supported by the fact that the percentage of 
multipolar spindles decreases over time in tetraploid clones.  
 
As discussed in Section 1.8.2.1, cells with supernumerary centrioles can divide in a 
bipolar fashion if they have efficient centriole clustering (Kwon et al., 2008). Since 
HCT-116 and diploid clones do have supernumerary centrioles (average 31% of 
cells with >4 centrioles Figure 3.8D), but few multipolar spindle configurations 
(average 3% multipolar spindles, Figure 3.9B and D) this suggests that efficient 
centriole clustering mechanisms are likely to already exist in diploid cells. The 
cloning process used to derive to tetraploid clones is likely to have positively 
selected for tetraploid cells that had efficient clustering mechanisms despite an 
increase in centriole number. This can also help explain why a change in centriole 
number over time was not observed in tetraploid clones. Without a selective 
pressure to lose centrioles (i.e. a detrimental effect on cell viability caused by their 
presence), there would be no reason for tetraploid cells to lose extra centrioles over 
continued passaging. This is in contrast to similar cell line systems where tetraploid 
cells have been shown to lose centrioles over time (Ganem et al., 2009). 
 
3.2.5 Types of segregation error in tetraploid clones 
Extra centrioles are thought to cause an increase specifically in lagging centric 
chromosomes (Ganem et al., 2009). In order to ascertain whether the increased 
centriole number in tetraploid clones has an effect on the type of segregation errors, 
anaphase segregation errors were classified using immunofluorescence. A CREST 
antibody was used to identify the centromeric regions of chromosomes in 
immunofluorescence (see insets, Figure 3.10A). This makes it possible to classify 
segregation errors into different types, in particular separating lagging 
chromosomes into either centric or acentric lagging chromosomes. Segregation 
error classification can shed light on likely mechanisms driving instability, as 
different mechanisms are thought to be responsible for causing different types of 
error (see Section 1.8). The profile of segregation error types for each individual 
diploid and tetraploid clone at passage 5 and passage 50 is shown in Figure 3.10B 
and C. There was no significant difference in the profile of segregation error types 
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between diploid and tetraploid clones (Figure 3.10D, P=0.178, Chi-squared test). 
There was no increase in lagging centric chromosomes in tetraploid clones, which 
is consistent with the fact that there was only a very small increase in pre-
anaphase spindle multi-polarity (Figure 3.9G) despite the increased levels of 
supernumerary centrioles (Figure 3.8). 
 
 
Figure 3.10: Tetraploid and diploid clones make a similar spectrum of 
segregation errors 
A) Representative merged images of the different types of segregation error that 
were classified in diploid and tetraploid clones using DAPI staining and CREST 
immunofluorescence. Inset shows close up of the error, and side panels show each 
channel separately. Scale bar (in white) = approximately 3µm. 
B) Quantification of the percentage of each type of error (only cells with errors were 
scored for this analysis) in passage 5 cells. Median number of cells with errors 
scored = 39. 
C) Quantification of segregation error types in passage 50 cells. Median number of 
cells with errors scored = 37. 
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D) Comparison of the proportions of different types of error between diploids and 
tetraploids (at both passage 5 and passage 50) shows no difference in the 
proportion of different types of error (P=0.178, Chi-squared test). 
 
The fact that tetraploid clones display a similar spectrum of segregation errors to 
diploid clones suggests that there is no ‘tetraploid-specific’ mechanism driving 
increases in any one type of segregation error.  
 
3.2.6 Structural instability in tetraploid clones 
Previous data has shown that tetraploid cells display elevated numerical 
chromosomal instability on a per cell, but not a per chromosome basis. To assess 
the relationship between ploidy and structural chromosomal instability, the level of 
structural chromosome abnormalities in all clones was analysed using metaphase 
spreads hybridised with a pan-centromeric probe (Figure 3.11A). The number of 
structural chromosome abnormalities in each cell was significantly increased in 
tetraploid clones at all three passages analysed (passage 5 P=0.0160, passage 25 
P=0.0067, passage 50 P=0.0301, diploid mean: 0.39 [0.26-0.58] abnormalities per 
cell; tetraploid mean: 0.93 [0.60-1.62] abnormalities per cell, Figure 3.11B). The 
number of chromosomes was also counted from each metaphase spread analysed, 
and the number of structural chromosome abnormalities on a per chromosome 
basis was then calculated. The number of structural abnormalities per chromosome 
was not significantly different between diploid and tetraploid clones at any passage 
analysed (Figure 3.11C, diploid mean=0.0088 [0.0058-0.0130]; tetraploid 
mean=0.0108 [0.0073-0.0180], P=0.1093, Student’s T-test).  These data suggest 
that the increased level of structural chromosomal instability in tetraploid cells 
results from the increased number of chromosomes.  
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Figure 3.11: Structural chromosome abnormalities in diploid and tetraploid 
clones 
A) Representative images of chromosomal abnormalities observed in metaphase 
spreads hybridised with a pan-centromeric probe (green) and stained with DAPI. 
Scale bar (in white) = approx. 2.5µm. 
B) A comparison of the number of structural abnormalities observed per cell 
between diploid and tetraploid clones at passage 5, 25 and 50. Median number of 
metaphase spreads scored for each passage: passage 5 = 25, passage 25 = 29, 
passage 50 =27 and HCT-116 n = 37. 
C) Number of structural abnormalities per chromosome, calculated from the 
number of chromosomes counted for each metaphase spread. 
 
The different types of structural abnormalities scored included dicentric 
chromosomes, acentric chromosome fragments and double strand breaks (Figure 
3.11A). The most common type of abnormality observed in both diploid and 
tetraploid clones was acentric chromosome fragments, accounting for a median of 
56% (27-90%) of abnormalities (average % of abnormalities in all passage 5 and 
passage 50 diploids and tetraploids), followed by dicentric chromosomes, which 
accounted for 14% (0-62%) of abnormalities on average. Double strand breaks 
were less frequently observed, at 10% (0-43%) of abnormalities on average. 
Occasionally other types of abnormality that were less common were observed, for 
example ring chromosomes and fragmented chromosomes. These were 
considered in a single category of “other” in this analysis, which accounted for a 
median of 15% (0-40%) of all abnormalities.  
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In two tetraploid clones, TC3 and TC4, some particular chromosome abnormalities 
appeared to be conserved as they were observed on the majority of spreads. 
These appeared to be dicentric chromosomes, but with no sister chromatid 
cohesion between one pair of centromeres. Examples of these chromosomes are 
shown in Figure 3.12. These conserved structural abnormalities could possibly 
represent chromosome fusion events where one pair of centromeres has been 
inactivated. This has been shown to occur in fission yeast (Sato et al., 2012). 
 
Figure 3.12: Conserved structurally abnormal chromosomes in TC 3 and TC 4 
Examples of the same type of abnormal chromosomes that were observed across 
multiple metaphase spreads in TC 3 and TC 4. Images are from metaphase 
spreads stained with DAPI (blue), and hybridised to a centromeric probe. 
 
An analysis of the percentage of each different type of abnormality between 
diploids and tetraploids was carried out (Figure 3.13). There were no significant 
differences in the frequencies of each type of structural abnormality between 
diploid and tetraploid clones at either passage 5 or passage 50 (Student’s T-test). 
However the frequencies of dicentric chromosomes are higher in tetraploids at both 
passages. This is likely due to the presence of the conserved dicentric 
chromosomes shown in Figure 3.12.  
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Figure 3.13: Diploid and tetraploid clones have similar frequencies of 
different structural abnormalities 
A) A comparison of the proportion of different types of structural chromosome 
abnormalities observed on metaphase spreads between diploid and tetraploid 
clones at passage 5 (DSB = double strand break). 
B) As above, for passage 50 clones. 
 
3.2.7 Interphase DNA damage in diploid and tetraploid clones 
Structural chromosome abnormalities are most likely to arise as a result of DNA 
double-strand breaks (DSBs) that have been erroneously corrected leading to 
chromosome fusions, or that have failed to be corrected leading to acentric 
chromosome fragments (Thompson and Compton, 2011b, Gisselsson, 2008, see 
Section 1.8.4). To assess the contribution of DNA damage to the increase in 
structurally abnormal chromosomes in tetraploid cells, the amount of basal DNA 
damage was analysed using indirect immunofluorescence for the DSB response 
proteins γH2AX and 53BP1. Examples of the images used to score these foci are 
shown in Figure 3.14A. Interphase nuclei were selected randomly using DAPI 
staining, and the number of co-localised γH2AX and 53BP1 foci per nucleus was 
scored.  
 
The percentage frequency for different categories of foci number (0-2, 3-4, 5-6, 7-8 
and >8) was calculated for both passage 5 (Figure 3.14B) and passage 50 (Figure 
3.14C). To compare between diploid and tetraploids at both passages, summary 
graphs are presented in Figure 3.14D and E. At passage 5 there is a significant 
difference between diploid and tetraploids in the frequency of cells with 3-4 foci 
(diploid average 7%, tetraploid average 13%, P=0.0147, Student’s T-test).  There 
are no significant differences between any of the other categories (Student’s T-
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Test).  This could suggest that tetraploid cells are subject to a greater frequency of 
low level DNA damage.  
 
 
Figure 3.14: Levels of interphase DNA damage in diploid and tetraploid 
clones 
A) Representative images used to score interphase DNA damage. Indirect 
immunofluorescence was carried out to detect γH2AX and 53BP1. The number of 
co-localised foci per nucleus was counted.  
B) The percentage frequency of different numbers of foci in passage 5 diploid and 
tetraploid clones. The key shows the colours indicating different numbers of foci. 
Median number of nuclei scored = 248, range 191-429.  
C) As for B), but in passage 50 clones. Median number of nuclei scored = 314, 
range 200-405. 
D) A comparison of percentage frequency of different numbers of foci between all 
diploid and tetraploid clones at passage 5.  
E) As above, but for passage 50 clones.  
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is a slight increase in the mean number of foci in tetraploids compared to diploids. 
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This suggests that there may be modest increases in the levels of DNA damage in 
tetraploid clones. However, these differences in passage 50 cells seem to be 
mainly driven by two clones, TC-16 and TC-17, which seem to have a different 
profile of numbers of DNA damage foci, with an increase in the number of cells with 
more than 8 foci (Figure 3.14C). Neither of these clones had noticeably higher 
frequencies of segregation errors or structural abnormalities that could explain 
these differences (Figure 3.7, Figure 3.11). This analysis could be improved by 
carrying out an automated analysis of basal DNA damage that does not involve 
scoring by immunofluorescence images by eye, which could have introduced 
artefactual errors. Using a comet-assay could achieve this, as automated image 
software can calculate the length of the tail-moment. 
 
All tetraploid clones have significant increases in the levels of segregation errors 
per cell (Figure 3.7), which are known to result in DNA damage (Janssen et al., 
2011, Crasta et al., 2012), as well as an increase in the levels of structural 
chromosome abnormalities (Figure 3.11), which themselves result from DNA 
damage, and therefore it is surprising that there is not a more substantial increase 
in interphase DNA damage in tetraploid clones. As tetraploid cells have twice as 
much DNA, it would be expected that they would also sustain twice as much 
spontaneous DNA damage. No large differences in the frequency of DNA damage 
foci were observed between diploids and tetraploids, which could suggest that 
either tetraploid cells are not subject to as much DNA damage, or that more 
efficient DNA repair processes operate in tetraploid cells. There is a more obvious 
difference between diploid and tetraploids across multiple categories at passage 50 
compared to passage 5, which would fit a model of gradual accumulation of DNA 
damage over time in culture, likely due to the increase in segregation errors and 
structural chromosome abnormalities.  
 
3.2.8 Replication stress in tetraploid clones 
It has been previously shown that replication stress is likely to be a major cause of 
segregation errors and structural chromosome abnormalities in chromosomally 
unstable CRC cell lines (Burrell et al., 2013). To see if tetraploid clones were 
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subject to replication stress the speed of DNA replication was assessed using DNA 
fibre assays. If cells are experiencing replication stress, a decrease in the 
progression of replication forks would be expected. To directly measure DNA 
replication rates, DNA fibre labelling was used. Briefly, exponentially growing cells 
were pulsed sequentially with two thymidine analogues 5-Chlorodeoxyuridine 
(CldU) and Iododeoxyuridine (IdU) that are incorporated into nascent DNA strands. 
These different analogues can be detected using immunofluorescence, and the 
speed of DNA replication can be inferred from the length of the fibres. 
 
Representative fibres from all passage 5 cells are shown in Figure 3.15A. Fork 
speed was measured from the green CldU labelled fibres only, as these were 
detected more strongly by the secondary antibody used. Conversion of fibre length 
into fork speed in kilobases of DNA replicated per minute (kb/min) is shown in 
Figure 3.15B. To compare fork speed between diploid and tetraploids data is 
shown as a histogram (Figure 3.15C). Tetraploid clones have a slight but significant 
reduction in fork speed compared to diploid clones at passage 5 (diploid mean 
1.095 ± 0.01436 kb/min [SEM] N=701, tetraploid mean 0.9746 ± 0.01095 kb/min 
[SEM] N=819, P<0.0001, Student’s T-test, Figure 3.15C). The mean fork speed of 
the parental cell line HCT-116 is 1.07 ± 0.02788 kb/min, which is comparable to 
data from published studies (Burrell et al., 2013 Petermann et al., 2008). An 
average reduction in fork speed of just 0.12	 kb/min between diploids and 
tetraploids is probably not significantly affecting the ability of tetraploid clones to 
synthesise DNA in a timely fashion. 
 
The replication rate was also analysed for diploid and tetraploid clones at passage 
50, after almost a year in culture (Figure 3.15D). Comparing between diploid and 
tetraploid clones at this passage revealed there was no significant difference in fork 
rate (diploid mean 1.009 ± 0.01646 [SEM] N=521, tetraploid mean 1.015 ± 
0.009971 [SEM] N=1161, P=0.734, Student’s T-test, Figure 3.15E). The changes in 
fork rate between passage 5 and passage 50 are very small, -0.086 kb/min for 
diploids, and +0.0404 kb/min for tetraploid clones. These small differences are 
unlikely to represent biological changes, and more likely is due to experimental 
variation. The fact that there is no significant change in tetraploid clones over time 
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supports the assumption that at passage 5 the slight reduction noted in fork rate 
compared to diploids is unlikely to be biologically relevant.  
 
 
Figure 3.15: DNA replication rate is similar between diploid and tetraploids 
A) Representative images from DNA fibres obtained from passage 5 diploid and 
tetraploid cells. Inset box indicates timing of CldU and IdU pulses (see Methods).  
B) Quantification of fork speed (kb/min) between diploid and tetraploid clones at 
passage 5. Median number of fibres scored for each clone =137 (range 92-304).  
C) Comparison of fork speed between passage 5 clones on a frequency histogram 
and quantification of fork speed differences. 
D) Fork speed of diploid and tetraploid clones at passage 50 (kb/min). Median 
number of fibres scored = 183 (range 149-220).  
E) Frequency histogram showing fork speed for all passage 50 clones, and 
quantification of fork speed differences. 
 
 
It could be of interest to use DNA combing to improve this analysis. The use of 
combing allows more accurate recognition of particular fork structures that can be 
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indicative of specific problems during DNA replication, including stalled forks and 
asymmetric fork progression. However, since only a very slight difference was 
noted between diploid and tetraploid clones with respect to fork speed, it was 
deemed unnecessary to extend this analysis.  
 
Replication stress has been shown to be linked to structural chromosomal 
instability (Burrell et al., 2013). Replication stress can result in a reduction in fork 
speed, however it does not appear that tetraploid cells are affected by replication 
stress to a great extent. This is in accordance with previous data (Figure 3.10) 
showing the spectrum of segregation errors in tetraploids is not significantly 
different from either the parental cell line or the diploid clones. Replication stress 
would likely result in an increase in acentric lagging chromosomes and anaphase 
bridges (Burrell et al., 2013).  
 
3.2.9 Cell cycle timing and proliferation rate in diploid and tetraploid clones  
Tetraploidy seems to have an effect on the levels of both numerical and structural 
chromosomal instability on a per cell, but not per chromosome basis. Next the 
effect of a doubled genome on cell cycle timing was investigated. Cell cycle 
duration in all diploid and tetraploid clones was assessed from live cell imaging of 
cells expressing a plasmid containing histone 2b tagged to red fluorescent protein 
(pH2B-mRFP) (Figure 3.16A). Cells were transfected with the H2B-mRFP 
expressing plasmid and sorted using FACS for RFP expression after selection in 
antibiotic (see Methods). Cells were imaged for approximately 6 hours on a 
climate-controlled microscope. A full cell cycle was defined as the time from mitosis 
to the next mitosis in resulting daughter cells. Only cells that underwent a normal 
mitosis with no visible segregation error defects were included in this analysis.  
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Figure 3.16: Tetraploid clones have a longer cell cycle duration than diploid 
clones 
A) Quantification of cell cycle length from live-cell imaging of diploid and tetraploid 
clones expressing H2B-mRFP. Median number of cells scored = 26 (range 5-45). 
Approximate passage number of all clones after transfection was passage 15. 
B) Comparison of cell cycle duration between diploid and tetraploid clones. 
C) A fixed cell analysis of proliferation rate over 96 hours for second-generation 
clones at passage 6, passage 26 and passage 49. Five replicate wells were plated 
for each clone, from which standard deviations were calculated, and shown on 
graphs as error bars. 
 
Cell cycle movies were captured between passage 6 and passage 11 (indicating 
the passage of cells at time of H2B-mRFP transfection). Although the cell cycle 
length was not remarkably different between all the clones (diploid range: 14 – 38 
hours, tetraploid range: 12 – 44 hours), taken together there was a significant 
increase in cell cycle length in tetraploid clones (Figure 3.16B, P<0.0001, Student’s 
T-test, diploid mean: 22 hours, tetraploid mean: 25 hours). In an analysis of fixed 
cells at three different passage numbers, all second generation clones showed a 
clear trend for an increase in proliferation rate over time (Figure 3.11C). It is likely 
that this is due to the selection pressure of passaging cells continuously, which will 
select for more rapidly growing cells over time.  
A) B)
C
el
l c
yc
le
 d
ur
at
io
n 
(h
r)
HC
T-
11
6
DC
 8
DC
-14
DC
-25 TC
 3
TC
4
TC
-13
TC
-16
TC
-17
TC
-35
0
10
20
30
40
50
C
el
l c
yc
le
 d
ur
at
io
n 
(h
r)
Diploids Tetraploids
0
10
20
30
40
50
p<0.0001
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
0 
10 
20 
30 
40 
50 
60 
0 24 48 72 96 
Fo
ld
 c
ha
ng
e 
in
 c
el
l n
um
be
r 
Hours 
passage 6
passage 26
passage 49
C)
DC-14 DC-25
TC-13 TC-16 TC-17 TC-35
Chapter 3 Results 
 
 116 
 
3.2.10  Tetraploid clones have an increased mitotic duration 
It has been previously reported that the number of chromosomes and presence of 
extra centrioles can increase the length of mitosis (Yang et al., 2008). The length of 
mitosis was analysed using live-cell imaging of H2B-mRFP expressing clones 
ranging between passage 6 and passage 11 (Figure 3.17A). Mitotic duration was 
significantly increased in tetraploid compared to diploid cells (diploid mean = 28 
minutes, tetraploid mean = 38 minutes, P<0.0001, Student’s T-test). The standard 
deviation also indicates that there is more variation in the tetraploid cells compared 
to the diploid cells (diploid SD = 7.6, tetraploid SD = 15.3). Mitotic duration can be 
split into two distinct phases using H2B-mRFP expressing cells (Figure 3.17B). The 
time from nuclear envelope breakdown (NEBD) until the last chromosome has 
congressed (LCC) to the metaphase plate is shown in Figure 3.17B. The length of 
this phase of mitosis is shortly but significantly increased in tetraploid clones 
compared to diploid clones (diploid mean =19 minutes, tetraploid mean = 23 
minutes, P<0.0001, Student’s T-test, Figure 3.17D). Similarly, the time between the 
last chromosome having congressed and anaphase onset (ANA) is also 
significantly increased in tetraploid clones (diploid mean = 9 minutes, tetraploid 
mean = 13 minutes, P=0.004, Student’s T-test, Figure 3.17E and 9F). 
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Figure 3.17: Increased mitotic duration in tetraploid clones 
A) Mitotic duration calculated from live-cell imaging of H2B-mRFP expressing 
clones from approximately passage 15. Mitotic duration is defined as the time from 
nuclear envelope breakdown (NEBD) to anaphase. Median number of cells scored 
for this and subsequent analysis = 26 cells.  
B) Images show the different phases of mitosis in H2B-mRFP expressing cells; 
time from start of movie is shown on each panel in the form hh:mm. NEBD, last 
chromosome congressed (LCC) and anaphase onset (ANA) are indicated. 
C) Quantification of duration between NEBD and LCC in individual diploid and 
tetraploid clones.  
D) Comparison of duration from NEBD-LCC between diploid and tetraploid clones.  
E) Quantification of duration between LCC and ANA in individual diploid and 
tetraploid clones.  
F) Comparison of duration from LCC-ANA between diploid and tetraploid clones. 
 
A delay in NEBD to LCC is likely to represent a delay while all chromosomes are 
correctly aligned to the metaphase plate, and a LCC to ANA delay is likely to be 
caused by prolonged signalling of the spindle assembly checkpoint (SAC) (see 
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Section 1.4.2). As discussed for yeast (see Section 1.10), polyploidy has been 
suggested to cause geometric defects in spindle pole body (SPB) and microtubule 
formation that could be responsible for the increase in syntelic attachments 
observed in polyploid yeast (Storchova et al., 2006). It is not yet clear whether 
these same geometric constraints occur in tetraploid mammalian cells. However, 
there may well be physical constraints that arise due to a doubled chromosome 
number, and if these cause an increase in mal-attached chromosomes, this might 
lead to an increase in mitotic duration as the cell attempts to correct these. As has 
been previously shown, extra chromosomes and centrioles do result in an 
increased mitotic duration due to a delay in satisfying the spindle assembly 
checkpoint (Yang et al., 2008). 
 
3.2.11 S-phase duration in tetraploid clones 
Having only noted a small delay in mitosis in tetraploid cells, the length of S phase 
was then assessed. To explore the length of S-phase, a pulse-chase assay 
followed by flow cytometry analysis was used. Exponentially growing cells were 
exposed to the synthetic nucleoside analogue of thymidine Bromodeoxyuridine 
(BrdU), which is incorporated into newly forming DNA in cells during S-phase. After 
the pulse of BrdU treatment, cells are fixed at regular intervals and the BrdU 
positive cells can be tracked through subsequent phases of the cell cycle using a 
DNA stain (Figure 3.18A). These experiments were carried out in second-
generation clones at passage 11. After 24 hours from the initial BrdU pulse there 
was no significant difference in cell cycle phase of the BrdU positive cells between 
the diploid and tetraploid clones (percentage of diploids vs. tetraploids in G1 after 
24 hours: P=0.3118, S phase: P=0.1487, G2 phase: P=0.6544, Student’s T-test, 
Figure 3.18B). These data indicate that there is no difference in the length of S 
phase between diploid and tetraploid clones. 
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Figure 3.18: S phase duration is similar in diploid and tetraploid clones 
A) Representative flow cytometry plots of a diploid clone pulsed with BrdU at 
different time points (T=0, T=6 and T=24 hours after BrdU pulse). Top panels 
compare DNA content (PI) on x-axis (linear scale) to BrdU positivity (green 
channel-488) on the y-axis (log scale). BrdU positive cells are demarcated by pink 
box at each time point (positivity was determined against a BrdU untreated control). 
Bottom panel shows a DNA histogram of the BrdU positive cells from the 
corresponding top panel. 
B) The percentage of BrdU positive cells in cell cycle phase at the indicated time 
points after the BrdU pulse in passage 12 diploid and tetraploid clones. Cell cycle 
phases were defined from an algorithm in the flow cytometry analysis software 
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FlowJo (Watson pragmatic – see Methods). Time points T=0, T=6, T=8 have 
standard deviations derived from three independent experiments, T=24 has error 
bars from two independent experiments.  
 
 
Taken together the data on cell cycle length has shown delayed cell cycle duration 
in tetraploid clones (Figure 3.16). However this delay (on average 3 hours longer in 
tetraploid clones) cannot be fully explained by the small increases in mitotic 
duration (on average 8 minutes longer, Figure 3.17). Furthermore, there does not 
appear to be systematic delay in the duration of S phase (Figure 3.18). It is 
possible that heterogeneity between different cells experiencing cell specific delays 
in different phases could account for the differences between diploid and 
tetraploids.  
 
It is interesting as there are not significant changes in replication fork speed in 
tetraploid clones (Figure 3.15), given that they have an S phase of similar duration 
(Figure 3.18). This means that DNA in tetraploid cells is being replicated within the 
same time frame as half the amount of DNA in diploid cells with no increase in the 
speed of replication. This could suggest that twice as much replication machinery is 
present in each cell to achieve the same rate of origin firing from each chromosome. 
 
3.3 Conclusions 
In this chapter an isogenic system of diploid and tetraploid clones derived from 
HCT-116 has been used to study the effects of a naturally occurring 
tetraploidisation event on chromosomal instability. The long-term impact on 
chromosomal instability was investigated by continual passage of all clones over 
more than a year. Tetraploid cells at passage 5 (approximately 1 month after 
isolation) were compared to those at passage 25 (approximately 6 months in 
culture) and at passage 50 (after a year in culture).  
 
Tetraploid clones demonstrated significantly higher levels of numerical 
chromosomal instability as evidenced by their increase in cell-to-cell variation in 
chromosome number and increase in the frequency of anaphase segregation 
errors per cell. However, there was no difference in the frequency of segregation 
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errors per chromosome, suggesting that the increase in segregation errors per cell 
results from the fact that there are more chromosomes in tetraploid cells. Despite 
tetraploid clones having a significant increase in the percentage of cells with extra 
centrioles, there was only a small difference in the number of cells undergoing a 
transient multipolar spindle intermediate in prophase between diploid and 
tetraploids, which has been suggested as a mechanism that drives increases in 
lagging chromosomes in cells with supernumerary centrioles (Ganem et al., 2009). 
These data are supported by the fact that there is no difference in the frequency of 
lagging centric chromosomes between diploid and tetraploid cells. 
 
Tetraploid clones also displayed increased levels of structural chromosomal 
instability, as evidenced by structurally abnormal chromosomes observed on 
metaphase spreads. Similarly to numerical instability, this structural instability was 
only observed on a per cell, and not per chromosome basis. No evidence of 
replication stress was noted for tetraploid cells at either passage 5 or passage 50, 
and only small increases were observed at passage 50 when assessing interphase 
DNA damage. Differences in cell cycle phases and duration were also investigated 
between diploid and tetraploid clones. Despite a small increase in cell cycle 
duration in tetraploid cells, no systematic defect in S phase or mitosis was 
observed that could account for this. It is likely that heterogeneous cell cycle 
profiles of different cells within the population account for the small increase in cell 
cycle duration.  
 
Taken together, these data indicate that tetraploidisation does not cause an 
increase in chromosomal instability above that which would be expected given the 
increase in the number of chromosomes in tetraploid cells. However a strong 
correlation was observed across multiple cancer types in TCGA between ploidy 
and chromosomal instability, which indicates that polyploid cells are able to 
maintain a high level of chromosomal instability that is positively selected for. In the 
next chapter, the ability of tetraploid cells to propagate chromosomal instability and 
segregation errors is investigated. 
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Chapter 4. Results 2: Tetraploid clones tolerate and 
propagate CIN 
4.1 Introduction  
An isogenic system of diploid and tetraploid clones has been described that was 
derived from the MIN CRC cell line HCT-116. Tetraploid clones exhibit increased 
numerical and structural chromosomal instability that seemed to remain at a 
constant level over the course of continual passaging for more than a year. Careful 
analysis showed that levels of chromosomal instability were not increased in 
tetraploids if their additional chromosome count was used to compare instability on 
a per chromosome basis. Chromosomal instability is a high-risk clinical phenotype, 
being associated with poor patient prognosis across a range of cancer types. Given 
that genome doubling events are noted to be associated with increased 
chromosomal instability across a range of cancer types, it was investigated how the 
increased chromosomal instability in tetraploid cells could affect the stability of the 
genome over time. It is clearly of clinical relevance to better understand how highly 
unstable cancers arise.  
 
All bioinformatics analyses presented in this chapter were informed from the in vitro 
studies carried out in Chapter 3, and carried out in collaboration with Nicholas 
McGranahan. 
4.2 Results 
4.2.1 Tetraploid cell lines can propagate aneuploidy in clonal FISH assays 
Clonal FISH assays can be used to assess a second measure of chromosomal 
instability as well as the cell-to-cell variation previously presented (see Section 
3.2.3). This is the modal chromosomal variation between colonies, or colony-to-
colony variation. An aneuploid modal chromosome number implies that an initial 
founding cell was aneuploid and has been able to grow into a colony. The number 
of colonies with colony modes differing from the expected modal chromosome 
number (2 for diploid and 4 for tetraploid colonies) gives information about the 
ability of a cell line to propagate an unbalanced, or aneuploid, chromosome number. 
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At both passage 5 and passage 50, aneuploid colonies were observed in tetraploid 
clones (Figure 4.1A and B) for either chromosome 2 or chromosome 8 (passage 5 
mean=25% of colonies [8-44%]; passage 50 mean=30% [18-43%]).  
 
 
Figure 4.1: Increased colony-to-colony variation in tetraploid clones 
A) Colony-to-colony variation (or deviation of the mode) of chromosome 2 analysed 
from clonal FISH data in both passage 5 and passage 50 diploid and tetraploid 
clones. Data is shown as percentage frequency of colonies with indicated modal 
chromosome numbers. Median numbers of colonies analysed: passage 5= 44, 
passage 50 = 39. 
B) Colony-to-colony variation of chromosome 8 for both passage 5 and passage 
50.  
C) Representative image of a pentaploid colony, observed in the tetraploid clone 
TC-35. Cells with five copies of chromosome 8 are outlined in white. 
D) Clonal FISH of HCT-116_MLH1 clones at passage 5 for both chromosome 2 
and chromosome 8. 
 
An example of an aneuploid colony that was observed in TC-35 is shown in Figure 
4.1C. Only one aneuploid colony was found in HCT-116 (1.7% of all colonies), and 
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no aneuploid colonies were found in the other diploid clones. One tetraploid colony 
was observed in DC-14, consistent with the observation that diploid clones can 
tolerate tetraploidisation as a rare event (Figure 4.1A and B). 
 
These data suggest that tolerance of aneuploidy is a rare event in diploid clones, 
but common in tetraploid cells. Further, the four tetraploid clones derived from a 
microsatellite competent clone of HCT-116 (HCT-116_MLH1) also displayed 
several aneuploid colonies in clonal FISH assays (Figure 4.1D). Taken together, 
these data suggest that tetraploid cells are better able to propagate aneuploidy 
than their diploid counterparts.  
 
This result is intriguing as it suggests tetraploid cells may have an aneuploidy 
tolerance mechanism that is not present in diploid cells. It has previously been 
suggested that chromosomal instability may be a composite phenotype involving 
not only increased genome stability, but also tolerance and propagation of genome 
instability. In fact, HCT-116 has been previously used to demonstrate that CIN 
cannot be artificially induced in cell lines just by increasing the segregation error 
rate (Thompson and Compton, 2010).  
 
4.2.2 Tetraploid clones can propagate segregation errors in live-cell imaging 
analysis 
Since clonal FISH gives an indirect measure of the ability of cells to tolerate 
aneuploidy, a more direct assay to measure tolerance to chromosome 
missegregation was carried out. Using the H2B-mRFP expressing diploid and 
tetraploid clones described previously (see Section 3.2.9), daughter cell fate after 
both normal cell division and divisions with segregation errors was assessed. 
Images were taken every 3 minutes for the first six hours of acquisition so dividing 
cells could be scrutinised for segregation errors. Further images were taken at 15-
minute intervals so that cell fate could be assessed over the next 60 hours. 
Daughter cell fate was split into three categories: mitosis, cell cycle arrest or cell 
death. Figure 4.2A-F show examples of the different cell fates analysed. Daughter 
cells were defined as arrested if they did not enter a subsequent mitosis within 48 
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hours of the first mitosis. Multipolar cell divisions were excluded from this analysis, 
as they are known to mainly result in unviable progeny (Ganem et al., 2009, Kuffer 
et al., 2013). Figure 4.2G shows the results of individual cell lines, indicating 
differences in cell fate after a normal division (no error), or an error. A summary of 
the number of daughter cells scored for each cell line is shown in Figure 4.2H. Data 
represented comes from an amalgamation of different passage numbers (see 
figure legend for details). Combining all the data from diploid and tetraploid clones 
shows that tetraploid cells have a significantly different response to segregation 
errors than diploid cells (Figure 4.2I). In diploid cells that made a segregation error 
in the first mitosis, the majority of daughter cells underwent cell cycle arrest or cell 
death (death and/or arrest- diploid mean: 58% - HCT-116: 43%, DC 8: 68%, DC-
14: 55%, DC-25: 68%). In comparison in tetraploid cells that made a segregation 
error, significantly fewer daughter cells died or arrested (death and/or arrest –
tetraploid mean: 16%, TC 3: 18%, TC 4: 12%, TC-13: 11%, TC-16: 10%, TC-17: 
34%, TC-35: 12%, P=0.0002, Students T-test). This indicates that tetraploid cells 
have a specific ability to tolerate segregation errors, and supports the observation 
made from the clonal FISH data that tetraploid cells are able to propagate 
aneuploidy more efficiently than diploid cells (Figure 4.1).  
 
Interestingly although an average of 42% of diploid cells continued cycling after a 
segregation error, observing aneuploid colonies was extremely rare, if not absent in 
the majority of diploid clones in the clonal FISH analysis (Figure 4.1). It is hard to 
discern using these live-cell imaging techniques whether a lagging chromosome 
was segregated into the correct or incorrect daughter cell, which can influence 
subsequent cell fate (Huang et al., 2012). It has been shown that in the majority of 
cells, a lagging chromosome will segregate to the correct daughter cell (Thompson 
and Compton, 2011a, Huang et al., 2012). This could explain why some diploid 
cells still manage to continue to a next mitosis after being classified as undergoing 
a segregation error. Additionally, this could be due to the fact that it was only 
possible to analyse cells for 60 hours, given the constraints of imaging live cells. A 
longer analysis would have allowed tracking of cells through more than one 
generation, and may have revealed that although some diploid cells do survive one 
division after a segregation error, they do not propagate for multiple generations.  
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Figure 4.2: An increased tolerance to segregation errors in tetraploid clones 
A-F) Example images to represent the different cell fates scored in this analysis. 
Time since start of movie is shown in the form hh:mm. 
G) Cell fate both after a normal mitosis (no error) and after a segregation error is 
shown for each diploid and tetraploid clone. Data shown is an amalgamation of the 
following passage numbers: passage 6, 14 and 56 (three experiments) for DC 8, 
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TC 3 and TC 4, passage 10 and 20 (two experiments) for DC-14, DC-25, TC-13, 
TC-16 and TC-35, passage 10, 12 and 20 for TC-17, three experiments for HCT-
116. 
H) N numbers (number of daughter cells scored) for each clone. 
I) Comparison of cell fate between diploid and tetraploid clones after a normal 
mitosis or after a segregation error. P-values from a Student’s T-test are shown 
over the relevant comparisons. 
 
4.2.3 Chromosomal instability emerges in tetraploid clones over time 
Based on both the clonal FISH colony analysis and the live cell imaging data, which 
indicate tetraploid clones have an increased tolerance to segregation errors and a 
greater ability to propagate aneuploidy than diploid clones, genomic changes in all 
diploid and tetraploid clones over 18 months of continual passaging were assessed 
using CGH (comparative genome hybridisation). DNA from clones at different time 
points during the continuous culture was subjected to Affymetrix SNP6.0 analysis 
to see whether these phenotypes manifested themselves over time in changes to 
the genome of the whole population in tetraploid clones.  
 
Figure 4.3 shows genomic changes over time in both diploid and tetraploid clones. 
Red represents gain relative to median ploidy, whereas blue represents loss. It is 
clear that tetraploid clones at all passages have greater levels of genomic 
aberrations than diploid clones. To quantify the level of genomic alterations 
between different clones, the wGII was calculated (Figure 4.4). All the diploid 
clones had similar wGII scores to the parental cell line at every passage analysed 
(passage 5, 25 and 50 for all clones, plus passage 75 for second generation 
clones). In comparison, tetraploid clones had significantly higher wGII scores at 
every passage, as well as showing a trend in the majority of clones for increasing 
wGII over time (averages for passage 5: diploids=0.066, tetraploids=0.122, 
passage 25: diploids=0.066 tetraploids=0.21, passage 50 diploids=0.067 
tetraploids=0.30, passage 75 diploids=0.067 tetraploids=0.33). 
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Figure 4.3: Genomic changes in all clones over time 
CGH analysis of all diploid and tetraploid clones at passage 5, 25 and 50 (and also 
passage 75 for DC-25, DC-14, TC-13, TC-16, TC-17 and TC-35). Gains (shown in 
red) and losses (in blue) are calculated relative to median ploidy (see Methods). 
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Strikingly all tetraploid clones by passage 50 had wGII greater then 0.2, a threshold 
which has been shown to accurately separate CRC tumours into CIN- (or MIN) and 
CIN+ (Lee et al., 2011), whereas diploid clones remained chromosomally stable. 
Continuous culture of tetraploid clones for a year has changed the genomic 
subtype of these cancer cells from chromosomally stable to chromosomally 
unstable.  
 
 
Figure 4.4: wGII increases over time in tetraploid clones 
wGII scores for all clones calculated from SNP6.0 arrays (see Methods). Lighter 
colours indicate later passages, blue showing diploid clones and red showing 
tetraploid clones (see key in Figure). Dashed line indicates a wGII score of 0.2, 
which has been shown to separate CRC tumours into CIN- (<0.2) and CIN+ (>0.2) 
(Lee et al., 2011). 
 
Strikingly there are genomic regions subjected to recurrent loss in all of the 
tetraploid clones (see Figure 4.3). A large but non-contiguous region of 
chromosome 4q was found to be lost to three copies in all the tetraploid clones by 
passage 50. This likely represents selection for loss of this region over prolonged 
culture. To assess the relevance of this genomic loss, CRC data from TCGA was 
sorted according to wGII score (Figure 4.5). The copy number state of this genomic 
region of chromosome 4 (schematically represented in Figure 4.5) was calculated. 
The correlation between loss of the genes on this region and increasing wGII is 
highly significant (P<0.001). This statistical analysis was tested for significance 
using simulations, which take into account the increased likelihood for genomic 
losses to occur in tumours with high wGII scores (see Methods). This result 
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suggests that there could be a beneficial phenotypic outcome for a genomically 
unstable tumour to lose copies of any or all of the 362 genes in this region. An 
alternative, but untested, hypothesis is that this region may be more likely to be 
subjected to copy number loss due to a unknown mechanism that makes it easier 
to lose genomic material from this region.  
 
 
Figure 4.5: Association of chromosome 4q loss with increasing wGII in CRC 
A relationship between the genes on chromosome 4q and highly unstable CRCs. 
CRC tumours from TCGA are ranked from left to right according to increasing wGII, 
and the copy number state for the genes on the regions of chromosome 4q 
(excluding regions in red) is shown as either white (no loss) or blue (loss). 
 
CGH analysis of the diploid and tetraploid clones derived from HCT116_MLH1 
revealed a very similar pattern of genomic loss (Figure 4.6). The wGII scores in the 
two tetraploid clones increased between passage 5 and passage 25 (0.07 to 0.13 
in MLHC11, 0.12 to 0.17 in MLHC16), whereas the diploid clone remained stable 
(0.1 to 0.09 in MLHC8). Similar to the HCT-116 tetraploid clones, tetraploid 
HCT116_MLH1 clones also showed loss of chromosome 4q (Figure 4.6). This data 
show that the specific loss of chromosome 4q is not a result of the microsatellite 
instability phenotype of HCT-116 tetraploid clones.  
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Figure 4.6: Copy number changes in microsatellite-competent HCT-116 
clones 
A) CGH analysis of copy number changes in HCT-116_MLH1 clones (MLH Diploid 
C8 and MLH Tetraploid C16 and C11) at passage 5 and passage 25. Blue shows 
copy number loss and red shows copy number gain (relative to median ploidy). 
 
4.2.4 Genomic evolution of tetraploid clones over time reveals the origin of 
some unstable CRC tumours 
Using the genomic data from CGH analysis, it was possible to compare the 
evolution of tetraploid clones over time to CRC data from TCGA. When the wGII 
scores and ploidy of HCT-116 clones at different passage numbers were compared 
to wGII and ploidy of TCGA tumours, a striking pattern emerges (Figure 4.7A). With 
increasing passage number, tetraploid clones tend to become more genomically 
unstable, and also tend to lose genomic material, becoming closer in genotype to 
the near-triploid, highly unstable, genome-doubled CRC tumours that were 
observed in the initial analysis of TCGA data (Figure 3.1).  
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Figure 4.7: Comparison of tetraploid clones to TCGA data reveals route of 
evolution of some unstable CRCs 
A) A comparison of wGII scores and mean chromosome copy number of diploid 
and tetraploid clones of HCT-116 and CRC tumours from TCGA. TCGA CRC 
tumours are shown as grey dots, and tetraploid HCT-116 clones are shown in 
different shades of red. Lighter red indicates later passage number (see key). All 
diploid clones (blue dots) at all passage numbers overlay the same point.  
B) Flow cytometry analysis of second-generation diploid and tetraploid clones at 
passage 10, 25, 50 and 75. All clones were stained with PI at the same cell number 
to dye concentration. 
C) Depiction of tumour stage specifically in TCGA CRC tumours that have been 
classified as genome doubled n=185. The bar plot shows percentage of tumours at 
stage I-IV in tetraploid and sub-tetraploid tumours.  
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The loss of genomic material over time is consistent with flow cytometry data of the 
tetraploid clones at different passage numbers (Figure 4.7B). These data fit a 
model whereby some CRC tumours are able to become highly genomically 
unstable through an initial genome-doubling event, which then results in the 
emergence of chromosomal instability over time. To assess whether this could be 
true of the TCGA tumours analysed here, the stage of all genome-doubled TCGA 
tumours was compared to their ploidy. Comparing sub-tetraploid (ploidy<4) to 
tetraploid tumours showed that sub-tetraploid tumours were more genomically 
complex and also enriched for Stage IV tumours (P=0.0062, Cochran-Armitage test, 
Figure 4.7C). This indicates that genome doubling is likely to be an early event in 
the evolution of high-stage (and hence metastatic), chromosomally unstable CRC. 
 
4.2.5 Genome doubling is a predictive marker of poor outcome in CRC 
Due to the known association between high chromosomal instability and poor 
outcome for patients, not just in CRC, but also in multiple cancer types (Lee et al., 
2011, McGranahan et al., 2012), the utility of using the genome doubling algorithm 
as a predictive marker for patient outcome was tested. Available survival data from 
TCGA was obtained for 150 patients with Stage 1-3 CRC. Using the genome 
doubling algorithm as described (see section 3.2.1 and Methods), it was found that 
patients whose tumours were likely to have undergone a genome doubling event 
suffered a poorer outcome in a 2 year analysis of relapse-free survival (Figure 4.8A, 
P=0.019, hazard ratio [HR]=5.1, 95% confidence interval [CI] 1.1-22.8). A 2-year 
cut-off for relapse free survival was used, since the majority of CRCs relapse within 
this period (Hellinger and Santiago, 2006). An uncensored relapse free survival 
curve is shown in Figure 4.9A. To confirm the initial findings from the TCGA 
discovery cohort, a larger validation cohort of 389 Stage 2-3 CRC patients was 
obtained. In this cohort genome doubling was also predictive of poor relapse-free 
survival (Figure 4.8B, P=0.0022, HR=1.80, 95% CI 1.2-2.8, and full survival curves 
in Figure 4.9B). This data concurs with that of Carter and colleagues, who showed 
that presence of genome doubling predicted worse recurrence free incidence in 
high-grade serous ovarian carcinoma (Carter et al., 2012). 
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Figure 4.8: Genome doubling predicts worse relapse-free survival in two 
independent CRC cohorts 
A) Kaplan-Meier relapse-free survival curves for genome doubled (GD, red line) 
and non-genome doubled (nGD, blue line) TCGA CRC tumours (n=150) censored 
at 2 years. P=0.019 log-rank test.  
B) Kaplan-Meier relapse-free survival curves for GD (red line) and nGD (blue line) 
colorectal cancer patients in the validation cohort (n=389). P=0.0022, log-rank test. 
 
 
Previous data has indicated that genome doubling is likely to be an early event in 
CRC occurring before the onset of chromosomal instability (see sections 3.2.1 and 
4.2.4). It was therefore hypothesised that use of the genome doubling algorithm 
may have better predictive power to identify patients at higher risk of relapse than 
other markers such as stage and age. Indeed, in a multivariate analysis including 
MSI status, stage and age, genome doubling remained a significant predictor of 
outcome (Table 4.1, TCGA data: P= 0.045, HR=4.70, 95% CI 1.04-21.37, 
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the reason genome doubling is predictive of outcome is not simply because it 
identifies tumours that are more genomically unstable.  
 
 
Figure 4.9: Full survival curves, and survival curves for only diploid tumours 
A) Full Kaplan-Meier relapse free survival curves for CRC patients from TCGA 
cohort (n=150). Blue = non-genome doubled (nGD), red = genome doubled (GD). 
P=0.099 long-rank test. 
B) Full Kaplan-Meier relapse free survival curves for CRC patients from the 
validation cohort (n=389). Blue = non-genome doubled (nGD), red = genome 
doubled (GD).  P=0.00081, log-rank test. 
C) Full Kaplan-Meier survival curves for diploid tumours from the validation cohort. 
Blue = non-genome doubled (nGD), red = genome doubled (GD). (n=262). 
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In addition, genome doubling remained a significant predictor of outcome when 
including ploidy (ploidy ≥ 3) in the multivariate analysis (Table 4.1). Indeed, when 
only considering diploid tumours from the validation cohort, genome doubling was 
still a strong predictor of outcome (P=0.0011, HR=2.2 95% CI 1.3-3.5, Figure 4.9C). 
 
 
Table 4.1: Multivariate analysis of survival in TCGA and validation cohorts 
A) Univariate and Multivariate analysis in TCGA cohort incorporating genome doubling and excluding wGII 
 
Relapse Free Survival, censor at 2 years, TCGA (Stage 1-3) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val   (log-rank) HR (95%) 
p.val 
(Wald) 
GD 5.052 (1.118 -22.84) 0.0193 4.703e+00 (1.03533-21.366) 0.045 
MSI 
0.3173   (0.04124 -
2.441) 0.2443 2.938e-01 (0.03609-2.392) 0.252 
Age 1.005 (0.9623-1.05) 0.813 9.998e-01 (0.95735-1.044) 0.993 
Stage (highest vs. lowest) 97328732  (0- Inf) 0.3251 8.692e+07 (0.00000- Inf) 0.998 
 
B) Univariate and Multivariate analysis in TCGA cohort incorporating wGII and excluding genome doubling 
 
Relapse Free Survival, censor at 2 years, TCGA (Stage 1-3) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val    (log-rank) HR (95%) 
p.val 
(Wald) 
wGII 6.086 (0.570 -64.93) 0.135 3.72 (0.307 - 45.036) 0.302 
MSI 
0.3173   (0.04124 -
2.441) 0.2443 0.313 (0.0374-2.617) 0.284 
Age 1.005 (0.9623-1.05) 0.813 0.997 (0.952-1.044) 0.897 
Stage (highest vs. lowest) 97328732  (0- Inf) 0.3251 8.952e+07 (0.00000- Inf) 0.998 
 
C) Univariate and Multivariate analysis in Validation cohort incorporating genome doubling and excluding 
wGII 
 
Relapse Free Survival, censor at 2 years, Validation (Stage 2-3) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val      (log-rank) HR (95%) 
p.val 
(Wald) 
GD 1.85 (1.24- 2.76) 0.00221 1.594 1.052- 2.415) 0.0279 
MSI 0.394 (0.1912- 0.8118) 0.00886 0.544 (0.255-1.158) 0.1141 
Age 1.012 (0.9954-1.03) 0.153 1.019 (1.001-1.036) 0.0389 
Stage (highest vs. lowest) 2.403 (1.484-3.89) 0.00023 2.238 (1.375-3.642) 0.00119 
 
D) Univariate and Multivariate analysis in Validation cohort incorporating wGII and excluding genome 
doubling 
 
Relapse Free Survival, censor at 2 years, Validation (Stage 2-3) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val     (log-rank) HR (95%) 
p.val 
(Wald) 
wGII 3.805 (1.44- 10.03) 0.00648 2.32 (0.795-7.013) 0.12182 
MSI 0.394 (0.1912- 0.8118) 0.00886 0.566 (0.255-1.254) 0.16079 
Age 1.012 (0.9954-1.03) 0.153 1.018 (1.000-1.036) 0.0466 
Stage (highest vs. lowest) 2.403 (1.484-3.89) 0.00023 2.264 (1.391-3.684) 0.00101 
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E) Univariate and Multivariate analysis in Validation cohort incorporating ploidy and genome doubling 
 
Relapse Free Survival, censor at 2 years, Validation (Stage 2-3) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val    (log-rank) HR (95%) 
p.val 
(Wald) 
GD 1.85 (1.24- 2.76) 0.00221 1.922 (1.104-3.347) 0.0209 
Ploidy (>= 3) 1.39 (0.929 – 2.08) 0.11 0.765 (0.442-1.324) 0.338 
MSI 0.394 (0.1912- 0.8118) 0.00886 0.539 (0.253-1.148) 0.109 
Age 1.012 (0.9954-1.03) 0.153 1.019 (1.001-1.036) 0.0412 
Stage (highest vs. lowest) 2.403 (1.484-3.89) 0.00023 2.238 (1.362-3.611) 0.00136 
F) Univariate and Multivariate analysis in TCGA low stage cohort incorporating wGII and genome doubling 
 
Overall Survival, censored at 5 years, TCGA (Stage 1-2) 
 
 
Univariate 
 
Multivariate 
 
Variable HR (95%) p.val      (log-rank) HR (95%) 
p.val 
(Wald) 
GD 9.612 (1.165-79.32) 0.01088 10.76 (1.065175-108.649) 0.0441 
MSI 1.239e-08 (0-Inf) 0.3436 2.264e-08 (0.0000-Inf) 0.9986 
Age 1.043 (0.9751-1.116) 0.2158 1.034 (0.970241-1.101) 0.3051 
Stage (highest vs. lowest) 1.512 (0.1836-12.45) 0.6989 2.911 (0.36- 23.42) 0.7722 
wGII 9.354 (0.3339-262.1) 0.1798 1.376 (0.158539-11.943) 0.7755 
 
 
Taken together these data indicate the genome doubling is a strong and 
independent indicator of patient outcome. Further, using genome doubling as a 
prognostic marker may be of greater clinical utility than using aneuploidy to predict 
high-risk tumours, at it appears to have more sensitivity than ploidy and wGII to 
predict patient outcome. 
 
4.3 Conclusions 
In this chapter the isogenic system of diploid and tetraploid clones described in 
Chapter 3 were tested for their ability to propagate chromosomal instability. 
Tetraploid clones were frequently shown to exhibit aneuploid colonies in clonal 
FISH assays, suggesting that they had an increased tolerance to aneuploidy. This 
was shown directly in live cell imaging analyses, where tetraploid cells were better 
able to continue cycling after a segregation error than their diploid counterparts. It 
would be interesting to assess whether tetraploid cells are also better able to 
tolerate induced segregation errors as well as endogenous missegregation events.  
Over time in culture this tolerance to chromosome missegregation has led to 
strikingly altered genome architecture in tetraploid clones. The genome duplication 
Chapter 4 Results 
 
 139 
event in HCT-116 cells has led to a cell line usually characterised as 
chromosomally stable to become chromosomally unstable based on wGII score. In 
patients with CRC, chromosomally unstable tumours (CIN+) have a worse 
prognosis than CIN- tumours (Walther et al., 2008, Mettu et al., 2010). It was 
therefore tested whether using an algorithm to identify tumours with genome 
duplication could be predictive of worse patient prognosis, as it had been observed 
that genome duplication in HCT-116 could lead to chromosomal instability. In two 
independent cohorts of CRC patients, genome doubling was found to be a strong 
predictor of worse relapse free survival. In these cohorts, genome doubling was a 
better prognostic marker than others that are used in this disease type such as MSI 
status, stage and age. Interestingly genome doubling also outperforms wGII as a 
predictive marker suggesting its prognostic value is greater than its tendency to 
associate with highly unstable tumours. Unfortunately, due to limitations in clinical 
data available from TCGA, it was not possible to compare genome doubling to 
other commonly used pathological markers, such as presentation with bowel 
obstruction, and immune cell infiltrate. It would be of interest to expand this 
analysis into a larger independent cohort, particularly of early stage patients, that 
had complete pathological annotation, to see whether genome doubling has 
predictive power over these pathology indicators.  
 
The data presented in this chapter suggest that tetraploidy can be permissive for 
the development of chromosomal instability, a high-risk clinical phenotype. Data in 
the next chapter explores the functional consequences of tetraploidy in tumour 
relevant conditions, as well as seeking a mechanistic basis for the tolerance of 
chromosome segregation errors that seems coincident with genome doubling.  
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Chapter 5. Results 3: Functional consequences and 
mechanistic basis of CIN tolerance in tetraploid cells  
5.1 Introduction 
In Chapter 3 data were presented characterising an isogenic system of diploid and 
tetraploid clones derived from HCT-116. In Chapter 4 evidence was presented 
suggesting that tetraploid cells have an increased ability to tolerate and propagate 
chromosome missegregation events. Over the course of more than a year in 
continuous culture the tetraploid genome became increasingly genomically 
unstable. In this chapter, the functional consequences of the chromosomal 
instability evident in tetraploid clones were investigated, including the relationship 
between tetraploidy, chromosomal instability and drug resistance, and also the link 
between tetraploidy and metastatic potential. Finally, experiments that were 
designed to find a mechanism for the segregation error tolerance detailed in 
Chapter 4 are presented.  
5.2 Results 
5.2.1 Investigating drug resistance in tetraploid clones 
Chromosomal instability has been linked with poor patient prognosis in many 
different cancer types (McGranahan et al., 2012).  It has also been shown that 
CIN+ cell lines display increased resistance to a panel of kinase inhibitors (Lee et 
al., 2011). However the relationship between tetraploidy and drug resistance is 
seemingly more complex, with some studies reporting increased resistance to 
drugs, and others reporting increased sensitivity (see Section 1.7.3). Furthermore, 
in Chapter 4, genome doubling was shown to predict worse patient outcome in 
CRC, an association that has already been shown for ovarian cancer (Carter et al., 
2012). Hence, finding a drug that could target tetraploid cells specifically could 
have significant clinical utility. To try to identify drugs that could specifically target 
tetraploid cells, all second-generation diploid and tetraploid clones were treated 
with an extensive panel of targeted kinase inhibitors at different passage numbers. 
A combination of Calbiochem Kinase Inhibitor Libraries I and II were used to treat 
diploid and tetraploid cell lines (a total of 160 inibitors). 
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Figure 5.1: Extensive kinase inhibitor screen in diploid and tetraploid clones 
Results of drug screen using Calbiochem Kinase Inhibitor Libraries I and II in 
diploid and tetraploid clones at the indicated passage numbers. The legend shows 
the different colours that represent different fractions of surviving cells (measured 
using CellTiter-Blue) in drug treated wells compared to DMSO treated control wells. 
Different cell lines are shown as columns. Blue line over column indicates a diploid 
cell line (ordered as follows: HCT-116 [passage 5 only], DC-14 and DC-25), and 
red line indicates a tetraploid cell line (ordered as follows: TC-13, TC-16, TC-17 
and TC-35). 
 
The parental cell line HCT-116 has previously been treated with this library at a 
10µM concentration (Lee et al., 2011), and therefore the same concentration of 
drug was used to treat the diploid and tetraploid clones derived from HCT-116. 
Cells were seeded and then treated 24 hours later with the drug panel. After 72 
hours of drug treatment the cells were assayed with CellTiter-Blue to assess cell 
viability. The results of this drug screen are shown in Figure 5.1. The plot shows 
the fraction of surviving cells left in each well, relative to wells treated with the 
vehicle control dimethyl sulfoxide (DMSO). The key displays different colours 
representing these different fractions, with darker colours indicating higher toxicity 
of a drug (black representing a 0 - 0.2 fraction of surviving cells compared to 
control). The three distinct blocks indicate different passage numbers. Second-
generation clones at passage 5, 25 and 50 were tested. From the broad similarity 
of the plots, it appears that the response to these different drugs is fairly uniform 
between diploids and tetraploids. 
 
In order to compare the relative resistance of diploid and tetraploid clones across 
the whole panel of kinase inhibitors, cumulative distribution frequency graphs were 
prepared. These graphs, presented in Figure 5.2, were prepared with 
bioinformatics and statistical help from Dr Pierre Martinez. 
 
These comparisons show that there is a small but significant increase (P=0.032) in 
resistance in tetraploid cell lines at passage 5 (Figure 5.2A). However, there is no 
significant difference in relative resistance between diploids and tetraploids at 
either passage 25 (P=0.3) or passage 50 (P=0.11) (Figure 5.2B and C). In Chapter 
3, the proliferation rates of diploid and tetraploid clones were assessed (Figure 
3.16). These data indicate that early passage tetraploid clones grow marginally 
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slower than diploid clones. It has been previously shown that there is a correlation 
between slower growth rate and increased drug resistance for CIN+ cell lines (Lee 
et al., 2011), which could explain why only the early passage tetraploid cell lines 
display a slight increase in relative resistance.  
 
 
Figure 5.2: Only early passage tetraploid clones show a slight increase in 
drug resistance 
A) Cumulative distribution of relative resistance to 160 kinase inhibitors between 
diploid (blue lines) and tetraploid (red lines) cell lines at passage 5. 
B) As above, for passage 25 clones.  
C) As above, for passage 50 clones. 
 
To search for drugs displaying a differential effect between diploids and tetraploids, 
the average fold change between surviving cell fraction between diploids and 
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tetraploids was calculated. Drugs that had a significant (P<0.05) fold change 
difference between diploid and tetraploid clones are shown in Table 5.1. 
 
Table 5.1: Drugs with differential effects on diploid and tetraploid clones 
Compound log FC 
Cdk4 Inhibitor II, NSC 625987 0.175279366 
SU9516 -0.053476514 
TGF-b RI Inhibitor III -0.057149269 
GSK3b Inhibitor XII, TWS119 -0.084596466 
MK2a Inhibitor -0.086524098 
Aurora Kinase Inhibitor III -0.089075077 
Gö 6976 -0.089515638 
Met Kinase Inhibitor -0.093726118 
SB220025 -0.098634217 
Gö 6983 -0.101923337 
Src Kinase Inhibitor I -0.108409306 
JNK Inhibitor V -0.110767403 
PD 169316 -0.120949154 
VEGF Receptor 2 Kinase Inhibitor III -0.132491271 
IGF-1R Inhibitor II -0.142376615 
Syk Inhibitor II -0.178415499 
AMPK Inhibitor, Compound C -0.201234992 
Indirubin-3′-monoxime -0.213204362 
Sphingosine Kinase Inhibitor -0.241125979 
VEGFR Tyrosine Kinase Inhibitor IV -0.299888443 
 
The only drug exerting a negative effect specifically in tetraploid clones was the 
compound Cdk4 Inhibitor II. The average surviving fraction for this drug was 0.93 in 
diploid clones and 0.85 in tetraploid clones, so although significant, this drug does 
not have a potent selective effect on tetraploid clones. The other significant drugs 
from this analysis were all more effective at targeting diploid compared to tetraploid 
cells. 
 
Taken together these data indicate that in a system of isogenic cell lines, ploidy 
does not exert a large effect on resistance to kinase inhibitors. Relative resistance 
was increased slightly only in tetraploid clones at early passage numbers which 
could be explained by a decrease in growth rate. Furthermore, even at late 
passages, when tetraploid clones display high levels of chromosomal instability 
(see Chapter 4), they are not more resistant than their diploid counterparts. This 
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could in part be due to the fact that a targeted kinase library was used, to which 
resistance or sensitivity is likely to be mainly due to defects in cell signalling 
pathways that are likely to be similar to the parental cell line used to derive the 
clones.  
 
To address this concern, drugs with more general mechanisms of action were used. 
The drug sensitivity of a select panel of diploid and tetraploid clones was assessed 
in response to three therapeutic agents used to target CRC: camptothecin, 
paclitaxel and cisplatin. Camptothecin is a quinolone alkaloid that inhibits 
Topoisomerase I, resulting in DNA complexes that cause replication fork collapse 
in S phase. Paclitaxel stabilises microtubules, thereby disrupting cell cycle 
progression. Cisplatin binds to DNA bases, resulting in DNA crosslinks, and 
subsequent DNA damage. It has previously been reported that tetraploid clones 
have increased resistance to camptothecin, amongst other DNA damaging agents 
(Castedo et al., 2006).  
 
A difference in sensitivity to camptothecin was not observed between the two 
diploid and two tetraploid cell lines analysed (Figure 5.3A). There was also no 
difference in sensitivity between diploid and tetraploids treated with paclitaxel or 
cisplatin (Figure 5.3B, C and D).  
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Figure 5.3: Comparing the response of diploid and tetraploid clones to 
chemotherapeutic agents 
A-B) Two diploid cell lines (DC-14 and DC-25) and two tetraploid cell lines (TC-16 
and TC-17) were treated with increasing concentrations of either camptothecin (A) 
or paclitaxel (B). The relative cell number compared to DMSO treated controls is 
shown.  
C) Dose response curve to increasing concentrations of cisplatin for all second-
generation clones.  
D) IC50 values for each cell line treated with the indicated drug, calculated using 
GraphPad prism software. All cell lines used were at passage 10.  
 
 
This system of tetraploid clones was not found to exhibit the same resistance to 
camptothecin that has been previously reported (Castedo et al., 2006). Although 
only four clones were used to test the sensitivity against camptothecin, all second-
generation clones were used to investigate the sensitivity to cisplatin. Cisplatin has 
a similar mechanism of action to oxaliplatin, another Platinum based DNA cross-
linking agent reported to have increased efficacy against tetraploid cell lines 
(Castedo et al., 2006). No differential effect of cisplatin on diploid and tetraploid 
clones was observed (Figure 5.3C). In the previous report by Castedo and 
colleagues, tetraploid cell lines derived from HCT-116 were shown to have a 5.2 
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fold increase in IC50 compared to diploid cell lines when treated with oxaliplatin 
(Castedo et al., 2006). The average IC50 of diploids to cisplatin was 1.016µM, and 
the average IC50 of tetraploids was 1.018µM (Figure 5.3D). Possible explanations 
for these differing results are discussed in the conclusion to this chapter.  
 
Taken together, these data indicate that in this isogenic system of diploid and 
tetraploid clones, there was no systematic increase or decrease in drug resistance 
based on ploidy status. Further, no increase in drug resistance was observed in 
later passages of tetraploid clones, despite higher levels of chromosomal instability. 
This could possibly suggest that in this cell line system, the nature of chromosomal 
instability is not the same as the chromosomal instability observed in CIN+ cell 
lines, which did show increased resistance to the same targeted panel of kinase 
inhibitors (Lee et al., 2011). This system may not recapitulate these findings due to 
the fact that HCT-116 derived tetraploid clones are not only chromosomally 
unstable, but also exhibit microsatellite instability. These two types of genetic 
instability do not commonly overlap in the clinical setting (see Section 1.11). It 
could be the case that having two different drivers of genetic diversity is not 
beneficial to cancer cells in the presence of environmental stress, such as that 
experienced under drug selection.  
 
5.2.2 Growth of diploid and tetraploid cell lines in 3D environments 
As discussed in Section 1.3, tetraploidy can occur as both an early or late event in 
tumourigenesis. In the HCT-116 cell line, it has been shown that the tetraploid 
fraction is continually generated (see Figure 3.3). However, this fraction remains at 
a constantly low percentage of the total population (as over many passages HCT-
116 remains a predominantly diploid cell line), likely due to a selection pressure 
against tetraploid cells. This could be accounted for by their poor cloning efficiency 
(see Figure 3.3), or possibly by the slight reduction in growth rate in tetraploid cells 
(Figure 3.16). However, as genome doubling appears to be a common event in 
CRC (Figure 3.1), it is of interest to ascertain which culture conditions favour the 
expansion of a tetraploid population. 
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In order to try to better mimic the tumour environment diploid and tetraploid clones 
were grown in three-dimensional spheroid culture, which may better represent the 
environment of tissues compared to two-dimensional culture techniques 
(Pampaloni et al., 2007, Fennema et al., 2013). It has been shown previously using 
Chinese hamster V-79-171 cells, which spontaneously form spheroids in culture, 
that the fraction of tetraploid cells increases as the spheroids get larger (Olive et al., 
1982). HCT-116 cells have also previously been grown in spheroid culture 
(McIntyre et al., 2012).  
 
 
Figure 5.4: Growth of diploid and tetraploid clones in spheroid culture 
A) Example of microscope image used to calculate volume of spheroids. Blue 
colouring indicates area that is used to calculate volume (see Methods).  
B) Growth curves of diploid and tetraploid spheroids imaged on Days 1, 3 and 7. 
Data is from three independent experiments.  
C) Slope of graphs shown in B) was calculated in order to compare between cell 
lines.  
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Spheroids were formed by seeding cells in ultra low attachment round-bottomed 
plates with 2.5% Matrigel and spinning the plates to condense the cells into a 
sphere at the bottom of the well (see Methods). In order to assess differences in 
growth between the diploid and tetraploid clones in spheroids, the growth rate of 
spheroids was determined. The spheroids were scanned using a phase-contrast 
microscope, and the total volume was calculated (Figure 5.4A, and see Methods). 
The growth curves for passage 8 and passage 50 are shown in Figure 5.4B. In 
order to compare between the growth curves, the slope of each line was calculated. 
Data shown is from three independent experiments, and the error bars indicate that 
the growth rate was fairly consistent in each cell line across different experiments 
(Figure 5.4C).  
 
There is no difference in the growth rate of spheroids derived from diploid or 
tetraploid clones at passage 8 (diploid average slope 6.3e-11, tetraploid average 
6.8e-11, P=0.8151, Student’s T-test, Figure 5.4C). There is also no difference in 
spheroid growth rate at passage 50 (diploid average slope 7.0e-11, tetraploid 
average slope 6.7e-11, P=0.7351, Student’s T-test, Figure 5.4C). Some cell lines 
exhibited growth in spheroids that appeared consistently faster than other cell lines 
(for example TC-16 passage 8, slope = 1.03e-10), whilst others showed 
consistently slower growth across all three experiments (for example TC-13 
passage 8, slope = 4.2e-11). These clone specific differences indicate that 
enhanced growth in spheroid culture is unlikely to be a phenotype that is 
intrinsically linked to the genotypes of either tetraploidy or chromosomal instability. 
There are many factors that could influence a cell lines ability to grow specifically in 
three-dimensional culture, such as signalling from cell-to-cell attachment. Although 
investigating the molecular mechanisms determining variations in spheroid growth 
could help gain new insights into tumour growth, it was unfortunately beyond the 
scope of this investigation.  
 
5.2.3 Investigating the role of tetraploidy in metastasis 
Several studies using artificially generated tetraploid cells (through a variety of 
different mechanisms), have demonstrated that tetraploid cells have increased 
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tumorigenic capacity compared to diploid cells (see Section 1.7.1). As well as a link 
between tetraploidy and carcinogenic onset that has been described for example in 
Barrett’s Oesophagus (Galipeau et al., 1996), tetraploidy can also occur later in 
tumourigenesis. Intriguingly recent work from this laboratory showed that the region 
of a primary renal cell carcinoma most likely to have seeded the metastasis was 
tetraploid (Gerlinger et al., 2012). It was therefore investigated using the system of 
diploid and tetraploid clones derived from HCT-116 whether tetraploid clones had 
an enhanced metastatic potential. It is well known that HCT-116 cells form tumours 
when injected into the tail-vein of nude mice (Langlois et al., 2010, Long et al., 
2013, Lu et al., 2013, Wu et al., 2012b, Fan et al., 2011), with the most common 
metastatic location being the lungs. Therefore this system was used to investigate 
whether tetraploid clones had increased metastatic potential in comparison to their 
diploid counterparts.  
 
By using bioluminescence imaging it is possible to effectively monitor and compare 
tumour growth in vivo. Given that HCT-116 cells are known to be tumorigenic in a 
metastatic tail-vein assay, it was reasoned that the best way to assess differences 
in growth between different clones was by using bioluminescence, since both 
diploid and tetraploid cells are likely to have tumour-forming capacity. One diploid 
clone (DC-14) and one tetraploid clone (TC-13) were infected using retroviruses 
expressing the Firefly (Photinus pyralis) luciferase gene. The pBabe-Hygromycin-
Luciferase-Poly-A plasmid was used with the kind permission of Dr Miguel M. 
Murillo (manuscript in preparation). The two cell lines were infected at passage 
seven. After selection and in vitro testing the cells had been passaged a further 
four times, and were therefore at passage 11 when injected into mice. 
 
The in vitro luciferase activity was confirmed by plating cells in a 96-well plate and 
treating with the substrate of luciferase, luciferin. The activity of luciferase was 
assessed by calculating photons emitted per second per cell, based on a range of 
cell seeding densities (Figure 5.5A). The bioluminescence activity was similar 
between DC-14 and TC-13. The data presented are from two independent 
experiments. In the first experiment, two different cell doses of 0.5 x 106 and 1.5 x 
106 were chosen, as the majority of studies using HCT-116 in tail-vein injections 
have used 1 x 106 cells (Langlois et al., 2010, Long et al., 2013, Lu et al., 2013, Wu 
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et al., 2012b, Fan et al., 2011). However when DC-14 and TC-13 were injected at a 
dose of 1.5 x 106 cells, only one out of three mice developed tumours and only one 
mouse injected with 0.5 x 106 TC-13 cells developed a tumour (Figure 5.5B). The 
cell dose was increased in the second experiment to 3 x 106 and 6 x 106 cells per 
mouse. At 3 x 106 cells, 3 out of 4 (DC-14) and 2 out of 4 (TC-13) mice developed 
tumours. At the higher cell dose, all mice injected developed tumours, 
predominantly at either the tail base, or in the lungs (Figure 5.5C).  
 
  
Figure 5.5: Tail-vein injection of DC-14 and TC-13 into nude mice 
A) Representative image of in vitro analysis of DC-14 p11 and TC-13 p11 
expressing luciferase. Photons per second per cell for each cell line was calculated 
from a range of cell numbers.  
B) Tumour forming capacity of each cell line is shown as number of mice with 
detectable tumours/number of mice injected for two experiments (EXPT1 and 2) 
using four different cell doses.  
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C) Tumour location for each mouse that developed a tumour in two different 
experiments with DC-14 p11 and TC-13 p11 at two different cell doses. LN = lymph 
node. In the first experiment 3 mice per cell dose were injected, and in the second 
four mice per cell dose were injected, apart from TC-13 p11 (6 x 106 cells) where 
one mouse died as a result of the injection.  
D) Example images of nude mice injected with luciferase expressing cell lines that 
formed either a lung tumour (left image) or a tumour at the base of the tail (right 
image).  
E) Example H&E staining of the lungs and tail base tumours that developed in nude 
mice after tail-vein injection of these two cell lines. Both 4X and 20X images are 
shown.  
 
From this data there does not seem to be a difference in the ability of either DC-14 
or TC-13 to form tumours, with both cell lines producing less tumours than has 
been reported for the parental cell line HCT-116. This could in part be due to the 
fact that both DC-14 and TC-13 are derived from single cell clones from a 
heterogeneous HCT-116 parental population, and therefore the heterogeneity and 
frequency of tumour-forming cells is likely to be reduced compared to the parental 
cell line. Further, DC-14 and TC-13 are second-generation clones, and were 
derived themselves from a clone of HCT-116, DC 8. This diploid clone might also 
have a lower tumour forming capacity than the parental cell line. 
 
The different locations of tumours arising in the two experiments are shown in 
Figure 5.5C. Many animals developed large tumours close to the tail base. 
Examples of bioluminescent signals arising from these tail base tumours, and also 
from lung tumours are shown in Figure 5.5D. In the first experiment tumour material 
was collected and fixed with 10% neutral buffered formalin (NBF) and subjected to 
haematoxylin and eosin (H&E) staining for pathological review.  
 
All pathology reviews were carried out by Professor Gordon Stamp. 
 
The tail base tumour shown in Figure 5.5D was described as fatty connective 
tissue containing a large mass of undifferentiated epithelial tumour, with 
intravascular tumour present at the peripheries. To ascertain the origin of these tail 
base tumours, one mouse was subjected to a whole body autopsy. The tail base 
tumour in this mouse was described as having multiple separate areas composed 
of differing morphologies, including an area of undifferentiated spindle cells, and 
another with a more epithelioid appearance. There was invasion into both soft 
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tissue and skeletal muscle, but the tumour did not appear to involve bone, although 
it extended close to the periosteum. The tumour displayed substantial 
intravascularisation. This morphology is consistent with the tumour having formed 
directly from injected cells that have become trapped in the pelvic venous system, 
and subsequently invaded the surrounding tissue. This mouse also had lung 
tumours displaying intravascular undifferentiated morphology and early invasion 
into the lung parenchyma. It could not be determined whether the tail base tumour 
had given rise to the lung tumours.  Future experiments could utilise 
bioluminescent imaging immediately after cell injection to determine whether 
injected cells trafficked directly from the tail-vein to the lung, or whether they were 
all trapped in the venous system. Similar techniques have been used before with B-
16 melanoma cell lines (Craft et al., 2005). 
 
To measure the growth rate of all tumours arising in both experiments, mice were 
subjected to bioluminescent imaging once a week. Mice were anaesthetised using 
Isoflurane and injected intraperitoneally with 100µl of Luciferin substrate at 
300µg/mL. Images were taken at regular intervals until a plateau of luminescent 
signal was reached (see Methods). The maximal bioluminescence signal for the 
whole body of each mouse was recorded. Only mice that developed tumours are 
shown in Figure 5.6. Figure 5.6A shows the three mice from experiment one that 
developed tumours. Both mice that developed tumours at the higher dose (1.5 x 
106) had rapidly growing tumours and therefore had to be sacrificed in accordance 
with Home Office regulations (see Methods). The only mouse to develop a tumour 
at the lower dose (TC-13, 0.5 x 106 cells) showed slower tumour growth. In the 
second experiment the difference between the two doses (3 x 106 and 6 x 106 cells) 
is even more apparent, with the majority of mice injected with the higher dose 
sacrificed before 60 days, but the mice injected with the lower dose tending to have 
a reduced tumour growth rate. A notable exception was one mouse injected with 
TC-13 at the lower dose, which had to be sacrificed at Day 34 (Figure 5.6B).  
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Figure 5.6: Growth rates of tumours derived from DC-14 and TC-13 
A) Bioluminescent maximal signals (log transformed) from mice injected with 0.5x 
106 or 1.5 x 106 cells of DC-14 and TC-13.  
B) Bioluminescent maximal signals (log transformed) from mice injected with either 
3 x 106 or 6 x 106 cells of DC-14 and TC-13. 
 
Analysis of tumour growth rates was carried out with statistical help from Stuart 
Horswell. 
 
The growth rate between tumours arising from diploid and tetraploid cells in the 
second experiment was compared using a multiple regression model. Using 
ANOVA to compare growth rates between DC-14 and TC-13 derived tumours is 
significant (P=0.028928), with an estimated increase in bioluminescence of 
0.59712 log units for TC-13 derived tumours. However, the standard error of this 
prediction (1.27548 log bioluminescence units) results in a confidence interval that 
crosses 0 (95% interval -1.94 to +3.1385). These data therefore do not provide 
strong statistical evidence that tumours derived from TC-13 have higher 
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luminescence, although increasing the numbers of tumours analysed could 
potentially resolve this issue.   
 
These data indicate that there is not a great statistical difference in the growth rate 
between DC-14 and TC-13 cells when they form metastatic tumours in nude mice. 
Given this result, the analysis was not extended into a larger panel of diploid and 
tetraploid cell lines. There are no reports in the literature regarding HCT-116 cells 
making similar tumours to those that were observed forming at the tail-base of the 
mice. This is most likely because most reports seem to use a lower cell dose 
(Langlois et al., 2010, Long et al., 2013, Lu et al., 2013, Wu et al., 2012b, Fan et al., 
2011). As discussed, the lower tumour forming capability could be due to the fact 
that the diploid and tetraploid cell lines used are derived from single cell clones. 
The higher cell dose used, coupled with the fact that the cells are epithelial in origin 
and quite large, is likely to have caused the trapping in the venous system of the 
pelvis. Although the cells still had to invade from this area to form tumours, it is not 
as stringent as a metastatic assay using fewer cells, as the cells are being kept in 
one location by physical blockage that may allow the invasion of more than one cell. 
This may not be analogous to what occurs during the metastatic process in 
humans, where although clumps of cells have been found circulating together in 
the blood stream (Cho et al., 2012), their contribution to metastasis is not yet well 
defined. Lower cell numbers were used in an experiment using NSG (NOD-scid-
gamma) mice (data not shown), but these mice have an extremely diminished 
immune capacity, so although tumours were formed more frequently, this system 
also does not model the metastatic process in humans very well. In summary, 
using nude mice and the high numbers of cells that had to be injected in order to 
achieve high penetrance of metastatic tumours is unlikely to represent a good 
method for comparing metastatic potential between these cell lines. Given this, no 
other diploid and tetraploid cell lines were tested in this way. 
5.2.4 Ploidy differences between primary and metastatic tumours 
Due to the difficulties and caveats of using tail-vein injections to model and 
compare metastatic potential between diploid and tetraploid cell lines, an analysis 
of material from patient tumours was carried out. A cohort of 64 matched colorectal 
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cancer samples (52 microsatellite stable, MSS, and 12 MSI+) and their liver 
metastases was provided by Dr Marcell Szasz (Department of Pathology, 
Semmelweis University, Hungary). The clinical features of this cohort are detailed 
in Table 5.2. 
 
Table 5.2: Clinical characteristics of CRC patient cohort 
Where available, clinical data is presented for patients in this cohort. Information for 
grade and TNM (Tumour, Node, Metastasis) staging, as well as MSI status (as 
defined by IHC staining) is shown. * Indicates samples where no data from IHC 
was provided, so MSI status was checked using PCR fragment analysis (see 
Methods). ** Indicates samples where there was a discrepancy in MSI status 
between the primary and the metastatic sample, and so MSI status was checked 
using PCR fragment analysis. 
ID Gender Age Grade: T: N: M: MSI status (IHC) 
431 male 75 II 3 0 x MSI+ 
3271 male 52 II 4 1 1 MSI+ 
7225 male 49 II 4 1 x MSI+ 
10197 female 66 II 4 1 x MSI+ 
12105 female 46 II 3 0 x MSI+ 
12379 female 70 II 3 1 x MSI+ 
15703 male 66 II 2a 0   MSI+ 
617 male 58   3 0 x MSI+ 
3986 male 78 I 3 0 1 MSI+ 
4823 male 78 II 3 0 1a MSI+ 
13598 male 57 III 3 1 1 MSI+ 
15764 female 53 II 1 0 x MSI+ * 
53 female 69         MSS 
217 male 40 II 3 1 1 MSS 
759 male 75 III       MSS 
2736 male 66 III 3 2a 1 MSS 
2950 male 67 II 3 0   MSS 
3038 male 48 II 4 2 x MSS 
3217 female 60 II 3 1 1 MSS 
3710 female 45 I 3 1 x MSS 
4182 male 64 II 3 1 1 MSS 
4937 male 70 III 3 2   MSS 
5262 female 53 II 3 2b x MSS 
5690 male 41 II 3 2 x MSS 
5887 female 72 II 4 2 x MSS 
6648 male 68 II 3 2 x MSS 
7430 male 63 II 3 1 x MSS 
7605 male 62 II 3 0 x MSS 
8045 female 56 II 3 1 x MSS 
9607 female 56 II 3 0 x MSS 
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10306 male 60 II 4a 1b   MSS 
11752 male 43 III 3 2 x MSS 
12080 male 71 II 3 1 x MSS 
12435 male 74 II 3 1b   MSS 
12961 male 61 II 3 0 x MSS 
13856 female 66 II 3 1 x MSS 
15539 male 52 II 3 2a   MSS 
1892 female 75   3 2 1 MSS 
2393 female 80 III 3 x 1 MSS 
2714 female 47 II 4 1 1 MSS 
3962 female 56 II 3 1 1 MSS 
4785 female 76 III 3 2b 1a MSS 
6405 female 51 II 3 x 1 MSS 
6744 male 70 II 3 1 0 MSS 
7732 female 54   3 0 1 MSS 
7906 male 61 II 4 2 1 MSS 
9070 male 64         MSS 
9240 female 49 II 4 0 1 MSS 
10043 male 57 II 3 x 1 MSS 
10067 female 80 II 4a 2a 1a MSS 
10814 female 61 II 4a 2b 1 MSS 
11984 male 70 II 3 0 1 MSS 
14642 male 49 III 3 1 1 MSS 
15648 female 63 III 3 1   MSS 
9438 female 45         MSS 
11508 male 48 II 3 1a   MSS * 
13487 female 73 II 3 0 x MSS * 
2900 female 71 II 3 2 1 MSS * 
3737 male 59 II 3 1 1 MSS * 
4129 male 69 II 3 0 1 MSS * 
15144 female 44 II 3 2 1 MSS * 
2383 male 74 II 3 1 x MSS ** 
8681 male 67 III 3 2a x MSS ** 
 
Image cytometry was performed by Dahmane Oukrif (UCL Pathology).  
 
The ploidy of each sample and its matched metastasis was assessed using image 
cytometry, where nuclei are isolated from a tissue scroll from a paraffin block and 
stained with Feulgen stain, before analysis on an image cytometer (see Methods). 
This method provides information on DNA index, a measure of the ratio of G1/G0 in 
the tumour sample compared to reference normal cells. Figure 5.7A shows 
example image cytometry plots from a diploid, aneuploid and tetraploid tumour 
sample. DNA indices are indicated for each sample.  
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Figure 5.7: DNA index increases from primary to metastatic lesion in a CRC 
cohort 
A) Examples of image cytometry histograms from a diploid, aneuploid and 
tetraploid tumour. Labels at 2C indicate diploid peaks, 4C tetraploid peaks, and AP 
= aneuploid peak. DNA index is indicated on each graph.  
B) The change in DNA index between primary and metastasis is shown. Each bar 
represents one patient, red bars are positive values where DNA index increases 
from primary to metastasis, and blue bars are negative values where DNA index 
decreases between primary and metastatic samples.  
C) DNA index changes plotted as a paired graph.  
 
To assess changes in DNA index between each primary tumour and metastasis, 
the difference in DNA index between the primary tumour and metastasis was 
calculated (Figure 5.7B). These data show that there is an increase in DNA index 
from the primary tumour to the metastatic site in the majority of patients (P=0.008, 
Paired T-test, Figure 5.7C).   
 
These data could potentially indicate a beneficial effect of increasing DNA index on 
the formation of metastasis. This increase in DNA index may be due to increases in 
ploidy, or an increase in the degree of aneuploidy in each tumour. Although these 
data show a clear trend towards an increasing DNA index, the magnitude of the 
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change is only infrequently close to 1 (i.e. from 1 in primary to 2 in the metastasis, 
Figure 5.7B), suggesting that a change from a diploid primary tumour to a polyploid 
metastasis is quite rare within this cohort. However there are frequent changes that 
are only slightly less than 1, and since previous data in this thesis has shown that 
after a genome duplication there is a trend towards loss of genomic material and 
increasing genomic aberrations (Figure 4.3, Figure 4.7), it may be that these 
smaller changes have resulted from a genome-doubling event and subsequent loss 
of genetic material. Genome doubling could not be assessed directly using copy 
number analysis in this cohort due to the poor quality of DNA that was available 
from the paraffin embedded tissue blocks. 
 
To confirm that an increase in ploidy can influence metastasis, it would be of 
interest to increase the size of the dataset to see whether there was a trend for 
primary tumours that present with metastasis (M1 in Tumour, Node, Metastasis 
staging) to have an increased DNA index. However, this analysis would not 
necessarily be able to discern a trend unless there were multiple tumour regions 
analysed from the same primary tumour, as it has been previously shown that 
different regions of a primary tumour can have variations in ploidy (Gerlinger et al., 
2012). Further, it would be interesting to use FISH for multiple chromosomes to 
assess the levels of chromosomal instability in these samples, in order to see if 
there was a correlation of increasing chromosomal instability with increasing DNA 
index. 
 
5.2.5 A mutational basis for the tolerance of chromosomal instability in 
tetraploid clones 
Chapter 4 demonstrated that tetraploid cells derived from HCT-116 could tolerate 
chromosome missegration events, and consequently their genomes become 
genomically unstable over time. Uncovering a mechanism by which cells could 
proliferate in a tetraploid state and tolerate chromosome missegregation events 
remained a priority.  
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All second-generation diploid and tetraploid clones at passage 4 and passage 50, 
plus parental HCT-116 cells were subject to whole-exome sequencing (WES) to 
search for somatic events common to all tetraploid clones. Alignment and variant 
calling from exome sequencing data, and mutation prediction analysis was carried 
out by Harshil Patel. 
 
No coding mutations were found in TP53, CDKN1A or RB1, genes known to 
influence tolerance to chromosome missegregation and/or polyploidy (see Section 
1.6). Additionally no common mutations were found in a list of genes relevant to the 
p53/p21 pathway, which is known to allow tolerance to chromosome 
missegregation (Table 5.3). Two individual tetraploid clones each had a mutation in 
one of the listed genes: a mutation in MYC in TC-16 and a mutation in PCNA in 
TC-35.  
 
Table 5.3: p53/p21 pathway genes 
No common mutations were found in any of the following genes. A mutation in 
MYC was found in TC-16, and a mutation in PCNA in TC-35 at passage 50. An ID1 
mutation was present in HCT-116. 
RHOD CCND1 
E2F4 CDKN1 
ID1* CCCNE1 
E2F1 CDKN1B 
MYC * CDK4 
CDK2ND CDKN2A 
PCNA * CDK2 
CDK2NC CDKN1A 
RB1 E2F5 
CDKN2B TP53 
 
Since no common mutation was found in members of the p53/p21 pathway, any 
mutations common to multiple tetraploid clones were collated. Only non-
synonymous mutations were considered. Mutations present in any diploid sample 
were excluded. A full list of mutations found in multiple tetraploid clones, but not 
present in any diploid sample is shown in Table 5.4. Mutations listed in Table 5.4 
are not necessarily the same amino acid change in all samples as all non-
synonymous mutations for each gene were considered. 
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Table 5.4: Mutations common to 2 or more tetraploid clones 
Gene Name Mutated tetraploid samples 
ALDH5A1 TC-16 p50 TC-17 p50   
ALDOB TC-17 p50 TC-35 p50   
ALG2 TC-35 p50 TC-17 p50    
ALS2CR11 TC-16 p50 TC-17 p50   
APOBEC3F TC-17 p50 TC-35 p4   
ASB6 TC-16 p50 TC-17 p4 and p50   
ATP6V0A1 TC-17 p50 TC-16 p4 and p50   
CACNA1F TC-35 p50 TC-13 p4 and p50   
CACNA1I TC-35 p50 TC-13 p50   
CAPN14 TC-17 p50 TC-13 p50   
CBX2 TC-16 p50  TC-17 p4 and p50   
CELSR3 TC-17 p50 TC-16 p4 and p50   
CNTN3 TC-35 p50 TC-13 p4 and p50   
DAZAP1 TC-16 p50  TC-35 p50    
ELFN2 TC-35 p50  TC-17 p50 TC-35 p50 
ESR1 TC-13 p50 TC-17 p4 and p50   
EXOC3L4 TC-13 p50 TC-17 p4 and p50 TC-17 p4 and p50 
FAM135A TC-13 p50 TC-16 p50    
FAM179B TC-17 p50 TC-35 p4 and p50   
FASN TC-13 p4 and p50 TC-16 p4 and p50   
FBXO18 TC-16 p50 TC-17 p4 and p50   
G6PC2 TC-13 p50 TC-16 p50   
GAA TC-13 p50 TC-16 p4 and p50   
GRAMD2 TC-13 p50 TC-16 p50   
HSPH1 TC-13 p50 TC-17 p4 and p50   
IGSF10 TC-13 p50 TC-17 p50   
INADL TC-17 p50 TC-13 p4 and p50   
KCNT1 TC-35 p50 TC-16 p4 and p50   
KIAA0317 TC-13 p50 TC-16 p50    
KIAA1239 TC-35 p50 TC-17 p50   
LIMK1 TC-17 p50 TC-35 p4 and p50   
LRP5 TC-16 p50  TC-17 p4 and p50   
MAN2B1 TC-13 p50 TC-16 p4 and p50   
MAPK3 TC-35 p50  TC-16 p50   
MYO18A TC-35 p50 TC-13 p4 and p50 TC-13 p4 and p50 
NAA30 TC-16 p50  TC-13 p50   
NDUFAF5 TC-17 p50 TC-16 p50    
NEFM TC-13 p50 TC-17 p50   
NKD2 TC-16 p50 TC-35 p50    
NLN TC-17 p50 TC-16 p4 and p50   
NOX3 TC-35 p50  TC-13 p50   
NSMAF TC-17 p50 TC-13 p50   
NTN1 TC-13 p4 and p50 TC-17 p4 and p50   
NTRK1 TC-16 p50 TC-17 p50   
OR51B6 TC-35 p50 TC-16 p50    
PAGR1 TC-17 p50 TC-13 p4 and p50   
PAN2 TC-35 p50  TC-16 p50    
PKD2 TC-16 p4 and p50 TC-17 p4 and p50   
PLCG2 TC-13 p50 TC-16 p4 and p50   
PLXNB3 TC-13 p50 TC-17 p50   
PTPN21 TC-16 p50  TC-17 p4 and p50   
RBM47 TC-13 p50 TC-17 p4 and p50   
RERE TC-35 p50 TC-16 p50    
SLIT1 TC-13 p50 TC-16 p4 and p50   
ST3GAL1 TC-16 p50 TC-17 p50   
STRN TC-13 p4 and p50 TC-16 p4 and p50   
SYNE1 TC-13 p50 TC-17 p50 TC-16 p50  
TACC2 TC-13 p4 and p50 TC-17 p4 and p50   
TMEM229A TC-35 p50 TC-35 p4 and p50   
TNS1 TC-17 p50 TC-13 p4 and p50   
TRPM3 TC-16 p50 TC-35 p4 and p50   
TTC-21A TC-16 p50  TC-17 p4 and p50   
TUBGCP6 TC-13 p50 TC-17 p50   
UROC1 TC-13 p4 and p50 TC-17 p4 and p50   
VWA5B1 TC-35 p50 TC-17 p50   
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WDR52 TC-17 p50 TC-16 p50 TC-35 p4 and p50 
ZBED4 TC-13 p50 TC-17 p50   
ZFPM2 TC-17 p50 TC-13 p50   
ZNF518B TC-17 p50 TC-17 p4 and p50   
ZNF568 TC-35 p50 TC-16 p50   
ZNF574 TC-35 p50  TC-16 p50   
ZNF619 TC-17 p50 TC-17 p4 and p50   
 
 
Only two genes were mutated in more than two different tetraploid clones. These 
genes are SYNE1 (Spectrin repeat containing nuclear envelope protein 1) and 
WDR52 (WD repeat containing protein 52/ cilia and flagella associated protein 44). 
SYNE1 is a nuclear membrane protein involved in linking the nucleoskeleton with 
the cytoskeleton and maintaining subcellular spatial organisation. WDR52 has no 
known function. Furthermore, neither of these genes are categorised as driver 
genes, or are mutated at high frequency in any cancer type (Intogen database, 
(Gundem et al., 2010). An analysis of the predicted outcome of each individual 
mutation was carried out for these two genes using three different algorithms (SIFT, 
PolyPhen and Mutation-taster, see Methods). The results of this analysis are 
shown in Table 5.5. Mutations were considered as damaging overall if they had 2 
or more predictions as damaging mutations from the three algorithms. These 
mutations are highlighted in grey in Table 5.5. Two of the mutations in SYNE1 are 
predicted to be damaging based on this analysis. None of the mutations in WDR52 
are predicted to be damaging.  
 
Table 5.5: Predicted outcome of mutations in more than 2 tetraploid clones 
Mutation outcome as predicted by three different algorithms; SIFT output (D = 
damaging, T = tolerated), PolyPhen output (D =damaging, P= possibly damaging, 
B = benign) and Mutation-taster output (D =disease causing, A = disease causing 
[automatic], N = polymorphism, P = polymorphism [automatic]). NA = not 
applicable. 
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SYNE1 TC-17 p50 D D D 3 
SYNE1 TC-16 p50  D P N 1 
SYNE1 TC-13 p50 D D D 3 
WDR52 TC-35 p4 and p50 T B N 0 
WDR52 TC-16 p50 T D N 1 
WDR52 TC-17 p50 NA NA NA 0 
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Since tetraploid clones have been shown to tolerate chromosome missegregation 
at early passage (see Chapter 4, Figure 4.2), any mutation resulting in 
chromosome segregation error tolerance, or indeed tetraploid cell proliferation, 
should be present in early passage cells. Only 6 genes were mutated in more than 
one early passage clone. These genes are listed in Table 5.6. No gene was 
mutated in more than two early passage tetraploid samples. Of the six genes 
mutated in two tetraploid samples at early passage, none has a known role in 
chromosome segregation error tolerance. Further, there are no gene ontology 
pathways that link these 6 genes (Ashburner et al., 2000). 
 
Table 5.6: Function of genes with multiple mutations in early tetraploid 
clones 
Gene Protein Name  Function 
FASN fatty acid synthase Mainly catalyses palmitate synthesis 
NTN1 netrin1 Unknown - in family of laminin related secreted proteins 
PKD2 polycystin-2 (aka TRPP2) Unknown 
STRN striatin Unknown - possibly calmodulin binding 
TACC2 transforming acidic coiled coil domain 2  In large family of centrosome and MT interacting proteins 
UROC1 urocanate hydratase Histidine catabolism 
 
 
The functional outcome of these mutations was also tested using the algorithms 
SIFT, PolyPhen and Mutation-taster (see Methods and Table 5.7). The only gene 
to be consistently classed as damaging across all the tetraploid samples was 
FASN. None of the mutations in NTN1 or STRN were consistently classed as 
damaging, and only one of the mutations in PKD2, TACC2 and UROC1 were 
classed as damaging using these methods. This suggests that these gene 
mutations may have occurred in multiple tetraploid samples by chance, as there 
does not appear to be selection for loss of function of these genes. 
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Table 5.7: Predicted outcome of mutations in early tetraploid samples 
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FASN TC-16 p4 and p50 T D D 2 
FASN TC-13 p4 and p50 T D D 2 
NTN1 TC-17 p4 and p50 T P D 1 
NTN1 TC-13 p4 and p50 T B D 1 
PKD2 TC-17 p4 and p50 D D D 3 
PKD2 TC-16 p4 and p50 NA NA A 0 
STRN TC-16 p4 and p50 T P D 1 
STRN TC-13 p4 and p50 NA NA A 0 
TACC2 TC-17 p4 and p50 D D N 2 
TACC2 TC-13 p4 and p50 NA NA NA 0 
UROC1 TC-17 p4 and p50 D D D 3 
UROC1 TC-13 p4 and p50 T B N 0 
 
These data suggest that there is no common somatic mutational mechanism 
present in all the tetraploid clones that is responsible for the tolerance to 
chromosome segregation errors. It is however possible that different mutational 
mechanisms exist in different clones. Given the high mutational load present in all 
samples due to their microsatellite instability phenotype, it is also possible that 
mutations in genes common to more than one tetraploid sample occurred by 
chance. None of the genes in Table 5.6 are described as driver genes or have high 
mutational frequencies in any cancer type (Intogen database, Gundem et al., 2010). 
It is therefore unlikely that the mutations in these genes represent common 
mechanisms for cells to tolerate chromosomal instability.  
 
5.2.6 A functional p53 pathway in tetraploid clones 
No mutations were found in p53, or in members of the p53 pathway (Table 5.3). 
However, as the p53 pathway is one of the few mechanisms known to allow 
tolerance to chromosome segregation errors, the functionality of the pathway was 
further tested.  
 
Diploid and tetraploid clones were treated with the DNA damaging agent 
Doxorubicin for an hour, and then allowed to recover in fresh media for 7 hours. 
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Lysates were prepared and probed for p53 and its downstream target p21 (Figure 
5.8).  All early passage diploid and tetraploid clones up-regulated p53 and p21 after 
Doxorubicin treatment, suggesting that the main axis of this pathway is indeed 
functional, at least in response to DNA damage. 
 
 
 
Figure 5.8: Up-regulation of p53 and p21 after DNA damage in all clones 
A) Western blots for p53 and p21 with (+) and without (-) Doxorubicin (Dox) 
treatment for 1 hour at 1µM, followed by a 7 hour recovery in fresh media. Passage 
numbers are indicated for each clone. Either Actin or β-catenin was used as a 
loading control.  
 
5.2.7 Changes in gene expression in tetraploid clones 
Since tetraploid clones have no common mutations to explain their tolerance to 
chromosome missegregation events, and appear to have a functional p53 axis, a 
genome wide analysis of gene expression was carried out using microarrays, in 
order to investigate if tetraploid cells had epigenetically regulated any pathways 
that could explain their chromosome missegregation tolerance phenotype.  
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RNA was extracted from all second-generation diploid and tetraploid clones at both 
early passage (passage 6) and late passage (passage 49), as well as the parental 
HCT-116 cell line, and subjected to a microarray analysis using Affymetrix Human 
Gene 1.0 ST Arrays. Microarray profiling was carried out by the Affymetrix 
Microarray Service at the Cancer Research UK Manchester Institute. Microarray 
clustering and preparation of the graphs in Figure 5.9 was carried out by Dr Tejal 
Joshi and Dr Nicolai Birkbak.  
 
A genome wide comparison of mean expression between early passage diploid 
and tetraploids showed very similar global patterns of gene expression (Figure 
5.9A). There is a very good correlation in global gene expression between diploids 
and tetraploids. Genes that showed a significant difference in expression between 
diploid and tetraploids are shown in the adjacent table. The log fold change is 
shown for each significant gene (positive values are genes that are more highly 
expressed in tetraploid samples). A very similar pattern was observed in the 
comparison between late passage diploid and tetraploid clones (Figure 5.9B). In 
both early and late passage, the majority of genes that are significantly differentially 
expressed are down-regulated in tetraploids compared to diploids.  
 
Figure 5.9C shows a comparison between all diploid and tetraploid clones at both 
early and late passage. Again, there are very similar global gene expression 
patterns between all diploid and tetraploid clones. Only one gene has a log fold 
change of greater than 2 fold (SYT1, Figure 5.9C).  
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Figure 5.9: Microarray profiling results in diploid and tetraploid clones 
A) Comparison of global gene expression patterns between early passage diploid 
and tetraploid clones. A list of significantly differentially expressed genes (P<0.05) 
is shown adjacent to the graph, with logFC (fold change) values indicated.  
B) As in A), but for late passage clones.  
C) Comparison between all diploid and tetraploid clones (both early and late 
passage).  
 
To see if the most differentially expressed genes in all the samples were related to 
the ploidy status of the sample the 250 most variable probes were selected, and 
hierarchical clustering was performed. This analysis was carried out by Nicholas 
McGranahan.  
 
 
Figure 5.10: Clustering of the 250 most variable microarray probes 
A) Graphical representation of the 250 most variable probes in the microarray 
analysis. Colours represent a z-score scale for each gene (red = overexpressed, 
blue = under-expressed). Each gene is scaled to have a mean of 0 and standard 
deviation of 1.  
B) Hierarchical clustering shows the relationship between the samples for the 250 
most variable probes.  
 
The graph in Figure 5.10A shows that there are no obvious trends separating 
diploids and tetraploids when comparing even the most differentially expressed 
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genes. Furthermore the clustering in Figure 5.10B shows that diploid and tetraploid 
samples do not cluster together in this analysis.  
 
These data indicate that there are no clear genome wide transcriptional changes 
associated with tetraploidy in this system. This result is consistent with the results 
of Kroemer and colleagues who also found few transcriptional changes between a 
panel of diploid cell lines derived from HCT-116 and RKO (Castedo et al., 2006). 
However comparing microarray data from tetraploid clones from both of these cell 
lines only resulted in a list of 29 genes that were altered as a function of ploidy 
(Castedo et al., 2006). Analysis of the differential expression of 15 of these 29 
genes that had adequate annotation from the microarray analysis described above 
is shown in Figure 5.11. This analysis again shows that there is no separation of 
diploid and tetraploids based on the expression of these genes. This analysis was 
carried out by Dr Nicolai Birkbak. 
 
 
Figure 5.11: Analysis of 15/29 genes shown previously to have altered 
expression based on ploidy 
Hierarchical clustering of expression of 15 genes from a list of 29 genes previously 
shown to have altered expression based on ploidy (Castedo et al., 2006). Blue 
colours in grid show under-expression compared to median expression, red colours 
indicate over-expressed genes (z-score). Clustering of different samples is shown 
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above graph, and ploidy status is indicated (red = tetraploid, blue = diploid, green = 
HCT-116 parental cell line). 
 
It is surprising that there are also few differences in late passage tetraploid clones 
compared to diploid clones, as late passage tetraploid clones show higher levels of 
genomic instability (Figure 4.3). Previous studies have shown that there may be a 
common transcriptional response to chromosome imbalances in cells (Sheltzer et 
al., 2012, Durrbaum et al., 2014). However, at late passage numbers, there are no 
obvious transcriptional changes in tetraploid clones, which exhibit many 
chromosome imbalances (Figure 4.3). This could indicate that in the context of 
tetraploidy, additional chromosome imbalances do not result in a typical 
transcriptional response. Many of the genes that have been shown to be altered as 
a general response to aneuploidy are linked to cellular stress (Sheltzer et al., 2012, 
Durrbaum et al., 2014). However, in late passage tetraploid clones, loss or gain of 
chromosomes (for example the loss of chromosome 4q that occurs in all tetraploid 
clones, Figure 4.3) is unlikely to have resulted in an anti-proliferative or stress 
response, as these chromosomal changes have been selected in the whole 
population. It is possible that different chromosomal changes have occurred during 
the passaging of tetraploid clones, but have not been selected for as they resulted 
in this stress response. The degree of stress initiated after a chromosome 
missegregation could be due to the size and number of genes on the aneuploid 
chromosome, which could explain why cancer cells have been shown to more 
frequently lose small chromosomes (Duijf et al., 2013). 
 
5.3 Conclusions 
Although tetraploid clones derived from HCT-116 do exhibit hallmarks of 
chromosomal instability, including increased levels of segregation errors and 
structurally abnormal chromosomes (Chapter 3), they do not exhibit increased drug 
resistance to an extensive panel of kinase inhibitors. This would not have been 
predicted based on previous work showing that CIN+ cells were more resistant 
than CIN- cells to the same panel of drugs (Lee et al., 2011). This may indicate 
fundamental differences in the type of chromosomal instability generated by a 
tetraploidisation event in a microsatellite unstable cell line and the CIN+ cell lines 
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that were tested in the previous study. It could also indicate that chromosomal 
instability coupled with microsatellite instability is detrimental to cell survival under 
stressful conditions. Indeed, CIN and MIN are rarely observed together in CRC 
(see Section 1.11). This may suggest that there is a threshold level of genetic 
instability that can be tolerated by cells. This idea is consistent with recent studies 
that have shown that high levels of CIN can be beneficial for patients treated with 
certain chemotherapeutics (Birkbak et al., 2011, Jamal-Hanjani et al., 2015).  
 
Additionally, no differences in sensitivity to a range of DNA damaging agents, some 
of which have previously shown to be less effective in tetraploid cells were 
observed (Castedo et al., 2006). These discrepancies may be due to different 
mechanisms that were used to generate tetraploid cells between this and the 
previous study. Tetraploid clones used in this study are naturally occurring in the 
parental HCT-116 population, but Castedo and colleagues used nocodazole or 
cytochalasin D to induce cytokinesis failure to generate tetraploid cells in HCT-116 
(Castedo et al., 2006). The frequency of surviving cells after this treatment was 
extremely low (1 in 10,000), which may indicate that this study selected tetraploid 
cells that had already altered key survival pathways that meant that they were more 
resistant to multiple drug treatments, including the DNA damaging agents that they 
later tested (Castedo et al., 2006). Additionally different protocols of drug treatment 
could affect the outcome of these experiments. Preliminary data generated by a 
colleague Andrew Crockford, has demonstrated that tetraploid clones from HCT-
116 are more resistant to some chemotherapeutic agents, but only in long-term, 
and not short-term assays. This could suggest that it is heterogeneity within the 
tetraploid population (for example the increase in cell-to-cell variation in 
chromosome number, Figure 3.5) that allows tetraploid cells to survive over long-
term treatment, rather than an inherent drug resistance.   
 
The ability of tetraploid cells to grow in 3D environments was investigated using 
spheroid culture. There were no significant differences in growth rate between 
diploid and tetraploid clones, and a large variation between clones. Using this 
system of clones has demonstrated that there is likely to be significant 
heterogeneity in phenotypes within the parental HCT-116 and DC-8 populations. 
This is probably due to the microsatellite instability inherent in HCT-116 cells, which 
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will continually be generating new mutations within cells of the population. Using 
bioluminescence imaging in mice revealed that there was no difference in 
metastatic potential between one diploid and one tetraploid clone. There was a 
small increase in tumour growth rate in the tetraploid clone TC-13, but the 
statistical evidence for this increase was ambiguous. It is difficult to assess the 
impact that tetraploidy has on metastatic potential using tetraploid clones derived 
from a cell line that is already metastatic in a tail-vein injection. If appropriate 
models of primary tumours that spontaneously metastasised in the mouse were 
available, it would be of greater interest to assess whether ploidy of the primary 
tumour changed the location, frequency or growth rate of metastases. This would 
be especially interesting given that in a cohort of matched primary CRC and their 
liver metastases, there was a significant increase in DNA index from the primary to 
the metastatic site. This could suggest that increasing ploidy is favourable for the 
formation of metastatic lesions. This would be an interesting area for further 
research.  
 
An extensive analysis of mutations in tetraploid clones failed to identify any 
mutation common to all tetraploid clones that can explain their ability to propagate 
segregation errors (Chapter 4). Furthermore, very few mutations were shared 
between more than two tetraploid clones at early passages, which suggests there 
is no common mutational mechanism in these tetraploid clones that allowed them 
to survive tetraploidisation and single-cell cloning, which appeared to be a barrier to 
tetraploid cell survival (Figure 3.3B). There were no mutations found in either 
diploid or tetraploid clones in p53 or p21, and the p53 pathway appeared to be 
active in response to DNA damage. There were also very few global changes in 
gene expression between diploid and tetraploid clones, at either late or early 
passage. Although surprising given the extensive genomic changes at later 
passages (Figure 4.3), this is similar to previous work which showed across a panel 
of diploid and tetraploid clones derived from HCT-116 and RKO that there were 
very few transcriptional alterations based on ploidy (Castedo et al., 2006). However, 
preliminary data has indicated that there may be specific genes that are de-
regulated at the mRNA level between diploid and tetraploid clones (Andrew 
Crockford, personal communication). It is likely that carrying out a large-scale 
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global analysis by using microarrays is not sensitive enough to pick up subtle but 
potentially important changes in gene expression.  
 
A proteomics analysis between one diploid and one tetraploid clone has also been 
carried out by a colleague, Andrew Crockford, to assess changes in proteomic 
regulation between diploid and tetraploids. This analysis has resulted in a list of 
proteins that are up or down regulated in tetraploids that are currently being 
validated in the panel of tetraploid clones and followed up with functional analysis. 
 
Given the data presented in this Chapter, which failed to reveal common changes 
in DNA sequence or gene expression that could explain the tolerance to 
chromosomal instability in tetraploid clones, a different approach to uncover genetic 
regulators of tetraploid cell survival was adopted in the next chapter.
Chapter 6. Results 
 
 175 
 
Chapter 6. Results 4: A screen for regulators of cell 
cycle re-entry after cytokinesis failure 
6.1 Introduction 
In Chapter 5 the functional consequences of tetraploidy in the isogenic system of 
clones derived from diploid HCT-116 cells was explored. No inherent drug 
resistance was observed in tetraploid clones when treated with a large panel of 
kinase inhibitors, or a selection of clinically relevant DNA damaging agents. 
Although there was no difference in the ability of one diploid and one tetraploid 
clone to form tumours when injected into nude mice, some tetraploid cell lines 
showed an enhanced ability to grow in 3D culture. Analysis of patient data also 
revealed an intriguing correlation of increasing DNA index in metastatic compared 
to primary tumour samples. Surprisingly there were no common mutations in 
tetraploid clones that are likely to account for their ability to propagate chromosome 
missegregation events. Additionally there did not appear to be global changes in 
gene expression common to tetraploid clones. It may be that in this system of 
diploid and tetraploid clones there is no singular mechanism that can explain their 
tolerance to chromosome missegregation. Tetraploid cells could propagate 
segregation errors due to a buffering of chromosomal content. If one chromosome 
is missegregated into the incorrect daughter cell the other daughter cell will still 
have three chromosomes present that might compensate for alterations in gene 
dosage. If this is indeed the case then there may be no mutation or change in gene 
expression that does allow tolerance to chromosome missegregation.  
 
Given the possibility that tetraploidy itself may allow the propagation of segregation 
errors, it is relevant to investigate the mechanisms by which tetraploid cells can 
initially proliferate. As discussed in Section 1.6, several studies have shown that 
after cytokinesis failure most primary cells undergo a p53 dependent cell cycle 
arrest. In this study it has also been shown that tetraploid cells are harder to clone 
than diploid cells (Figure 3.3B). As many tumours show evidence of whole genome 
doublings during their evolutionary histories (Carter et al., 2012, Zack et al., 2013 
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2014), it is likely that cells have found mechanisms to bypass this proliferative 
checkpoint. Although mutations in p53 occur frequently in GD tumours, a significant 
proportion (43%) of GD tumours (from a pan-cancer analysis) do not have p53 
mutations (McGranahan et al., 2015). This suggests that alternative mechanisms 
for bypassing this checkpoint do exist in cancer cells. A recent study by Pellman 
and colleagues used this logic to design a screen for regulators of cell cycle arrest 
after cytokinesis failure (Ganem et al., 2014). Ganem and colleagues identified 
LATS2 (large tumour suppressor 2), a member of the Hippo signalling pathway, 
which is activated in response to cytokinesis failure. In this chapter a similar 
screening protocol is used to assay genes that are more frequently mutated in 
genome-doubled tumours to ascertain if they have a role in allowing the initial 
proliferation of tetraploid cells.  
 
6.2 Results 
6.2.1 Selection of genes to screen 
The lists of genes in this analysis were provided by Nicholas McGranahan, using 
the data sets and criteria detailed below. 
 
In order to establish a list of candidate genes contributing to cell cycle arrest after 
cytokinesis failure when silenced, publically available data from TCGA were utilised. 
SNP6.0 and somatic variant data from breast cancer, bladder cancer, lung 
adenocarcinoma, lung squamous cell carcinoma, melanoma, glioblastoma 
multiforme, colon adenocarcinoma and head and neck cancer was obtained from 
TCGA. All tumours were assessed for evidence of genome doubling using the 
algorithm described in Chapter 3. All non-silent mutations in all samples for each 
tumour type were used to assess whether a difference in prevalence of somatic 
aberrations was observed in specific genes in genome doubled (GD) compared to 
non-genome-doubled (nGD) tumours (see Methods). A graphical illustration of this 
analysis for colon adenocarcinoma is shown in Figure 6.1.  
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Figure 6.1: Relationship between mutations and genome doubling status of 
colon adenocarcinoma 
A) Analysis of relationship between individual mutations and genome doubling 
status of colon adenocarcinoma. Mutations plotted according to Fisher’s exact-test 
P-value and odds ratio.  
B) Mutations plotted according to a simulated P-value and odds ratio (see Methods 
and text). NB: not all mutations in A) could be named on the graph due to space 
constraints. 
 
All genes with at least five non-silent mutations are represented as circles. To 
assess whether any genes harboured an enrichment or depletion of non-silent 
mutations in GD compared to nGD tumours, a Fisher’s exact-test was implemented 
for each gene, yielding an odds ratio – reflecting the association between mutations 
in that gene and the likelihood of the tumour having undergone GD – and an 
associated P-value. Genes depicted on the right hand side of each graph have a 
higher odds ratio, and hence occur more frequently in GD tumours.  
 
The second graph presented depicts the simulated P-value for each mutation 
(Figure 6.1B). This simulated P-value was calculated from a permutation-based 
analysis, which takes into account the mutational load of each tumour. As most of 
the nGD tumours in colon adenocarcinoma are likely to be diploid and 
microsatellite unstable they are likely to have a high mutational burden, and in the 
Fisher’s exact-test analysis many genes pass the threshold for being significantly 
mutated. However when the total number of mutations in each sample is taken into 
account using the simulated P-value then fewer mutations pass the significance 
threshold of P<0.05 (Figure 6.1B). This analysis was repeated across breast 
cancer, bladder cancer, lung adenocarcinoma, lung squamous cell carcinoma, 
melanoma, glioblastoma multiforme, and head and neck cancer samples from 
TCGA. To develop a list of genes to screen, only genes with a positive odds ratio 
for occurring more frequently in genome doubled samples were selected. All genes 
that had significant Fisher’s exact test P-values or significant simulated P-values 
were taken forward. 
 
The bioinformatics tool MutSigCV was developed at the Broad Institute to find 
significantly mutated genes in large datasets whilst avoiding false positive results 
that may stem from, among other factors, gene size or replication timing (Lawrence 
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et al., 2013). MutSigCV analysis was applied to all genes that were mutated 
significantly more frequently in GD tumours, and only those genes which passed a 
threshold of P<0.05 were taken forward for screening analysis.  
 
Any genes that were discarded following the MutSigCV analysis were reanalysed 
to investigate if they overlapped with any of the four following relevant gene lists. 
These four gene lists were: the list of genes mutated in more than one tetraploid 
clone derived from HCT-116 (presented in Chapter 5, Table 5.4), a list of genes 
that are mutated specifically in aneuploid tumours from a cohort of colorectal 
cancers (used with the kind permission of Dr Carlos Lopez-Garcia, data not shown, 
manuscript in preparation), a list of hits from a reversine screen for regulators of 
segregation error tolerance (used with the kind permission of Dr Laurent 
Sansregret, data not shown, manuscript in preparation), and the list of significant 
genes from the original two screens found in the recent publication by Pellman and 
colleagues (DNA damage and tetraploidy tolerance) (Ganem et al., 2014). Any 
genes that were found to overlap with any of these gene lists were included if they 
had an odds ratio associated with GD of greater than 4. A schematic detailing the 
gene selection process is shown in Figure 6.2. 
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Figure 6.2: Schematic of gene selection for screen 
An outline of how genes were selected for inclusion in a screen for regulators of 
cell cycle arrest after cytokinesis failure. 
 
 
A complete list of all genes used in the screen is shown in Table 6.1. This list 
indicates from which cancer type the genes were selected and also whether each 
gene overlapped with any of the gene lists described above. Control genes 
selected as positive controls are also included. A complete list of all the siRNA 
sequences used for these genes is shown in Appendix Section 8.2. 
 
Table 6.1: Full list of genes included in screen 
Abbreviations for cancer types: BLCA: bladder cancer, LUAD: lung 
adenocarcinoma, LUSC: lung squamous cell carcinoma, SKCM: melanoma, GBM: 
glioblastoma multiforme, COAD: colon adenocarcinoma, HNSC: head and neck 
cancer. * indicates 3 additional genes included as they were found to be mutated in 
p53 WT but wGII high tumours (see Methods). 
Fisher’s exact test P<0.05 Simulated P<0.05
Positive odds ratio: associated with GD
Non-synonymous mutations present across multiple different cancer types 
MutSigCV analysis
Significant (P<0.05) Not significant (P>0.05) 
Overlap with relevant 
gene lists (see text)
Odds ratio >4
Final gene list
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ZFPM2 LUAD yes     yes 
LGR5 SKCM yes       
LRP5 SKCM yes       
TG LUAD yes       
TP53 ALL!   yes yes yes 
DNAH5 HNSC   yes   yes 
INHBA SKCM     yes yes 
SORCS1 LUAD     yes   
CNGB3 LUAD       yes 
ELTD1 LUSC       yes 
LILRB2 LUAD       yes 
NRXN1 LUAD       yes 
OR51B5 SKCM       yes 
RB1 GBM       yes 
RGS7 LUAD       yes 
SALL4 LUAD       yes 
SCN1A LUSC       yes 
SIGLEC6 SKCM       yes 
ZNF208 LUAD       yes 
ABCA13 LUAD         
APC COAD         
ARHGAP5 COAD         
ARID1A BLCA         
ATXN1 COAD         
BCAM SKCM         
C12orf50 SKCM         
CCDC11 SKCM         
CD2 SKCM         
CDH10 LUAD, LUSC         
CDH9 COAD         
CHD2 SKCM         
COL11A1 HNSC, LUSC         
COL14A1 LUAD         
COL1A2 LUAD         
COL22A1 SKCM         
COL3A1 LUAD         
COL6A3 LUAD, BLCA         
CSMD2 LUAD         
FAM171B LUAD         
FAM194B COAD         
FSHR LUSC         
GFRAL LUAD         
HEATR7B2 HNSC, LUAD         
IDH1 GBM         
INSRR LUAD         
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ITGAX LUAD         
KCNA5 COAD         
KIR2DL1 SKCM         
KLHL1 LUAD         
KRTAP4-5 COAD         
LRRIQ4 SKCM         
MUC7 LUAD         
MYADML2 COAD         
NAV3 LUAD         
NBAS LUAD         
NCKAP1L LUSC         
NID1 LUAD         
NOTCH4 LUAD         
PON1 SKCM         
PTEN GBM         
PXDNL LUAD         
PZP LUAD         
RUNX1T1 LUAD         
SCN9A COAD         
SELP LUSC         
SLC13A1 LUSC         
SLC18A2 SKCM         
SLITRK1 LUAD         
SLITRK3 LUAD         
SNTG1 SKCM         
ST6GAL2 LUAD         
TCF7L2 COAD         
TPO LUAD         
TRPS1 LUAD         
VCAN LUAD         
DGKI* COAD         
DMXL1* COAD         
SATB2* COAD         
DCP1A       yes   
CDKN1A        yes   
LATS2       yes   
PTBP1       yes   
SPINT2       yes   
  
The positive control genes used were TP53 and CDKN1A (p21) as knockdown of 
these genes will allow cells to bypass cell cycle checkpoints. Four genes were also 
included that were strong hits in the Ganem et al., 2014 paper: LATS2, SPINT2, 
PTPB1 and DCP1A. A custom 96-well plate format of pooled On-Target-Plus 
(OTP) small interfering RNAs (siRNAs) from Dharmacon were ordered for each 
gene. Separately ordered control siRNAs were also added to the plate layout. The 
non-targeting OTP Controls 1-4, si-Genome Control-5 and RISC-free siRNAs were 
Chapter 6. Results 
 
 183 
used. In addition to the positive controls within the plate layout, separate p53 and 
p21 siRNAs were also used (four individual OTP siRNAs for p53 [14-17] and one 
additional OTP siRNA for p21 [12]). The sequences of these additional siRNAs can 
be found in Methods Table 2.4. 
6.2.2 Outline of screening procedure 
The protocol for screening for genes regulating cell cycle re-entry after cytokinesis 
failure was followed from Ganem et al., 2014. The primary hTERT immortalised cell 
line RPE (retinal pigment epithelium) that expresses two fluorescent markers from 
the FUCCI (fluorescent ubiquitin based cell-cycle indicator) system was used to 
distinguish between cells in G1, S and G2 phases (Sakaue-Sawano et al., 2008). 
The RPE-FUCCI cell line was kindly provided by Dr Laurent Sansregret. These 
cells express a fragment of human Geminin tagged to the Venus protein and a 
fragment of human Cdt1 tagged to mCherry protein. As these two proteins are 
degraded in distinct phases of the cell cycle (Geminin in M and G1, Cdt1 in S and 
G2/M) by ubiquitination and proteasome targeting, cells express different 
fluorescent markers in the different phases of the cell cycle (mCherry in G1, Venus 
in S, G2 and M) (Sakaue-Sawano et al., 2008).  
 
A schematic of the screening procedure is shown in Figure 6.3A. The purpose of 
the screen was to identify siRNAs that increase the fraction of cells re-entering the 
cell cycle after cytokinesis failure. Briefly, cells were treated with the actin 
polymerisation inhibitor dihydrocytochalasin B (DCB), which inhibits cytokinesis, as 
cells are unable to form a contractile ring around the cleavage furrow. Cells were 
then treated with the DNA dye Hoechst so that cells that had undergone 
cytokinesis failure and subsequently had a 4N DNA content could be identified. The 
FUCCI system was then used to distinguish between normal diploid cells in G2, 
and binucleated tetraploid cells in G1. This method of using FUCCI in flow 
cytometry to distinguish between cells in different cell cycle phases has been used 
previously (Wu et al., 2010). Cells with a 4N DNA content, but expressing the 
mCherry Cdt1 gene fragment (G1 cells) were selected and sorted. Cells were then 
reverse transfected with siRNA in 96-well plates, and the plates fixed 96 hours later. 
The plates were stained with DAPI and automatically scanned so the fraction of 
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Venus expressing cells (identifying cells in S/G2) could be calculated. This allows 
the identification of siRNAs which increase the fraction of cycling cells after 
cytokinesis failure, as the majority of untreated cells remain in G1 for the duration 
of the experiment. 
 
Figure 6.3: Outline and set-up of screening protocol 
A) Outline of screening procedure followed from Ganem et al., 2014.  
B) A transfection test using siRNA targeting LaminA/C and different concentrations 
of three different transfection reagents (RNAi Max, Lullaby and Interferin). Amount 
of reagent indicated is quantity used per well of a 96-well plate.  
C) Effect of increasing concentration of the different transfection reagents on cell 
number.  
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D) Example images of control transfected cells, as well as the two positive controls 
p53 and p21 are shown from fixed plate analysis at 96 hours 
 
Extensive optimisation was carried out on RPE-FUCCI cells to maximise 
transfection efficiency and viability after the sorting procedure detailed in Figure 
6.3A. Using three different transfection reagents (RNAi Max, Lullaby and Interferin), 
cells were transfected with a pool of Control siRNAs (OTP Controls 1-4, 
Dharmacon), or si-LaminA/C at differing concentrations of transfection reagent per 
well. After 72 hours cells were fixed and the knockdown of LaminA/C was assessed 
using indirect immuno-fluorescence. Plates were scanned using a Cellomics 
ArrayScan Vti machine and the percentage of LaminA/C expressing cells was 
calculated using the target Activation Cellomics Bioapplication (see Methods). The 
results of the optimisation are presented in Figure 6.3B. Compared to mock 
transfected wells, all reagents resulted in a significant reduction in LaminA/C 
staining. However Interferin resulted in a less efficient knockdown than either RNAi 
Max or Lullaby reagents. To test the toxicity of the transfection reagent the number 
of cells per well was calculated for both the control and LaminA/C transfected wells 
using DAPI to count total cell number. Figure 6.3C shows the cell number after 72 
hours for different concentrations of each reagent. Interferin showed the most 
obvious reduction in cell number at increasing concentrations, and RNAi max also 
showed a decrease in cell number (indicating toxicity) at the highest concentrations 
of reagent used. Lullaby did not have a striking effect on cell number at increasing 
concentrations. The reagent Lullaby was therefore chosen to use in the screen, at 
a concentration of 0.15µL per well, as this resulted in a significant reduction in 
LaminA/C staining. Example images of control, p53 and p21 transfected cells after 
the cell sort using these transfection conditions are shown in Figure 6.3D, showing 
that very few control cells start cycling after cytokinesis failure, whereas p53 or p21 
siRNA transfection resulted in an increase in the number of cycling cells. 
 
6.2.3 First two screen repeats  
The screen was carried out twice in triplicate in two independent experiments. The 
results of these first two screens are shown in Figure 6.4. The siRNAs are ordered 
from left to right as decreasing percentages of cycling cells at 96 hours. All control 
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siRNAs for p53 and p21 are highlighted by blue and red bars respectively. In the 
first screen the average percentage of Venus positive cycling cells for all control 
siRNAs was 2.3% (standard deviation, SD 0.7%) (Figure 6.4A). The average 
percentage of cycling cells for p53 siRNAs was 15.5% (SD 7.2%), and for p21 
siRNAs the average percentage of cycling cells was 22% (SD 9.8%), suggesting 
that technically the screen procedure had worked (Figure 6.4A). No siRNAs from 
the gene list appeared to increase the percentage of cycling cells above 
background levels. 
 
 
Figure 6.4: Two independent screen repeats 
A) The percentage of Venus positive cells from the first screen is shown. The 
screen was carried out in triplicate (error bars are standard deviations from plate 
replicates). All p53 siRNAs are shown as blue bars, and p21 siRNAs as red bars. 
Six control siRNAs are shown in green (OTP Controls-1-4, si-Genome Control-5 
and RISC-free). Positive controls chosen from Ganem et al., 2014 are shown as 
orange bars (LATS2, PTBP1, SPINT2 and DCP1A). All other siRNAs tested are 
shown as black bars.  
B) As above, for the second screen repeat.  
 
A second repeat of the screen was carried out, again in triplicate plates. The results 
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percentage of cycling cells in control siRNAs was higher than in the initial 
experiment, at 6.5% (SD 1%). The average of all p53 siRNAs was 26.6% (SD 
8.9%), and p21 siRNAs averaged 32.6% (SD 6%) (Figure 6.4B). This is 
comparable to the results obtained by Ganem and colleagues. Similarly to the first 
repeat, no test siRNAs (including positive controls from Ganem et al., 2014) 
increased the percentage of cycling cells significantly above the levels in control 
siRNAs, although siRNAs targeting PTBP1 and LATS2 resulted in the highest 
percentages of cycling cells after si-p53 and si-p21. 
 
To investigate further the control siRNAs used from the Ganem et al., 2014 screen, 
individual plate data from the second experiment was examined. The percentage of 
cycling cells from each siRNA from each plate is shown in Figure 6.5A-C. The 
positive control siRNAs used from the Ganem et al., 2014 screen are each 
highlighted. For plates one and two there did not appear to be an effect of any of 
the positive control siRNAs (Figure 6.5A and B). However, in the third plate, two of 
the positive control siRNAs from the Ganem et al., 2014 screen appeared higher 
than the majority of controls. These two siRNAs were targeting LATS2 and PTPB1. 
The control siRNA average in the third plate was 6.9% cycling cells. LATS2 
knockdown increased the percentage of cycling cells to 10.5%, and PTPB1 
knockdown increased the percentage of cycling cells to 11.8%. Representative 
images from LATS2 and PTPB1 knockdown wells in the third plate are shown in 
Figure 6.5D. Although the percentage of cycling cells was not as high as the results 
reported in the Ganem et al., 2014 paper, the fact that two of their strongest hits 
were the top two siRNAs above the control siRNAs lead to speculation that the 
screen set up may not be optimal.  
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Figure 6.5: Data from each individual plate from screen 2 
A-C) Data from the three plate replicates for screen 2. Control siRNAs are shown 
as green bars, p53 siRNAs as blue bars, p21 siRNAs as red bars and the Ganem 
et al., 2014 screen hits as orange bars.  
D) Representative images from the plate scans of wells for LATS2 and PTPB1 
siRNAs, showing the channels for DAPI, Venus (S-G2/M cells) and Cherry (G1 
cells). 
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siRNAs was checked after DCB treatment and the cell sorting procedure detailed in 
Figure 6.3A. The protein levels of p53 and p21 were examined using indirect 
immuno-fluorescence after 72 hours, and the average intensity of the secondary 
antibody compared to a control siRNA is shown (Figure 6.6). Across different 
concentrations of transfection reagent, the poorest knockdown was observed using 
Lullaby, which was the reagent used in the first two screen repeats. The most 
consistent knockdown for both p53 and p21 was obtained using RNAi Max reagent 
(Figure 6.6A and B). Furthermore, RNAi Max is the same reagent used in the 
Ganem et al., 2014 paper, and so it was chosen to replace Lullaby in subsequent 
experiments at a concentration of 0.2µL per well.  
 
 
Figure 6.6: Knockdown efficiency of p53 and p21 with different reagents 
A) The knockdown of p53 in 96-well plates was assessed by indirect immuno-
fluorescence after 72 hours. The average intensity of p53 staining compared to 
control siRNAs is shown.  
B) The knockdown of p21 was assessed by indirect immuno-fluorescence after 72 
hours. The average intensity of p21 staining compared to control siRNAs is shown. 
 
An additional concern with the original experimental set up was the length of the 
assay. After 96 hours the wells containing control p53 and p21 siRNAs were quite 
confluent as the cells were dividing rapidly after the cell sorting procedure. 
A)
RNAi Max
Lullaby
Interferin
si-Control
p21 staining intensity
A
ve
ra
ge
 In
te
ns
ity
C
on
tro
l
C
on
tro
l
C
on
tro
l
C
on
tro
l0
200
400
600
800
0.15µl/well 0.2µl/well 0.25µl/well 0.3µl/well
RNAi Max
Lullaby
Interferin
si-Control
p53 staining intensity 
A
ve
ra
ge
 In
te
ns
ity
0
100
200
300
400
C
on
tro
l
C
on
tro
l
C
on
tro
l
C
on
tro
l
0.15µl/well 0.2µl/well 0.25µl/well 0.3µl/well
B)
Chapter 6. Results 
 
 190 
Furthermore, the potency of some siRNAs may be diminished after 96 hours. The 
Incucyte imaging system (Essen Bioscience) was used to identify the best time 
point to fix cells after transfection. This device allows continued phase-contrast 
imaging at regular intervals within a tissue-culture incubator and has capability to 
image in the green fluorescence channel. It was therefore used to assess when 
RPE-FUCCI cells started to enter S phase based on Geminin-Venus expression. 
Importantly, it allowed temporal dissection of the effects of each siRNA, as 
described below.  
 
Figure 6.7 shows at what time point after sorting and transfection individual cells 
started expressing Venus protein, and were hence entering S phase and 
subsequently G2. Each line on the graph indicates a single cell. It should be noted 
that because RPE cells are relatively motile, it was not possible to track individual 
cells for the duration of the movie and hence distinguish when an individual cell had 
completed G2 and stopped expressing Venus protein. Therefore although the 
green lines for every cell extend to the final time point (84 hours) the cell may not 
have been expressing Venus for the complete duration that the line depicts. RPE-
FUCCI cells that had been treated with DCB but not sorted (and therefore including 
some G1 and G2 diploid cells as well as G1 tetraploid cells) were imaged as a 
control to check that the drug washout was working, and that treatment with DCB 
had not arrested all cells, regardless of their ploidy status. This is clearly not the 
case, as DCB treated but unsorted cells steadily started to enter S/G2 after 24 
hours (Figure 6.7). Transfection with p21 siRNA had a striking effect, with cells 
synchronously entering S/G2 just 12 hours after sorting. siRNA targeting p53 had a 
slightly delayed effect compared to si-p21, with cells beginning to enter S/G2 after 
24 hours. As expected, very few cells transfected with a control siRNA entered 
S/G2 after sorting, and those that did enter S/G2 did so randomly throughout the 
duration of imaging (Figure 6.7).  
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Figure 6.7: Scoring S-phase entry by live-cell imaging after cytokinesis failure 
Depiction of when cells enter S phase or G2 after transfection with different siRNAs 
(si-p53, si-p21, si-Control) or unsorted cells that had been treated with DCB. Each 
horizontal line represents a single cell. The total number of cells entering S/G2 
phase for the field of view scored is shown on the right hand side. Cells were 
imaged every 30 minutes after transfection using the Incucyte imaging system. 
Results were obtained by visualising the resulting movies and noting when cells 
start expressing Venus protein. 
 
These results suggest that if a test siRNA has a significant effect it is likely to result 
in a pattern of S/G2 phase entry that is somewhere between the S/G2 phase entry 
patterns obtained from si-p21 and si-p53 cells and control transfected cells. If the 
knockdown of a particular test siRNA was having a substantial effect in a large 
proportion of cells, the cells should enter S/G2 in a more synchronised manner 
compared to control cells (since the cells begin the assay synchronised in G1). 
However, this is unlikely to occur as quickly as it does for p21 and p53 knockdown. 
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A further concern with the original screening set up used was that no test siRNAs 
had an effect because the arrest imposed by the DCB treatment was too harsh, 
and only knockdown of the two most potent cell cycle regulators (p53 and p21) 
could overcome it. This issue was addressed in Figure 6.7, where DCB treated, but 
not sorted, cells were imaged and observed to enter S/G2 after 24 hours. However 
previous studies have indicated that arrest after cytokinesis failure can be 
overcome by changing cell culture conditions and the concentration of the drug 
used to induce the failure (Uetake and Sluder, 2004, Wong and Stearns, 2005, and 
see Section 1.6). Specifically it was shown that the drugs used to induce 
cytokinesis failure were responsible for the damage that resulted in cell cycle arrest 
(Wong and Stearns, 2005), and that reducing the concentrations of those drugs or 
changing the culture conditions by coating the culture surface with Fibronectin 
could abrogate the arrest (Uetake and Sluder, 2004). To address these points in 
the cell line system that was being used for the screen, an experiment was carried 
out to see whether DCB concentration or Fibronectin coating of the plates would 
affect cell cycle arrest. 
 
Cells were treated with three different concentrations of DCB (4, 2 and 0.5µM) and 
either sorted using Hoechst staining for 4N tetraploid cells in G1 (as described in 
Figure 6.3A) or not sorted (therefore containing a mixture of diploid cells in G1 and 
G2, as well as 4N G1 tetraploid cells). Cells were plated into normal uncoated 
plates, or plates coated with Fibronectin. The Incucyte imaging system was used to 
assess when cells entered S/G2, and it was noted whether those cells were 
mononucleated or binucleated using the phase contrast images. The total number 
of cells for each field of view was also noted, and so the number of cycling cells is 
expressed as a percentage in Figure 6.8A and B.  
 
 The addition of Fibronectin did not result in a clear abrogation of the arrest after 
cytokinesis failure in binucleated cells (Figure 6.8B). Although in some conditions it 
did increase the percentage of cycling binucleated cells, this was not consistent 
across all the different combinations (for example there was a decrease in cycling 
cells in the 4µM sorted condition with Fibronectin). Furthermore the increases 
observed in the other conditions were quite modest, and do not indicate that 
Fibronectin can completely rescue cell cycle arrest after cytokinesis failure, as had 
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been previously reported (Uetake and Sluder, 2004). Due to difficulties in 
controlling for the even coating of Fibronectin across multiple plates, and its modest 
effect on the percentage of cycling cells, plates were left uncoated in subsequent 
experiments.  
 
 
Figure 6.8: Effect of DCB concentration and Fibronectin coating on cell cycle 
arrest  
A) Different concentrations of DCB were used to arrest cells. Cells were either 
sorted for only 4N G1 tetraploids, or unsorted, and plated into uncoated plates or 
plates coated with Fibronectin (indicated by the colour of the bars – see key). The 
percentage of mononucleate cells entering S/G2 is shown.  
B) The percentage of binucleated cells entering S/G2 in the same conditions is 
shown. 
 
The different drug concentrations also did not have markedly differing effects in 
terms of their ability to arrest cells. The difference in percentage of cycling 
binucleated cells between 4µM and 2µM DCB was only 2%. Only 0.5µM treated 
cells had a slight increase of 4% compared to 4µM (Figure 6.8B). However, the 
formation of binucleated tetraploid G1 cells was very inefficient when treating with 
0.5µM DCB (as evidenced by the high percentage of mononucleated cycling cells 
in the unsorted condition), and therefore this concentration could not be used in 
subsequent experiments. The differences in cycling mononucleated cells between 
the different drug concentrations in unsorted cells are more likely to reflect the 
differences in number of mononucleated cells after the treatment, as opposed to 
higher concentrations of drug inhibiting cell cycle re-entry (Figure 6.8A). Taken 
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together, these results suggest that lowering the concentration of DCB does not 
completely abrogate the cell cycle arrest. However, in order to mitigate against this 
possibility, 2µM DCB was used for subsequent experiments, as binucleated cells 
still underwent cell cycle arrest with the same efficiency as 4µM treated cells 
(Figure 6.8B).  
6.2.5 Screen repeat using new conditions 
After the above modifications to the screening protocol the screen was repeated. 
Cells were treated with 2µM DCB, and the transfection reagent used was RNAi 
Max instead of Lullaby. In order to be sure that no positive hits were missed due to 
fixation at 96 hours, plates were continuously imaged using the Incucyte system, 
and plates were fixed at intervals throughout the screening. In this screen OTP 
Control siRNAs 1-4 and si-Genome Control-5 were used. In addition, new pooled 
siRNAs were ordered for LATS2, the strongest tetraploid specific hit in the Ganem 
et al., 2014 screen. The results of this screen repeat are shown in Figure 6.9. The 
three plates were fixed at 36, 50 and 74 hours (Figure 6.9A-C). Again, siRNAs are 
ordered from left to right as the number of cycling cells decreased.  
 
At 36 hours the highest number of cycling cells was found in wells transfected with 
si-p21 (Figure 6.9A). Although the Ganem et al., 2014 positive controls were 
towards the left hand side of the graph (more cycling cells), they were not 
significantly higher than the control siRNAs at this time point. At 50 hours the 
highest percentages of cycling cells were found in wells transfected with p53 siRNA 
(Figure 6.9B). These data confirm what was observed using live cell imaging; that 
p21 knockdown induces the most rapid cell cycle re-entry and p53 transfected cells 
are approximately 12 hours delayed compared to si-p21 transfected cells (Figure 
6.7).  
 
In the plate fixed at 50 hours, two of the Ganem et al., 2014 screen hits resulted in 
the highest percentage of cycling cells apart from p53 and p21 knockdown (si-
LATS2 = 5.29% cycling cells, siPTBP1 = 4.47%), along with two siRNAs from the 
gene list. These two genes were KCNA5 (5.05%) and CNGB3 (4.96%). At the final 
time point of 74 hours, three of the Ganem et al., 2014 hits were the next highest in 
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terms of cycling cells after p53 and p21 knockdown (Figure 6.9C). However at this 
time point there was little difference between these siRNAs and other test siRNAs, 
with the graph showing a smooth decrease from left to right. 
 
 
Figure 6.9: Screen repeat with new conditions 
A) The percentage of Venus expressing cells for each siRNA at 36 hours. Control 
siRNAs are shown as green bars, p53 siRNAs as blue bars, p21 siRNAs as red 
bars and the Ganem et al., 2014 screen hits as orange bars. Two novel candidates, 
KCNA5 (purple bars) and CNGB3 (pink bars), are also shown.  
B) As above, for the plate fixed at 50 hours.  
C) Results for the plate fixed at 74 hours. 
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cells are shown in Figure 6.10. It is clear from these images that siRNAs targeting 
KCNA5 and CNGB3 resulted in increases in cycling cells at least as great as the 
best positive controls from the Ganem et al., 2014 screen (LATS2 and PTPB1) 
(Figure 6.10B and C). Although the effects of gene knockdown of KCNA5 and 
CNGB3, as well as the Ganem et al., 2014 positive controls were modest, they all 
resulted in increases in the percentage of cycling cells above background levels. 
This prompted further investigation of these two novel candidates.  
 
 
Figure 6.10: Images from screen repeat with new conditions, fixed at 50 
hours 
A) Representative images from control wells of plate fixed at 50 hours after 
transfection. G1 cells appear as red, and S/G2 cells appear green. The effects of 
using STLC to arrest mitotic cells can be clearly observed in the si-p21 panel, as 
many cells are arrested in mitosis (see Methods). 
B) Images from positive controls taken from the Ganem et al., 2014 screen.  
C) Images from CNGB3 and KCNA5 transfected cells at 50 hours. 
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6.2.6 Deconvolution of screen hits 
Given these intriguing results, it was decided to take KCNA5 and CNGB3 forward 
for deconvolution screening. As the screen was carried out with a pool of 4 
individual siRNAs, it was important to test these siRNAs individually to mitigate 
against off-target effects. Deconvolved siRNAs from these two genes were ordered 
from Dharmacon, and the screen was carried out again, this time fixing plates at 50 
hours and 74 hours. The results of this experiment are shown in Figure 6.11. 
 
 
Figure 6.11: Deconvolution of KCNA5 and CNGB3 
A) Analysis of percentage of Venus positive cycling cells 50 hours after siRNA 
transfection of two potential screen hits. Control siRNAs are shown in green, 
KCNA5 siRNAs in purple, CNGB3 siRNAs in yellow, p53 siRNAs in blue, p21 
siRNAs in red, and LATS2, a positive control from the Ganem et al., 2014 screen, 
in orange. The y-axis is split as p53 results in a much higher percentage of cycling 
cells than the rest of the siRNAs.  
B) As in A, but 74 hours after transfection. The y-axis is split as both p53 and p21 
knockdown results in a much higher percentage of cycling cells than the rest of the 
siRNAs. 
 
At 50 hours after siRNA transfection, the average percentage of cycling cells was 
1.2% (SD 0.7%) for all control siRNAs, including a mock transfected well (Figure 
6.11A). None of the KCNA5 siRNAs, including the pool, raised the percentage of 
cycling cells significantly. The largest increase was noted for KCNA5_siRNA2 that 
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resulted in 1.67% cycling cells. CNGB3 siRNAs resulted in slightly higher 
percentages of cycling cells, with siRNAs 1 and 4 increasing the percentage of 
cycling cells above 2%. LATS2 knockdown resulted in 1.44% of cycling cells. At 74 
hours there was also little increase caused by either KCNA5 or CNGB3 siRNAs 
(Figure 6.11B). The average percentage of cycling cells for all control siRNAs 
(including mock transfected cells) was 1.24% (SD 0.7%). None of the KCNA5 
siRNAs increased the percentage of cycling cells above 2%. Only the CNGB3 pool 
of siRNAs increased the percentage of cycling cells to 2.5%. LATS2 knockdown 
only increased the percentage of cycling cells to 1.7%. In order to make sure the 
knockdown of KCNA5 and CNGB3 was working efficiently in the conditions used, 
the levels of mRNA after transfection with siRNAs against each of these genes was 
assessed using qPCR (Figure 6.12). 
 
 
Figure 6.12: qPCR of mRNA levels after knockdown of target genes 
A) Comparative qPCR of mRNA levels of KCNA5 relative to the housekeeping 
gene β-actin. Average cycle number for mock and control transfected samples: 
34.8.  
B) As in A) but for CNGB3. Average cycle number for mock and control transfected 
samples: 36.2.  
A) KCNA5 relative expression
Mo
ck
siC
on
tro
l-1
siC
on
tro
l-2
siK
CN
A5
-1
siK
CN
A5
-2
siK
CN
A5
-3
siK
CN
A5
-4
0.0
0.5
1.0
FC
 fr
om
 M
oc
k
CNGB3 relative expression
FC
 fr
om
 M
oc
k
Mo
ck
siC
on
tro
l-1
siC
on
tro
l-2
siC
NG
B3
-1
siC
NG
B3
-2
siC
NG
B3
-3
siC
NG
B3
-4
0
2
4
6
8
10
B)
p21 relative expression
Mo
ck
siC
on
tro
l-1
siC
on
tro
l-2
si-
p2
1
0.0
0.5
1.0
FC
 fr
om
 M
oc
k
C)
Chapter 6. Results 
 
 199 
C) Positive control showing relative p21 knockdown in the same experiment. 
Average cycle number for mock and control transfected samples: 19.9. 
 
 
Figure 6.12A shows the relative expression of KCNA5 after knockdown with each 
of the individual siRNAs. Only KCNA5_siRNA2 results in a reduction in mRNA 
levels to less than 50% of the level observed in mock transfected wells. However 
this is the same siRNA that showed the greatest increase in the percentage of 
cycling cells in the deconvolution screen (Figure 6.11). These results suggest that 
KCNA5 could have a role in allowing cell cycle re-entry after cytokinesis failure, 
however the levels of knockdown achieved with the reagents available was likely 
not sufficient to result in large increases in the fraction of cycling cells. Only better 
knockdown conditions could help rule out an effect of KCNA5 on this cell cycle 
checkpoint.  
 
The relative expression of CNGB3 after knockdown of each individual siRNA is 
shown in Figure 6.12B. This shows that no knockdown was achieved with any of 
the siRNAs used against CNGB3. This could be due to the apparently low 
expression of CNGB3 within RPE cells, as the cycle number in qPCR was almost 
37 cycles. This low abundance could mean that the results obtained in Figure 
6.12B represent noise rather than real changes in expression of CNGB3 after 
knockdown. A positive control of p21 expression after knockdown from the same 
experiment is also shown in Figure 6.12C.  
 
In order to investigate the knockdown efficiency of LATS2 siRNAs, the positive 
control identified from the Ganem et al., 2014 screen, the levels of mRNA for this 
gene were also checked after 72 hours of siRNA mediated knockdown.  The results 
of this analysis are shown in Figure 6.13A. Two out of four siRNAs (siRNAs 1 and 
2) for LATS2 gave a fairly efficient knockdown, reducing the levels of mRNA to less 
than 20% of that found in control cells. These are the same two siRNAs reported by 
Ganem et al., 2014 to give the best knockdown in their screening procedure 
(Ganem et al., 2014). The knockdown of two positive controls p21 and p53 was 
also efficient in this experiment (Figure 6.13B).  
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Figure 6.13: mRNA and protein validation of knockdown for LATS2 
A) The expression of LATS2 relative to housekeeping gene β-actin after control 
transfection and transfection of the deconvolved pool of OTP LATS2 oligos. 
Average cycle number of LATS2 in control sample: 22.7.  
B) Expression of two positive controls (relative to housekeeping gene β-actin), p21 
and p53 after knockdown in the same experimental repeat as in A.  
C) Detection of LATS2 protein after knockdown. Actin is used as a loading control. 
D) Repeat of the screening procedure with each individual LATS2 oligo. The 
percentage of Venus positive cycling cells is shown after fixed plate analysis at 96 
hours.  
 
The knockdown efficiency was also examined by assessing LATS2 protein levels 
after 72 hours (Figure 6.13C). The lower band detected by the LATS2 antibody 
mirrors the results of the qPCR, with LATS2 siRNAs 1 and 2 resulting in the best 
knockdown. There is still residual protein visible for LATS2 siRNAs 3 and 4 at the 
level of the lower band. Each deconvoluted siRNA was used in a repeat of the 
original screening procedure as described in Figure 6.3A, but using RNAiMax as 
the transfection reagent. None of the individual LATS2 siRNAs increased the level 
of cycling cells significantly above that of control wells (Figure 6.13D).  
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6.3 Conclusions 
Taken together these results suggest that the results of the screen were likely to 
have been influenced by two main factors. Firstly, the knockdown efficiency of each 
gene tested could not be controlled for within the screen. Although when setting up 
the transfection conditions three different approaches were taken (using LaminA/C, 
p53 and p21 knockdown followed by indirect immuno-fluorescence), the 
knockdown efficiency, even of control genes, could not be tested in every 
subsequent plate replicate. Furthermore, the knockdown of p53 and p21 is likely to 
be very efficient, as these genes are commonly targeted using siRNA, and 
therefore the siRNA sequences are being frequently modified and improved. 
Furthermore, both these proteins are turned over at a high rate, so knockdown 
using siRNA has a rapid effect. The results from the transfection efficiency test 
using these genes could therefore have given ‘false positive’ results. The 
knockdown efficiency of other genes, for example KCNA5, was not as efficient 
using the same transfection conditions (Figure 6.12). Secondly, the expression of 
some of the test genes in RPE cells might be low, and therefore knockdown is 
unlikely have a reproducible effect. This is possibly the case for both CNGB3 and 
KCNA5 (Figure 6.12).  
 
Although the knockdown efficiency appeared good for two out of four siRNAs 
targeting LATS2, as well as the pool, this level of knockdown was not sufficient to 
elicit an effect on cell cycle re-entry after cytokinesis failure (Figure 6.13A and D). 
Even in three replicate plates, only one plate showed a significant difference in 
percentage of cycling cells after LATS2 knockdown and the other two plates did not 
(screen 2, Figure 6.5). This could suggest that LATS2 is a difficult gene to knock 
down consistently. However, both mRNA and protein levels suggested a 
reasonable level of knockdown with the reagents used in the screen, and although 
the knockdown could not be directly tested within the screen format, these results 
suggest that LATS2 is not a potent regulator of cell cycle arrest after cytokinesis 
failure. 
 
Technically, the set up and screening procedure worked well. This is evidenced by 
the fact that knockdown of the positive controls p53 and p21 consistently resulted 
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in high numbers of cycling cells. As the initial screen, following the protocol as 
published in Ganem et al., 2014, did not result in any positive hits, the screen was 
modified in a logical fashion, following reports in previous papers regarding the use 
of cytokinesis inhibitors to arrest cells (Uetake and Sluder, 2004, Wong and 
Stearns, 2005). Only two weak positive hits were identified using the modified 
screening protocol, KCNA5 and CNGB3. CNGB3 is an ion channel gene, encoding 
cyclic nucleotide gated channel beta 3. This gene was included in the screen as it 
is significantly mutated in GD lung adenocarcinoma, and overlapped with an 
extended list of genes identified in a screen for segregation error tolerance (Table 
6.1). However, the knockdown of CNGB3 using deconvoluted siRNAs could not be 
validated, possibly due to low expression of CNGB3 in RPE cells.  
 
KCNA5 encodes a potassium channel subunit (potassium channel, voltage gated 
shaker related subfamily member 5, Kv1.5). KCNA5 was included in the screen as 
it is significantly mutated in GD colon adenocarcinoma (Table 6.1). Intriguingly, the 
altered expression of potassium channels has been linked to various hallmarks of 
carcinogenesis, including increased proliferation and resistance to cell death 
(Huang and Jan, 2014). A recent study showed that KCNA5 expression was 
repressed in aggressive cancer cells due to polycomb protein epigenetic repression 
(Ryland et al., 2014). The repression of KCNA5 allowed cancer cells to survive 
under hypoxic stress conditions. These results implicate the Kv1.5 potassium 
channel as a mediator of apoptosis under hypoxic stress conditions (Ryland et al., 
2014). The knockdown of KCNA5 using the available OTP siRNAs in the screen 
was potentially not sufficient to result in completely non-functional potassium 
channels. However, the deconvolved siRNAs that resulted in the best knockdown 
of the gene at the mRNA level also resulted in the greatest number of cycling cells 
after DCB treatment (Figure 6.11, Figure 6.12). Given the link between KCNA5 loss 
of expression and cancer cell survival under stressful conditions, it would be of 
interest to use different methods to impair potassium channel functionality (Ryland 
et al., 2014). This could include testing the efficacy of Kv1.5 specific inhibitors such 
as DPO-1 (diphenyl phosphine oxide-1) and 4’AP (4’aminopyridine) in allowing 
cells to start cycling after DCB treatment (Stump et al., 2005, Fedida et al., 1996).  
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In conclusion, from a gene list selected from tumour relevant mutations, no genes 
were found to have a significant or reproducible effect on cell cycle re-entry after 
cytokinesis failure. Despite this, the list of genes may still be relevant to the 
evolution of GD tumours. It may be that mutation of these genes occurs after 
genome duplication, rather than as a tolerance mechanism for the initial 
tetraploidisation event. Alternatively these gene mutations could be beneficial for 
the proliferation of tetraploid cells. Interestingly the list of gene mutations that were 
screened had a strong bias towards genes that were annotated as integral to 
membrane function or to the extracellular matrix. This is shown in Table 6.2, where 
the entire list of genes screened was subject to gene-set enrichment analysis 
(GSEA), using a publically available web-based tool from the Broad Institute 
(Subramanian et al., 2005, Mootha et al., 2003). This could indicate a deregulation 
of normal membrane function in genome-doubled tumours. It would be interesting 
to investigate this potential link further.   
 
Table 6.2: GSEA of selected gene list 
Gene Set Name GO Term 
# 
G
en
es
 in
 G
en
e 
S
et
 (K
) 
# 
G
en
es
 in
 
O
ve
rla
p 
(k
) 
k/K p-value 
PLASMA_MEMBRANE_PART GO:0044459 1158 14 0.0121 3.57E-09 
PLASMA_MEMBRANE GO:0005886 1426 15 0.0105 5.95E-09 
MEMBRANE_PART GO:0044425 1670 16 0.0096 6.41E-09 
MEMBRANE GO:0016020 1994 17 0.0085 1.12E-08 
PROTEINACEOUS_EXTRACELLULAR_MATRIX GO:0005578 98 6 0.0612 1.22E-08 
EXTRACELLULAR_MATRIX GO:0031012 100 6 0.06 1.38E-08 
INTEGRAL_TO_MEMBRANE GO:0016021 1330 14 0.0105 2.03E-08 
INTRINSIC_TO_MEMBRANE GO:0031224 1348 14 0.0104 2.40E-08 
EXTRACELLULAR_MATRIX_PART GO:0044420 57 5 0.0877 3.45E-08 
INTEGRAL_TO_PLASMA_MEMBRANE GO:0005887 977 12 0.0123 4.46E-08 
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Chapter 7. Discussion 
Tetraploid cells have long been observed in pre-malignant conditions such as 
Barrett’s oesophagus, and the theory that tetraploidy could result in the aneuploidy 
that is a hallmark of cancer has persisted for decades (Shackney et al., 1989, 
Galipeau et al., 1996). A landmark study by the Pellman laboratory was the first to 
show that experimental tetraploidisation could directly lead to tumourigenesis 
(Fujiwara et al., 2005). However, it is only over the last three years that the 
prevalence of tetraploidisation events across the majority of solid tumour types has 
begun to be appreciated (Carter et al., 2012, Zack et al., 2013). It appears that 
whole genome duplications can occur at many different points in a tumour’s 
evolutionary history, and the relevance of these whole genome duplications are 
now the subject of intense study from many different laboratories. This thesis has 
contributed to the understanding of the consequences of tetraploidisation by 
demonstrating that tetraploid cells are able to propagate CIN and contribute to on-
going tumour evolution. As such, it is likely that tetraploidy influences the 
development of intra-tumour heterogeneity, one of the major challenges facing 
cancer medicine.  
 
7.1 Tetraploid cells exhibit chromosomal instability 
In this thesis an isogenic system of diploid and tetraploid clones derived from the 
microsatellite unstable cell line HCT-116 has been used to investigate the effect of 
genome duplication on chromosomal stability over time. All tetraploid clones 
showed consistently increased levels of both numerical and structural chromosome 
aberrations compared to diploid clones over 18 months of continuous culture. 
Analysis of genomic copy number changes over time in diploid and tetraploid 
clones revealed that tetraploid cells developed high levels of instability, comparable 
to that which is observed in CIN+ CRC.  
 
These results support previous studies that have shown that genomic instability 
emerges after experimentally induced tetraploidisation (Fujiwara et al., 2005, Davoli 
and de Lange, 2012). In contrast to these studies, the tetraploid cells examined in 
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this thesis were naturally occurring, and therefore the increased chromosomal 
instability is unlikely to have been caused by the experimental procedure used to 
generate tetraploid clones. Indeed, it has been shown that using cytochalasins to 
induce cytokinesis failure can result in DNA damage (Wong and Stearns, 2005). 
Although the mechanism by which the tetraploid cells arise in HCT-116 was not 
investigated, it is likely that tetraploid cells arise stochastically and at a low 
frequency in many tumour cell populations. Understanding the consequences of 
naturally occurring tetraploidisation events for genomic stability within a tumour cell 
population was one of the principal aims of this thesis.  
  
The level of both segregation errors and structural aberrations was calculated on a 
per cell and per chromosome basis. This analysis has shown that tetraploidy does 
not initiate an increase in chromosomal instability above that which would be 
expected given the increased number of chromosomes in this cell line. The study 
by Fujiwara and colleagues shows a similar result using tetraploid MMECs, as 
diploid MMECs also had high levels of aneuploidy and translocations that 
increased over time, but the level of these aberrations was always higher in 
tetraploid MMECs (Fujiwara et al., 2005). Given that HCT-116 cells show evidence 
of segregation errors and structurally abnormal chromosomes, neither this nor the 
study by Fujiwara and colleagues directly addresses whether tetraploidy can 
induce CIN in a stable cell line (Fujiwara et al., 2005). It would be of great interest 
to extend this study to stable diploid cell lines in which the driving mechanisms of 
CIN were not already present. However this presents difficulties, as stable diploid 
cell lines are unlikely to contain naturally occurring tetraploid cells. A recently 
published study has used the approach of inducing cytokinesis failure to study the 
effects of tetraploidisation on a stable diploid cell line. Kuznetsova and colleagues 
treated the stable diploid cell line RPE-1 with cytochalasin D, and isolated rare 
clones that were tetraploid after this treatment (Kuznetsova et al., 2015). One out of 
three RPE-1 tetraploid clones showed an increase in segregation errors, 
suggesting that tetraploidy can also result in chromosomal instability in non-
transformed diploid cells, albeit with lower frequency than in diploid cancer cells 
(Kuznetsova et al., 2015).  
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The frequency of different types of chromosome missegregation events was also 
compared between diploid and tetraploid cells. This analysis showed that there was 
no difference in the frequency of errors thought to arise through either mitotic 
(lagging centric chromosomes) or pre-mitotic (chromosome bridges and acentric 
chromosome fragments) mechanisms. This suggests that, in this system of diploid 
and tetraploid clones, there is not a tetraploid-specific mechanism that results in an 
increase in any one type of segregation error. The same result was obtained by 
Kuznetsova and colleagues in their analysis of segregation error profiles of 
tetraploid clones derived from cytochalasin D treatment of HCT-116 cells 
(Kuznetsova et al., 2015). However, the authors did find that the frequency of 
segregation errors in tetraploid HCT-116 clones was increased above the increase 
in chromosome number observed in tetraploid clones. This is in contrast to work 
presented in this thesis that shows that segregation error frequency in HCT-116 
tetraploid clones is likely to be a consequence of the total increase in number of 
chromosomes. Interestingly the frequency of mitotic errors reported in parental 
HCT-116 cells in the above study is significantly lower than that reported in this 
thesis, as well as in other studies (Janssen et al., 2009, Bakhoum et al., 2014, 
Thompson and Compton, 2008). This potentially illustrates different sub-clones of 
HCT-116 that are used by different laboratories, as well as different scoring bias. 
Furthermore, the percentage of anaphases in cytochalasin D derived tetraploid 
cells displaying segregation errors is significantly lower than was observed in 
naturally occurring HCT-116 tetraploid cells. These differing results could suggest 
that different mechanisms of forming tetraploid cells result in different levels of 
chromosomal instability.  
 
All tetraploid clones were found to have supernumerary centrosomes, the number 
of which was rather heterogeneous both within and between clones. Despite the 
increase in centrosomes no increase in lagging centric chromosomes was 
observed in tetraploid clones. This is in contrast to previous studies that have 
shown that extra centrosomes can cause chromosome segregation errors through 
the promotion of improper kinetochore-microtubule attachments (Ganem et al., 
2009, Silkworth et al., 2009). As the parental cell line, HCT-116, also contains a 
relatively high frequency of cells with supernumerary centrosomes, it is likely that 
efficient mechanisms for clustering extra centrosomes already exist in this cell line, 
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and hence its tetraploid derivatives. The number of centrosomes were analysed at 
both early and late passage (after a year of continuous culture), and no difference 
in the frequency of supernumerary centrioles was observed in tetraploid cells over 
time. This further supports the assertion that supernumerary centrioles are not 
detrimental to tetraploid clones, as otherwise a selection for cells with lower 
numbers of centrioles would have been expected to occur over the culture period. 
Many cancer cells exhibit supernumerary centrioles (Nigg, 2002, Lingle et al., 1998, 
Pihan et al., 1998). However, whether the presence of extra centrioles always 
causes increases in chromosome missegregation in tumours is not yet known, 
although centriole number has been shown to correlate with CIN in cell lines and 
human tumours (Kramer et al., 2003, Koutsami et al., 2006, Levine et al., 1991, 
Pihan et al., 2001, Ghadimi et al., 2000). This study has shown that the presence of 
extra centrioles is not always linked to an increase in segregation errors. The ability 
of cells to efficiently cluster extra centrosomes without an increase in segregation 
errors may be required in MIN cell lines such as HCT-116, to restrain the amount of 
genetic instability. Indeed, it has been shown that increasing the number of 
centrioles in HCT-116 will only cause an increase in CIN when coupled with 
deregulation of the key mitotic kinase Aurora A (Lentini et al., 2007). Further, MIN 
diploid CRC tumours tend to have fewer supernumerary centrosomes than CIN+ 
CRC (Pihan et al., 2001, Ghadimi et al., 2000), suggesting that there may be 
selection against centrosome amplification in MIN tumours. The study by 
Kuznetsova and colleagues also showed that the number of centrosomes does not 
directly influence the level of chromosome missegregation, as two tetraploid RPE-1 
clones had similar numbers of extra centrosomes, but only one clone displayed an 
increase in segregation errors (Kuznetsova et al., 2015). These intriguing data 
support the observations made in this thesis, and suggest that segregation errors 
are not an obligatory consequence of supernumerary centrosomes.   
 
7.2 Tetraploid cells tolerate chromosome missegregation 
Clonal FISH assays and live cell imaging using H2B-mRFP expressing cells have 
shown that HCT-116 tetraploid cells are better able to survive after segregation 
errors than diploid cells. This result sheds light on the frequent observation of 
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aneuploidy arising as a consequence of tetraploidisation in tumours as well as in 
vitro studies (Galipeau et al., 1996, Olaharski, Lv et al., 2012, Fujiwara et al., 2005, 
Davoli and de Lange, 2012). This result has recently been confirmed by 
Kuznetsova and colleagues, who also showed that tetraploid clones, derived from 
cytochalasin D treated HCT-116 cells also less frequently died or underwent cell 
cycle arrest after segregation errors than diploid cells (Kuznetsova et al., 2015).  
 
Attempts to find a mutational mechanism for this segregation error tolerance did not 
reveal any mutations common to all tetraploid clones. It is possible that different 
mutational mechanisms for tolerating chromosome missegregation are present in 
different tetraploid clones. Using a cell line that was microsatellite unstable also 
complicated this analysis, as HCT-116 cells acquire mutations at a high frequency. 
Therefore many mutations that were identified are unlikely to have been positively 
selected for, but rather occurred by chance. It would be of great interest to repeat 
this sequencing analysis in tetraploid clones derived from a microsatellite stable 
diploid cell line. Future work will focus on profiling tetraploid cells derived from the 
microsatellite stable diploid colon cancer cell line C-99.  
 
No mutations were found in either p53 or p21, which would be expected to allow 
tolerance to chromosome missegregation (Thompson and Compton, 2010, Li et al., 
2010, Kumari et al., 2014). Surprisingly, no altered expression of p53, or p53 target 
genes was identified in tetraploid clones. This is in contrast to Kroemer and 
colleagues, who profiled expression differences between HCT-116 and RKO 
clones, and reported a slight de-regulation of the p53 pathway in tetraploid cells, as 
41% of the genes that showed altered expression in tetraploids contained a p53 
consensus binding site (Castedo et al., 2006). Similarly, HCT-116 and RPE-1 
tetraploids were shown to have deregulation of 23% of 388 genes annotated as 
p53 interactors (Kuznetsova et al., 2015). These differing results suggest that 
deregulated expression of multiple p53 pathway genes may not be an obligatory 
consequence of tetraploidisation. It would be interesting to expand this to include a 
proteomics analysis of a panel of diploid and tetraploid cell lines, as regulation of 
different genes can be at the protein rather than the mRNA level.   
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Interestingly it has been shown that p53 is necessary for the clustering of extra 
centrosomes via its interaction with Aurora A (Nam and van Deursen, 2014, Vitale 
et al., 2010b, Wu et al., 2012a). It is possible that p53 mutations in these HCT-116 
tetraploid cells are negatively selected as they could lead to an increase in the 
frequency of multipolar spindles and chromosome missegregation due to the 
increased numbers of centrioles in tetraploid cells. This could result in tetraploid 
cells passing the threshold for viable levels of chromosomal instability.  
 
A plausible explanation for the increased tolerance to chromosome missegregation 
in tetraploid cells is that with a doubled genome the gain or loss of genetic material 
does not result in the same genetic imbalances as in diploid cells, and hence in the 
same cellular consequences. Aneuploidy, arising from imbalances in single 
chromosomes has been shown to lead to conserved transcriptional responses 
across different organisms (Donnelly and Storchova, 2014). It is possible that on a 
tetraploid background single chromosome aneuploidy will not cause a stress 
response, as there would still be one homologous chromosome remaining. In 
support of this theory, late passage tetraploid cells, which display distinct 
aneuploidy, did not show significant expression differences compared to diploid 
clones. Furthermore, the majority of the chromosome losses that developed in 
tetraploid clones were losses to three gene copies, rather than complete loss or 
loss to two gene copies that would result in loss of heterozygosity. This mirrors the 
genomic landscape of CRC, as the majority of GD tumours have a triploid 
karyotype. It has recently been shown that polyploidy can foster rapid adaptation in 
yeast (Selmecki et al., 2015). Polyploid yeast evolved quicker in response to a poor 
carbon source environment, and part of their adaptation involved increased 
frequencies of whole chromosome aneuploidy (Selmecki et al., 2015). Diploid and 
haploid yeast under the same conditions did not evolve whole chromosome 
aneuploidy, supporting the idea that polyploidy might be a permissive state for the 
acquisition of unbalanced karyotypes (Selmecki et al., 2015, Dewhurst et al., 2014). 
It is challenging to design experiments that could either prove or disprove the 
theory of buffering as a mechanism of segregation error tolerance in tetraploid cells. 
In transformed cell lines this is particularly difficult, as there are many pre-existing 
genetic aberrations that could alter the cellular response to a segregation error. It 
would be of great interest to know whether the non-transformed RPE-1 tetraploid 
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clones derived by Kuznetsova and colleagues also showed tolerance to 
segregation errors (Kuznetsova et al., 2015). Since RPE-1 cells make a low 
frequency of endogenous segregation errors, this could be achieved by 
experimentally inducing segregation errors and tracking cell fate.  
 
It would also be of interest to explore whether tetraploid cells tolerate chromosome 
missegregation because of a difference in the molecular response to segregation 
errors compared to diploid cells. It is known that chromosome missegregation up-
regulates p53, although the mechanism causing this up-regulation remains elusive 
(Thompson and Compton, 2010). This continues to be an active and important area 
of research. Live-cell imaging followed by immunofluorescence, or live cell imaging 
with a p53 or p21 reporter could shed light on whether tetraploid cells have 
dampened the response to segregation errors, and this is the mechanism by which 
they are able to continue proliferating. Preliminary experiments carried out by a 
colleague, Andrew Crockford and not presented in this thesis, would suggest that 
this is not the case, as tetraploid cells up-regulate p53 to the same extent as diploid 
cells in response to segregation errors induced with the Mps1 inhibitor reversine. 
However the response to endogenous segregation errors has not been profiled. 
This is a crucial area for future experiments.  
 
7.3 Genome doubling predicts worse patient prognosis 
The use of algorithms that can identify genome duplication in tumours from copy 
number data has shown that the majority of solid tumour types can be subject to 
genome duplications during their evolution (Carter et al., 2012, Zack et al., 2013). 
In this thesis the identification of genome duplication events in two different CRC 
cohorts was found to predict poor relapse free survival. The in vitro analysis of 
genomic instability arising after genome duplication presented herein is likely to 
explain the association of genome doubling with poor patient prognosis. This is 
likely because increased levels of chromosomal instability are associated with poor 
patient prognosis, and resistance to different drugs (McGranahan et al., 2012, Lee 
et al., 2011). However, tetraploid clones derived from HCT-116, even at late 
passage when they showed evidence of chromosomal instability, did not show 
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evidence of increased drug resistance. As discussed, this may be a caveat of using 
a cell line that already displays microsatellite instability. Alternatively, longer-term 
assays should be used to explore whether the cell-to-cell heterogeneity present in 
tetraploid clones leads to drug resistance over long periods of selective pressure 
rather than short-term assays. The ability of the GD algorithm to predict patient 
survival was most striking in the validation cohort of 239 patients, where GD also 
predicted uncensored relapse free survival and survival when only considering 
diploid GD tumours. These results are in accordance with those of Carter and 
colleagues, who demonstrated genome doubling to be predictive of poor survival in 
ovarian cancer (Carter et al., 2012), and also of the association in multiple studies 
of aneuploidy and poor patient prognosis (Araujo et al., 2007).  
 
Further work still needs to be undertaken to ascertain whether genome doubling is 
a better prognostic marker than other pathological tumour characteristics, such as 
immune cell infiltrate, that could not be analysed in this thesis due to limitations in 
the completeness of clinical data available in both cohorts. It would be of interest to 
investigate the utility of genome doubling as a prognostic marker across different 
cancer types, as it has been shown to be a common occurrence in most solid 
tumours, albeit to different degrees (Zack et al., 2013). The differing prevalence of 
genome doubling between different cancer types could shed light on the 
environmental conditions in which genome doubling is beneficial for tumours, or the 
most likely route of whole genome duplication. It would also be of interest to dissect 
further the timing of genome doubling in different cancer types, especially pre- and 
post-therapy.  
 
7.4 Genes selectively mutated in GD tumours do not contribute 
to the response to cytokinesis failure 
A focussed approach for selecting genes that are more frequently mutated in 
genome doubled tumours was employed to create a shortlist of genes to screen for 
their potential involvement in allowing tetraploid cells to re-enter the cell cycle. 
Despite extensive optimisation and modification of a published screening protocol 
for genes which, when knocked down, allow cells to start cycling after cytokinesis 
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failure (Ganem et al., 2014), no novel gene was found to have a strong effect on 
this cell cycle checkpoint.  
 
This could in part be due to technical limitations of the approach taken. Although 
the level of gene knockdown was optimised for specific genes, the efficacy of the 
knockdown of each different gene tested in the screen could not be validated. If the 
assumption is made that the reagents provided by Dharmacon are effective in 
knocking down the intended target, then it must be concluded that none of the 
genes tested in the screen have a strong effect on the tetraploidy checkpoint. This 
is even true of siRNAs against LATS2, which did result in gene knockdown at the 
mRNA and protein level, but which did not greatly influence the proportion of 
tetraploid cells re-entering the cell cycle.  
 
An important factor to consider is whether any of the genes tested would be 
expected to be as efficient as knockdown of either p53 or p21. Since p53 and p21 
are master regulators of this checkpoint, whose knockdown was shown to rapidly 
allow cells to re-enter the cell cycle (within 12 hours for si-p21 treated cells), it 
seems unlikely that any other gene would have an effect as striking as these two 
genes. Surprisingly Ganem and colleagues report that the knockdown of SPINT2 
and PTPB1 resulted in greater percentages of cycling cells than p21 knockdown 
(Ganem et al., 2014). The strong effects of knockdown of these two genes could 
not be replicated in this study. The use of p53 and p21 as positive controls in the 
screen may have masked any other novel hits. For example KCNA5, which did 
increase the percentages of cycling cells during some experiments, was not a 
significant hit when compared to either p53 or p21. It is possible that some of the 
genes included in the screen do play a minor role in cell cycle arrest after 
cytokinesis failure, but the striking effects of p53 and p21 knockdown eclipse these. 
In future experiments, chemical inhibition of the potassium channel that KCNA5 is 
part of will be used to either confirm or exclude a role of KCNA5 in regulating cell 
cycle arrest after cytokinesis failure.  
 
Furthermore, whether this screen has relevance for the cancer scenario that exists 
when genome duplication occurs should also be considered. Although genome 
doubling has been shown to occur as a relatively early event in colorectal cancer, 
Chapter 7. Discussion 
 
 214 
at this stage it is likely that several oncogenic mutations already exist, and cells are 
somewhat transformed. The existence of a tetraploidy checkpoint in transformed 
cells is debateable (Andreassen et al., 2001, Uetake and Sluder, 2004, Wong and 
Stearns, 2005). In this thesis, genes were selected for the screen based on their 
association with genome-doubled tumours in vivo. It is possible that these genes 
do provide a specific benefit for genome-doubled tumours, but this benefit may not 
be in altering the cell cycle response to the initial tetraploidisation event. It would be 
of interest to test the function of these genes in different assays that could mimic 
the tumour cell environment. In this regard, it is interesting that the final list of 
genes that were screened had strong gene set enrichment analysis (GSEA) 
associations with many terms that were related to membrane function and 
extracellular matrix function. This could indicate the genome-doubled tumours have 
a requirement, or selective pressure to de-regulate key membrane and/or 
extracellular matrix functions. It would be interesting to test the function of 
knockdown of the gene list in three-dimensional (3D) environments that more 
closely imitate the tumour microenvironment. This could be achieved by modelling 
the growth rate of spheroids formed from diploid and tetraploid cells after gene 
knockdown, to assess whether any of the genes normally restrain growth in a 3D 
environment specifically in polyploid cells.  
 
Finally, the gene list that was screened was created from a pan-cancer analysis of 
mutations. It is possible that each cancer type has specific and differing 
requirements for cells to tolerate whole genome duplications. Repeating the screen 
in different cell lines in a tissue-specific matter could help address this question.  
 
7.5 The role of tetraploidy in cancer evolution 
In this thesis the tetraploidisation of a chromosomally stable diploid cell line has 
been shown to result in rapid genomic evolution. All tetraploid clones examined, 
even those derived from a microsatellite stable clone of HCT-116, displayed a 
similar loss of chromosome 4q. Chromosome 4q loss was also shown to occur in 
more genomically unstable colorectal cancers. This striking example of parallel 
evolution suggests that chromosome 4q loss is associated with chromosomal 
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instability. Whether the loss of chromosome 4q has a functional impact on the 
acquisition of chromosomal instability, or whether 4q loss is a consequence of 
chromosomal instability remains unknown. However, in the system of diploid and 
tetraploid clones analysed in this study, it seems unlikely that the loss of 
chromosome 4q has a functional impact on the ability of tetraploid cells to tolerate 
chromosome missegregation. This is because chromosome 4q is subject to copy 
number loss at late passage (after passage 25 in most clones), and tetraploid cells 
could already propagate aneuploidy before this time point. This suggests that 
chromosome 4q may be intrinsically easier to lose than other chromosomes, 
possibly due to the presence of particular fragile sites that make it prone to DNA 
damage and structural re-arrangements. Alternatively loss of the genes on 
chromosome 4q does not have a detrimental effect on cellular fitness, or may even 
be advantageous. The loss of chromosome 4q has been shown to be predictive of 
worse patient outcome in CRC (Brosens et al., 2011). This association could be 
due to the frequency of chromosome 4q loss in CIN+ CRCs, thus identifying 
patients with more unstable cancers. Taken together, the results in this thesis have 
shown that tetraploidisation can lead to the emergence of high-risk karyotypic 
alterations in CRC. 
 
This study, as well as others, has shown that genomic instability seems to be an 
inherent consequence of tetraploidisation. An important question then arises of 
which phenotype is actually being subject to selection. Is tetraploidy so common in 
cancer merely because it provides a platform for genomic instability?  
 
To answer this question, it will be important to understand whether tetraploidy 
results in additional benefits for cancer cells aside from an increase in genomic 
instability. Although no inherent drug resistance as a result of tetraploidisation was 
observed in this study, others have shown that tetraploid cells are more resistant to 
some drugs (Castedo et al., 2006, Kuznetsova et al., 2015). This may be a 
phenotypic consequence of tetraploidisation that is not related to the CIN+ 
phenotype of tetraploid cells, since RPE-1 tetraploid cells did not all display CIN, 
but were all generally more resistant to a small selection of drugs than RPE-1 
parental cells (Kuznetsova et al., 2015). The observation that many normal 
mammalian tissues undergo polyploidisation when subject to stress also suggests 
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that tetraploidy can result in other cellular consequences apart from increasing 
genomic instability. Although the result of tetraploidisation under these 
circumstances is not fully understood, it has been suggested that tetraploidisation 
could result in more efficient use of energy (Lee et al., 2009). It would be interesting 
to explore metabolic differences between diploid and tetraploid cancer cells to 
understand whether tetraploidy affects energy utilisation.  
 
Polyploidy has played a role in the evolution of many species (Otto and Whitton, 
2000). It has been suggested that polyploids have an inherent advantage over 
diploids due to their ability to mask deleterious mutations (by virtue of having one 
intact gene copy still present). Indeed it has been shown that an increased 
mutation rate, coupled with a doubled genome in yeast can enhance adaptation to 
novel environments (Thompson et al., 2006). However recessive mutations will be 
slower to benefit a polyploid compared to a diploid organism, which could provide a 
selective pressure to reduce genome size after polyploidisation. This could explain 
the high prevalence of triploid karyotypes in CRC. Other work from this laboratory 
has indicated that polyploidy could act as a buffer to protect against deleterious 
mutations. In a multi-region sequencing analysis of a renal cell carcinoma, one 
tetraploid region had a lower ratio of synonymous to non-synonymous mutations 
than other diploid regions, which could indicate that non-synonymous mutations are 
buffered against in polyploid cells (Gerlinger et al., 2012). On-going efforts within 
this laboratory to carry out multi-region sequencing on different cancer types will 
hopefully be able to shed light on whether polyploid tumour regions consistently 
have a reduction in the ratio of synonymous to non-synonymous mutations.  
 
In this study, naturally occurring tetraploid cells were found in the diploid MIN cell 
lines HCT-116 and RKO. Tetraploid sub-fractions were also found in the 
microsatellite stable cell line C-99, as well as in UO31, a renal cell carcinoma cell 
line (data not shown). The fact that tetraploid cells seem to be generated with high 
frequency in diploid cell lines, as well as the fact that a myriad of genetic defects 
have been shown to lead to tetraploidisation (see Introduction, Section 1.5) 
suggests that tetraploidisation will be a common event in tumours. However, it is 
not known which conditions favour the expansion of a tetraploid cell population. 
Future work will focus on uncovering environmental conditions that favour the 
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growth of tetraploid compared to diploid cells to understand when tetraploid cells 
become most relevant for tumour evolution. This work could also shed light on 
whether tetraploidy results in additional benefits to tumours other than increasing 
levels of genomic instability, which could lead to novel therapeutic strategies to 
target tetraploid cells.  
 
7.6 Conclusion 
It is clear from the work presented in this thesis that tetraploidy can lead to genomic 
instability and foster the evolution of unstable cancer genomes. In the absence of 
any mechanistic basis for the chromosome segregation error tolerance observed in 
tetraploid cells, the conclusion that tetraploid cells buffer chromosome changes by 
virtue of their doubled genetic content is favoured. This CIN tolerance phenotype in 
tetraploid cells meant that over 18 months in culture, tetraploid clones derived from 
HCT-116 cells began to resemble highly unstable CRC tumours. Likely due to the 
emergence of CIN in genome-doubled cells, observing genome doubling in two 
independent cohorts of CRC patients predicted poorer relapse free survival. 
Tetraploidy is likely to play a significant role in shaping the on-going evolution of 
cancers, and will likely contribute to the intra-tumour heterogeneity that has been 
observed in many cancer types. It will be of great clinical interest to develop novel 
ways to target tetraploid cancer cells in order to limit their contribution to genetic 
instability, evolution and adaptation in human tumours.  
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Chapter 8. Appendix 
8.1 List of papers and reviews published during the production 
of this thesis 
 
Primary research articles: 
 
Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability 
and Accelerates Cancer Genome Evolution. Sally M. Dewhurst*, Nicholas 
McGranahan*, Rebecca A. Burrell, Andrew J. Rowan, Eva Gronroos, David 
Endesfelder, Tejal Joshi, Dmitri Mouradov, Peter Gibbs, Robyn L. Ward, Nicholas J. 
Hawkins, Zoltan Szallasi, Oliver M. Sieber and Charles Swanton. Cancer Discovery, 
4(2): 175-185 (2014). 
(Also included as a supplement at the back of this thesis). 
 
Replication Stress Links Structural and Numerical Cancer Chromosomal 
Instability. Rebecca A. Burrell*, Sarah E. McClelland*, David Endesfelder, Petra 
Groth, Marie-Christine Weller, Nadeem Shaikh, Enric Domingo, Nnennaya Kanu, 
Sally M. Dewhurst, Eva Gronroos, Su Kit Chew, Andrew J. Rowan, Arne Schenk, 
Michal Sheffer, Michael Howell, Maik Kschischo, Axel Behrens, Thomas Helleday, 
Jiri Bartek, Ian P. Tomlinson and Charles Swanton. Nature 494:492-496 (2013).  
 
Reviews: 
 
Cancer: Evolution within a lifetime. Marco Gerlinger*, Nicholas McGranahan*, 
Sally M. Dewhurst*, Rebecca A. Burrell, Ian P. Tomlinson and Charles Swanton. 
Annual Review of Genetics 48: 215-36 (2014). 
 
* denotes shared first authorship 
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8.2 Full list of siRNA sequences used in screen for regulators 
of cell cycle arrest after cytokinesis failure 
 
Well 
Duplex 
Catalogue 
Number 
Gene 
Symbol Sequence 
A01 J-003296-23 RB1 GAACAGGAGUGCACGGAUA 
A01 J-003296-24 RB1 GGUUCAACUACGCGUGUAA 
A01 J-003296-25 RB1 CAUUAAUGGUUCACCUCGA 
A01 J-003296-26 RB1 CAACCCAGCAGUUCGAUAU 
A02 J-009296-05 DNAH5 UAAAGGAACCUACGGACUA 
A02 J-009296-06 DNAH5 GGACAUCACUGAAUAUUGA 
A02 J-009296-07 DNAH5 GAAACUAAAUCGUCCAAUU 
A02 J-009296-08 DNAH5 GGGCAAGGCUGUGCUAUUA 
A03 J-006161-06 CNGB3 GCAAAUAGGAUGUUAAAGU 
A03 J-006161-07 CNGB3 GUACUAAAGUUCUGGUUAC 
A03 J-006161-08 CNGB3 CUAUUUGCCUGGUGACUUU 
A03 J-006161-09 CNGB3 UCGAACAACUGGAUACUUG 
A04 J-020017-05 LILRB2 CGAUAUGGCUGUCAGUAUU 
A04 J-020017-06 LILRB2 UGACAGGAGCCUACCCAAA 
A04 J-020017-07 LILRB2 GCAGACUCCACACUCAGUA 
A04 J-020017-08 LILRB2 CGAAAUAACUAAUAUCCCU 
A05 J-011941-17 NRXN1 GGGUAUGGUCGUUGGGAUA 
A05 J-011941-18 NRXN1 GCUCAUACCAUGUGGACGA 
A05 J-011941-19 NRXN1 GGCCAGUGAUCGAGCGCUA 
A05 J-011941-20 NRXN1 CCAUUAUGUGGGCAGGUUA 
A06 J-015720-05 RGS7 GAAGGAACCUGGACGAUAC 
A06 J-015720-06 RGS7 UUAGAUAGACAUCGGUUAA 
A06 J-015720-07 RGS7 GACUGGAGCUCGCAGACUA 
A06 J-015720-08 RGS7 ACACAGAUUAUGCCGUUUA 
A07 J-007033-06 SALL4 GAACCAACACAUCCAUUAA 
A07 J-007033-07 SALL4 CCACCUCCGUUGUGAAUAA 
A07 J-007033-08 SALL4 CAAGAUUGCGGUCAGCUAA 
A07 J-007033-09 SALL4 GAACCGAGUCUUUCUUUAG 
A08 J-012405-05 ZFPM2 CAGCUUUGGUGUACAACUA 
A08 J-012405-06 ZFPM2 GAUACAGCCUACAACAAAU 
A08 J-012405-07 ZFPM2 GAUGGCAGCAGAUGGCUAA 
A08 J-012405-08 ZFPM2 CAAGCUGCCUUCCGAUGUA 
A09 J-019511-17 ZNF208 AAUCCUAGCCAGAGAAUAA 
A09 J-019511-18 ZNF208 GGAAUUAACUCCCUAUUUA 
A09 J-019511-19 ZNF208 ACUCAUACAUGGAUGCUAA 
A09 J-019511-20 ZNF208 CGAGAGACAAUGCAAAUAA 
A10 J-021612-09 ELTD1 AGAGUCAUAUCUUCAGUAA 
A10 J-021612-10 ELTD1 GAUGUGCAUUGAAGGCAUA 
A10 J-021612-11 ELTD1 UGAUGGAACCGUCUGUAUA 
A10 J-021612-12 ELTD1 GUACCUGGCUUCAGAUCCA 
A11 J-006297-06 SCN1A GCACUACUAUGUGGAAAUA 
A11 J-006297-07 SCN1A GAAAGACGAUUAAGACGAU 
A11 J-006297-08 SCN1A UGACGGACCAUUUCAAUAA 
A11 J-006297-09 SCN1A AGGAGUAGCUUAUGUGAAA 
A12 J-011701-06 INHBA GAACGGGUAUGUGGAGAUA 
A12 J-011701-07 INHBA GAGUGUGGGUGCUCAUAGA 
A12 J-011701-08 INHBA GGAUUUCUGUUGGCAAGUU 
A12 J-011701-09 INHBA GGAGUGAACUGUUGCUCUC 
B01 J-032495-17 OR51B5 CAUUAUGAGCUAUGCCUAU 
B01 J-032495-18 OR51B5 GUGCUGGAUUAUCUGAUUA 
B01 J-032495-19 OR51B5 GAAAGCAGGUUCCACAUAU 
B01 J-032495-20 OR51B5 GGGCCAAGGCUCUCAUUAC 
B02 J-004226-10 SIGLEC6 GCAUACUUCUUUCGGUUGA 
B02 J-004226-11 SIGLEC6 CACAAACGACCCAGACGAA 
B02 J-004226-12 SIGLEC6 GCAAUGUACCACAAACCGA 
B02 J-004226-13 SIGLEC6 GAACCAAAGGUCACCGACA 
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B03 J-006717-07 DGKI AAGCAGGCGUUUCACAAUA 
B03 J-006717-08 DGKI GGGAGAUUGUGAAAUAUAU 
B03 J-006717-09 DGKI AAGAUGCGCUUGAAUUGUA 
B03 J-006717-10 DGKI GAACUAGUGCAGUCAUUUG 
B04 J-012091-09 DMXL1 AGUAAUGAGAGUACGUUAA 
B04 J-012091-10 DMXL1 CCUCAAAAUUAUAUCGCAA 
B04 J-012091-11 DMXL1 GGGAUUAUAUAGAGCUGAA 
B04 J-012091-12 DMXL1 CAUAUGAGCCUAACAGGAA 
B05 J-023161-09 SATB2 UGUCUGAGAUUCUGCGUAA 
B05 J-023161-10 SATB2 AGUUUGUCCUGGUGCGGAA 
B05 J-023161-11 SATB2 UAAUAAGCCUGCUCGUUUA 
B05 J-023161-12 SATB2 GCCAGAUCUUUGCGAAUUA 
B06 J-003329-14 TP53 GAAAUUUGCGUGUGGAGUA 
B06 J-003329-15 TP53 GUGCAGCUGUGGGUUGAUU 
B06 J-003329-16 TP53 GCAGUCAGAUCCUAGCGUC 
B06 J-003329-17 TP53 GGAGAAUAUUUCACCCUUC 
B07 J-017263-05 ARID1A GAAUAGGGCCUGAGGGAAA 
B07 J-017263-06 ARID1A AGAUGUGGGUGGACCGUUA 
B07 J-017263-07 ARID1A GCAACGACAUGAUUCCUAU 
B07 J-017263-08 ARID1A GGACCUCUAUCGCCUCUAU 
B08 J-003869-09 APC GAUGAUAUGUCGCGAACUU 
B08 J-003869-10 APC AUGAUAAGCUCCCAAAUAA 
B08 J-003869-11 APC GAGAAUACGUCCACACCUU 
B08 J-003869-12 APC GAACUAGAUACACCAAUAA 
B09 J-009580-05 ARHGAP5 GUACGAAUUUGCAACCAUA 
B09 J-009580-06 ARHGAP5 GCUGAUACAACCACAAUUA 
B09 J-009580-07 ARHGAP5 GAUCAUGGCCGCUUAAGAU 
B09 J-009580-08 ARHGAP5 GGAAUCAGUUAAACACAAU 
B10 J-004510-06 ATXN1 GGGAAUAGGUUUACACAAA 
B10 J-004510-07 ATXN1 GGUCUAAUGUAGGCAAGUA 
B10 J-004510-08 ATXN1 CCAGCCAGCUCUUUGAUUU 
B10 J-004510-09 ATXN1 GAAGAACGGCUCUGUUAAA 
B11 J-013169-05 CDH9 CAACAACCCUCCUCGAUUU 
B11 J-013169-06 CDH9 GGAAUCAGUUCUUCUUAUU 
B11 J-013169-07 CDH9 UGUAAUGCCUGAAACUAUU 
B11 J-013169-08 CDH9 GAGACUAAGAGGAUUGUUU 
B12 J-018973-17 FAM194B CGACAGAACUGCCGUAAAA 
B12 J-018973-18 FAM194B GAUUAAGAGGAGACGUGAA 
B12 J-018973-19 FAM194B GCUCAUCUUAUAUGCGAAA 
B12 J-018973-20 FAM194B CGAGAUAAGGAAUGGAUAC 
C01 J-006215-06 KCNA5 CUAGAGAAGUGUAACGUCA 
C01 J-006215-07 KCNA5 ACAGAGGAGUCCAGCGGAA 
C01 J-006215-08 KCNA5 GAAAGGAGAUUCAGGCAGA 
C01 J-006215-09 KCNA5 GAACCCAUUUCUCUAGCAU 
C02 J-013660-25 KRTAP4-5 CUAAUGUCUCCUUGUGAUA 
C02 J-013660-26 KRTAP4-5 CAGACAAUCACAUUCAUUA 
C02 J-013660-27 KRTAP4-5 CAUUCAGAGUGGACAUUCA 
C02 J-013660-28 KRTAP4-5 CAUUCGAAGGGGACACUAA 
C03 J-022981-09 MYADML2 GCUAGAAGCAUUUGCGAGG 
C03 J-022981-10 MYADML2 CAGGGGAGAUGAAGUACAA 
C03 J-022981-11 MYADML2 GCUGGUCACUGGAACAUCA 
C03 J-022981-12 MYADML2 CCAAGUACGGUGAGCCCAA 
C04 J-006503-05 SCN9A UUUAAGGGAUGGACGAUUA 
C04 J-006503-06 SCN9A GCACACAAAUUCUUGAUCU 
C04 J-006503-07 SCN9A CAGCUGAAAUGGUAUUAAA 
C04 J-006503-08 SCN9A CUAUGUGCCUUAUUGUUUA 
C05 J-003816-05 TCF7L2 CAGCGAAUGUUUCCUAAAU 
C05 J-003816-06 TCF7L2 CGAGACAAAUCCCGGGAAA 
C05 J-003816-07 TCF7L2 ACACUUACCAGCCGACGUA 
C05 J-003816-08 TCF7L2 GAUGUCGGCUCACUCCAUA 
C06 J-010216-06 SPINT2 GAAGACCACUCCAGCGAUA 
C06 J-010216-07 SPINT2 GCUCAAAGGUGGUGGUUCU 
C06 J-010216-08 SPINT2 GCAAUAAUUACCUGACCAA 
C06 J-010216-09 SPINT2 CCUGCCAGCUGUUUGUGUA 
C07 J-008294-09 IDH1 UGUCAUAGAUAUCCCGUUU 
C07 J-008294-10 IDH1 GCAUAAUGUUGGCGUCAAA 
C07 J-008294-11 IDH1 GCUUGUGAGUGGAUGGGUA 
C07 J-008294-12 IDH1 CCGCAGGAGAGUUUGGAAU 
C08 J-003023-09 PTEN GAUCAGCAUACACAAAUUA 
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C08 J-003023-10 PTEN GACUUAGACUUGACCUAUA 
C08 J-003023-11 PTEN GAUCUUGACCAAUGGCUAA 
C08 J-003023-12 PTEN CGAUAGCAUUUGCAGUAUA 
C09 J-003471-09 CDKN1A CGACUGUGAUGCGCUAAUG 
C09 J-003471-10 CDKN1A CCUAAUCCGCCCACAGGAA 
C09 J-003471-11 CDKN1A CGUCAGAACCCAUGCGGCA 
C09 J-003471-12 CDKN1A AGACCAGCAUGACAGAUUU 
C10 J-018452-17 MROH2B UAGCUAAGAUUGUCAGUAA 
C10 J-018452-18 MROH2B UCGGAGAACUACCGGAUAA 
C10 J-018452-19 MROH2B AGGAAAUGCUGGACGGUCU 
C10 J-018452-20 MROH2B CUUCCAGAUCACUGCGAAA 
C11 J-011614-07 COL11A1 AGAAUUUGGUCCAGGUGUA 
C11 J-011614-08 COL11A1 GAUGUUACCGUUCCGUUAU 
C11 J-011614-09 COL11A1 GAACGUGGGUCAGCAGGUA 
C11 J-011614-10 COL11A1 GGAUUCUGAUCUUCUGGUA 
C12 J-009032-09 ABCA13 CUGCAAGACAUGAUCGAAA 
C12 J-009032-10 ABCA13 GACAAACGGUGCCGGGAAA 
C12 J-009032-11 ABCA13 GCUUCAAUAUGGAGGAGUA 
C12 J-009032-12 ABCA13 GCUGAUGGGUUCAAAUAUA 
D01 J-025907-05 COL14A1 GAUCAAUGGUUAUCGAAUU 
D01 J-025907-06 COL14A1 UAUAACCGGUUGCGCAUUA 
D01 J-025907-07 COL14A1 GUACAAUGUUGCCGAAUUC 
D01 J-025907-08 COL14A1 GCAUUGAUCUUGCAGGAUU 
D02 J-004758-05 COL1A2 CAGAGGUCUUCCUGGCUUA 
D02 J-004758-06 COL1A2 CAGGUUCACUUACACUGUU 
D02 J-004758-07 COL1A2 GGAACUUUGCUGCUCAGUA 
D02 J-004758-08 COL1A2 CCAAUGGGCUUAAUGGGAC 
D03 J-011012-05 COL3A1 GGUCAGUCCUAUGCGGAUA 
D03 J-011012-06 COL3A1 ACAAAUAGAAAGCCUCAUU 
D03 J-011012-07 COL3A1 GAUGGUGGUUUUCAGUUUA 
D03 J-011012-08 COL3A1 GGACACAGAGGCUUCGAUG 
D04 J-007868-17 CSMD2 CUACAUAGAAAUCCGGAAU 
D04 J-007868-18 CSMD2 CAAUAUAGGUGACAUCGUA 
D04 J-007868-19 CSMD2 GGACCAUCACCGCGGAAGA 
D04 J-007868-20 CSMD2 CAUUAAGUUCAGCGCCAAA 
D05 J-018304-17 FAM171B GUAGAAAGCUCGAGAGGGA 
D05 J-018304-18 FAM171B GGUUUAAGGCUCACUGAUA 
D05 J-018304-19 FAM171B CAAGCAGAGUAAAUGGUAA 
D05 J-018304-20 FAM171B GCUUCAAGAUGUUAGUUAU 
D06 J-032083-17 GFRAL AAACAUGCUUGGAGAGUAA 
D06 J-032083-18 GFRAL GUGAGGAAUCUUUGUGUAA 
D06 J-032083-19 GFRAL GCAACCACGUCAAGACAAC 
D06 J-032083-20 GFRAL CAGUUGGCCUCUUACCUUA 
D07 J-005332-05 INSRR GGGAGCAGAUCUCGAUAAU 
D07 J-005332-06 INSRR CGUAAUAGCAGCAGCAUAU 
D07 J-005332-07 INSRR GAUGGGAACUACACUCUCU 
D07 J-005332-08 INSRR CAGCGCCUCUGAUAUGUAU 
D08 J-008009-07 ITGAX GUUCAUACCUGCCGAGAUC 
D08 J-008009-08 ITGAX CCCAUUACCUUGCGUCUGA 
D08 J-008009-09 ITGAX GCACAGAUACCAGGUCAAU 
D08 J-008009-10 ITGAX CAACUUCUCUAGGUUUCAA 
D09 J-010912-05 KLHL1 GGACAUUUGUAGCCAGUAU 
D09 J-010912-06 KLHL1 CGAAAGAUACCUGCACAUA 
D09 J-010912-07 KLHL1 GUUCCCGGCUACUGGAUUA 
D09 J-010912-08 KLHL1 CAGCAACUUUGUGAUGUUA 
D10 J-015885-09 MUC7 ACAGAAUUAUUGACGACAU 
D10 J-015885-10 MUC7 GCUACUUGGUAUACGGAGA 
D10 J-015885-11 MUC7 GAUCAUGAACUACGUCACA 
D10 J-015885-12 MUC7 CCACAAGACCUAUUAACAA 
D11 J-018348-05 NAV3 GGACUUAACCUAUAUACUA 
D11 J-018348-06 NAV3 GAGAGGGUCUUCAGAUGUA 
D11 J-018348-07 NAV3 CAGGGAGCCUCUAAUUUAA 
D11 J-018348-08 NAV3 GCUGUUAGCUCAGAUAUUU 
D12 J-020986-05 NBAS GUAAAGAGAUGACUAGAAA 
D12 J-020986-06 NBAS UAUCAGUGCUUCACCAUUA 
D12 J-020986-07 NBAS GAAGACACUGGGAUUAUUA 
D12 J-020986-08 NBAS GGUCAACGUUGCUUCAAUU 
E01 J-019674-05 NID1 CAACGGAGCUUAUAACAUA 
E01 J-019674-06 NID1 GGGCGAACCUGCUAUGAUA 
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E01 J-019674-07 NID1 UAACCUGGAUCGAAUAGAA 
E01 J-019674-08 NID1 CCUCCACUCUUACGUAGUA 
E02 J-011883-05 NOTCH4 GCACGGACGGUGUCAGUAA 
E02 J-011883-06 NOTCH4 GCAGGAGGGUCCACGUUGU 
E02 J-011883-07 NOTCH4 GGUGAGACGUGCCAGUUUC 
E02 J-011883-08 NOTCH4 GCCCAACCCUGCGAUAAUG 
E03 J-008450-09 PXDNL CUGAGAAAGUUGUACGGCU 
E03 J-008450-10 PXDNL GGAUUCAGUCUAUGCACGA 
E03 J-008450-11 PXDNL GCUACAACCCCAACGUGAA 
E03 J-008450-12 PXDNL UACCUGAACUGCAGCGAGA 
E04 J-010105-09 PZP GUGACAAAUCAGACGCUAA 
E04 J-010105-10 PZP CUACCAGUAUCUCGGUUAA 
E04 J-010105-11 PZP CUACAGAACCGCAGUAUAU 
E04 J-010105-12 PZP GAGCAGUAGGUCAAGGAUA 
E05 J-011824-05 RUNX1T1 AAGCGACCAUGCACUAUUA 
E05 J-011824-06 RUNX1T1 GAGAGUUGCUGGAAUUGUG 
E05 J-011824-07 RUNX1T1 CGACAACGUUAACUAAUGG 
E05 J-011824-08 RUNX1T1 CCGAUACUGUGGCUCAUUU 
E06 J-021768-09 SLITRK1 GGGCAGAGGGAAGGCGAUA 
E06 J-021768-10 SLITRK1 AGAUAGACCUCCACGGAAA 
E06 J-021768-11 SLITRK1 CCGAAGUGCUGAUGAGCGA 
E06 J-021768-12 SLITRK1 CUGAUAAGUUCCAUCGUAU 
E07 J-020435-09 SLITRK3 CCUUAAUGGCAACGAUAUA 
E07 J-020435-10 SLITRK3 AAGUGAUUACCUCGAGUUA 
E07 J-020435-11 SLITRK3 UGGAAAGGACCUACGAGAA 
E07 J-020435-12 SLITRK3 CUUCAAACCAAGCCGGAUU 
E08 J-013422-05 SORCS1 GGACAUCGGUCGAGUCAUC 
E08 J-013422-06 SORCS1 GAAUGGAGGACGCCAGUAA 
E08 J-013422-07 SORCS1 CAAAUGAAGCUUCCGAAAU 
E08 J-013422-08 SORCS1 CGGCUGAACUUCUACAUUC 
E09 J-008402-09 ST6GAL2 CAGAGAGGUGCACGUGUAU 
E09 J-008402-10 ST6GAL2 ACCCGGAGGAUGACGACUA 
E09 J-008402-11 ST6GAL2 CGUCAUGUCUGCAGGCGCA 
E09 J-008402-12 ST6GAL2 UACACGUGGUUAUGAGAAA 
E10 J-009299-06 TG ACUCAAAGCUGCACACAUA 
E10 J-009299-07 TG CAAUGGAAAUCAAUCACUA 
E10 J-009299-08 TG GGGAUUAGAUUCAAAUUCU 
E10 J-009299-09 TG CCACAGACAUGAUGAUUUU 
E11 J-009863-05 TPO CCAGAUGACUUGUGAGAAC 
E11 J-009863-06 TPO GGUUAUGGCCUGCACAGAA 
E11 J-009863-07 TPO GUACGUGGGUCCCUAUGAA 
E11 J-009863-08 TPO GCACGGGUAUGAGCUCCAA 
E12 J-009644-05 TRPS1 GAAUGCAAAUGGCGGAUAU 
E12 J-009644-06 TRPS1 CAACUCAUCCACCGAAUUA 
E12 J-009644-07 TRPS1 GCUGGAAGCUCGCGAGUCA 
E12 J-009644-08 TRPS1 CCACAGAUCUGAUUAAGCA 
F01 J-016071-05 VCAN CCACUACCCUUGAAGAUAU 
F01 J-016071-06 VCAN CCUAGAGGAUAUUGAUUUA 
F01 J-016071-07 VCAN GAAGGUAGUGGGUCAGUAA 
F01 J-016071-08 VCAN GAGCAUGACUUCCGUUGGA 
F02 J-003646-06 COL6A3 CGACAUGGCUUUCAUCUUA 
F02 J-003646-07 COL6A3 GAAGGAACUUGCAGGGAUU 
F02 J-003646-08 COL6A3 GAGAUGUGGUCUUGAGUAU 
F02 J-003646-09 COL6A3 UAGAGAGGCUGGUUGACUA 
F03 J-013520-05 CDH10 CGAAAUGUCUGUUGUAGGU 
F03 J-013520-06 CDH10 GGGUAUGCCUGCCACAUUU 
F03 J-013520-07 CDH10 CAGCUAAUACAGACUAUAA 
F03 J-013520-08 CDH10 GCCACAAGGCGAAUUGAUA 
F04 J-005497-06 FSHR CCAGUGAGCUGUCAGUCUA 
F04 J-005497-07 FSHR UUACAUACUUGUCCCUCUA 
F04 J-005497-08 FSHR UAUCACAACUAUGCCAUUG 
F04 J-005497-09 FSHR GGCAAGAAGUUGAUUAUAU 
F05 J-019219-09 NCKAP1L GGACCAGUACAUCGUGAAA 
F05 J-019219-10 NCKAP1L GAUUGAAGAUCGGCGGAUA 
F05 J-019219-11 NCKAP1L GUCAGAUGGUCUUGGAGUA 
F05 J-019219-12 NCKAP1L CGAAACAGCACGCAACAUU 
F06 J-008079-05 SELP GCUGAGAGGAGCCGAUAUA 
F06 J-008079-06 SELP GCUGAGAACUGGGCUGAUA 
F06 J-008079-07 SELP GUAAAGCUGUGCAGUGUCA 
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F06 J-008079-08 SELP CUAGAGGGCCAGUUACUUA 
F07 J-007391-09 SLC13A1 CUGACUAUCUUGCGGUAAU 
F07 J-007391-10 SLC13A1 UAGAAGUGAGGAUGCGAAA 
F07 J-007391-11 SLC13A1 AAUGAAAACUGCUGACGUA 
F07 J-007391-12 SLC13A1 UCUUGUUGGUGGAGGGUUU 
F08 J-003865-09 LATS2 GCACGCAUUUUACGAAUUC 
F08 J-003865-10 LATS2 ACACUCACCUCGCCCAAUA 
F08 J-003865-11 LATS2 AAUCAGAUAUUCCUUGUUG 
F08 J-003865-12 LATS2 GAAGUGAACCGGCAAAUGC 
F09 J-010608-05 BCAM GCUAAAGACAGCGGAAAUA 
F09 J-010608-06 BCAM CGGGAACCCACGACCAUUA 
F09 J-010608-07 BCAM GAGGUGCGCUUGUCUGUAC 
F09 J-010608-08 BCAM CGAGGAAAGUCUGUCAUUC 
F10 J-016856-17 C12orf50 ACGCAUGGGUCCUACAAUA 
F10 J-016856-18 C12orf50 CCAGACAAAUAUACGUCAA 
F10 J-016856-19 C12orf50 GGUCAUAUUUCUUGGAGUC 
F10 J-016856-20 C12orf50 GAAAAUAUAUCACGACCCA 
F11 J-016630-17 CCDC11 GUAACAACGCACAGAUUAA 
F11 J-016630-18 CCDC11 CCGUACAGCGGGAGGUUAA 
F11 J-016630-19 CCDC11 CAUUGAAGAAAGACGAAAU 
F11 J-016630-20 CCDC11 GCUCCGUGUUGAAUUGUUA 
F12 J-017854-05 CD2 CCAAAGAGAUUACGAAUGC 
F12 J-017854-06 CD2 GAACUGACCCCGAAUUAAA 
F12 J-017854-07 CD2 CCGAUGAUCAGGAUAUCUA 
F12 J-017854-08 CD2 CCAAAGAUCUCCUGGACUU 
G01 J-008948-22 CHD2 CCGAAGACUCAGCGUGGAA 
G01 J-008948-23 CHD2 GACAAGAACCAUCGCGAUU 
G01 J-008948-24 CHD2 ACAGCAAUGCAUCGAGUCA 
G01 J-008948-25 CHD2 AGAGGAGGACAGUUCGCUA 
G02 J-025842-17 COL22A1 GAUCAUAUGUCUUGGCCAA 
G02 J-025842-18 COL22A1 CGGAAAAGUCAGAGGGUCA 
G02 J-025842-19 COL22A1 CCAAGGGUCACCUGGGAAA 
G02 J-025842-20 COL22A1 GGGACGUGCAUUUGGAAAA 
G03 J-020683-05 KIR2DL1 CAACAGAUAUCAUCGUGUA 
G03 J-020683-06 KIR2DL1 GAAACAGAACAGCGAAUAG 
G03 J-020683-07 KIR2DL1 UCACAAUUCCAAACAUACA 
G03 J-020683-08 KIR2DL1 CAACCUAACUGGCUUACUU 
G04 J-005577-05 LGR5 CCUAGAGACUUUAGAUUUA 
G04 J-005577-06 LGR5 GACAAUGCGUUAACAGAAA 
G04 J-005577-07 LGR5 CCUCACAAAUAACUGAAUU 
G04 J-005577-08 LGR5 UCAAUUAACUCUGAUGAUG 
G05 J-003844-05 LRP5 CGUCAAAGCCAUCGACUAU 
G05 J-003844-06 LRP5 CGUCAUGGGUGGUGUCUAU 
G05 J-003844-07 LRP5 GGACGGACCUACGGAGGAU 
G05 J-003844-08 LRP5 GUACAGGCCCUACAUCAUU 
G06 J-023646-09 LRRIQ4 AGAUCUACCUGAAGCGAAA 
G06 J-023646-10 LRRIQ4 CCCAGGAGAUUCAGCGUUU 
G06 J-023646-11 LRRIQ4 GAAAUCGGGCUGAGCGGGA 
G06 J-023646-12 LRRIQ4 AGUGUGUGCUGAAGGCAAU 
G07 J-009229-05 PON1 CAUCAGAGGUGCUUCGAAU 
G07 J-009229-06 PON1 GACAUAAACUUCUGCCUAA 
G07 J-009229-07 PON1 GGUCGUAUGUUGUCUACUA 
G07 J-009229-08 PON1 GUUGCUGGCUCAUAAGAUU 
G08 J-007420-09 SLC18A2 GAAGAGAGAGGCAACGUCA 
G08 J-007420-10 SLC18A2 GAUCACAACUGCCCUAUUA 
G08 J-007420-11 SLC18A2 GGGAAUGAUAAUUGUUGGA 
G08 J-007420-12 SLC18A2 GCUAGUAUCUCUUAUCUCA 
G09 J-021231-05 SNTG1 GGAUUUGGAUUAAGCAUAA 
G09 J-021231-06 SNTG1 GCUCAUGUCUCUACAAGUU 
G09 J-021231-07 SNTG1 GCACAGGAUUUAUCUGCUU 
G09 J-021231-08 SNTG1 UAAUGGGACUCACAAUUGA 
G10 J-021242-05 DCP1A GCAAGCUUGUCGAUAUAUA 
G10 J-021242-06 DCP1A ACUCAUGGCUGAUGUGGUA 
G10 J-021242-07 DCP1A ACAAGCAUCUGACGGUAGA 
G10 J-021242-08 DCP1A CCAAUUCAUUCCUACCAUU 
G11 J-003528-06 PTBP1 CGUCAAAGGAUUCAAGUUC 
G11 J-003528-07 PTBP1 GGCACAAGCUGCACGGGAA 
G11 J-003528-08 PTBP1 GAACUUCCAGAACAUAUUC 
G11 J-003528-09 PTBP1 GCAUCACGCUCUCGAAGCA 
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G12 J-003916-07 NF1 GAACAAACCAUAGCUAUAA 
G12 J-003916-08 NF1 CAGAUAAUCCGUAUUCUUA 
G12 J-003916-09 NF1 CGAAGUCGCUGCAGCCUAA 
G12 J-003916-10 NF1 GCAAGUACUUACAUCAAUU 
H01 J-003020-14 PIK3R1 AGUAAAGCAUUGUGUCAUA 
H01 J-003020-15 PIK3R1 CCAACAACGGUAUGAAUAA 
H01 J-003020-16 PIK3R1 GACGAGAGACCAAUACUUG 
H01 J-003020-17 PIK3R1 UAUUGAAGCUGUAGGGAAA 
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